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Abstract 
 
Sally Shoshana White:  Examining the Effects of Gestational Exposure to Perfluorooctanoic 
Acid on the Developing and Differentiating Mammary Gland, Their Consequences, and the 
Possible Modes of Action by Which They are Mediated 
(Under the direction of Suzanne E. Fenton) 
 
 
 
Perfluorooctanoic acid (PFOA) is a persistent industrial compound, which is 
commonly detected in human and wildlife sera.  Low-dose prenatal PFOA exposure 
negatively affects postnatal growth and survival with little prenatal effect, indicating the 
potential for PFOA to alter lactation in the nursing dam.  These studies aim to understand the 
impact PFOA has on development and differentiation of the mammary gland (MG).  To 
address this, timed-pregnant CD-1 mice were gestationally exposed to 0 or 5 mg PFOA/kg 
body weight.  PFOA-treated dams exhibited significant histopathologic delays in MG 
lactational differentiation and alterations in milk protein gene expression, and their exposed 
female offspring displayed stunted mammary epithelial branching and growth.  The roles of 
timing and route of exposure were then addressed by cross-fostering litters, and the 5 mg/kg 
dose, under either lactational- or intrauterine-only exposures, was determined sufficient to 
delay MG development as early as postnatal day (PND) 1, with effects persisting beyond 
PND63. The consequences to F1 lactational function and subsequent development of F2 
offspring were investigated, and F1 dams exhibited delayed lactational differentiation, 
though no effect of early-life exposure on milk production or F2 offspring body weight was 
detected.   Finally, the potential mode of action for the effects of PFOA on the MG was 
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investigated, by treating pregnant wild-type (WT) and peroxisome proliferator-activated 
receptor alpha (PPAR!) knock-out (KO) mice similarly with PFOA.  At weaning, PFOA 
treatment caused diminished lactational differentiation in WT, but not KO dams.  In 
offspring, however, effects of PFOA exposure were apparent in both strains at weaning, 
suggesting a non-PPAR! mode of action may be responsible for offspring MG effects.  In 
total, these studies defined a window of MG sensitivity in late fetal and early neonatal life, as 
well as the persistence of MG effects beyond the age at which serum PFOA concentrations 
reach background levels.  This suggests a permanent, non-PPAR! mediated effect in the 
offspring, though without clear functional consequences.  The characterization of MG effects 
in light of PFOA dosimetry data, as well as the discovery that MG effects are not strictly 
controlled by PPAR!, will greatly assist in the regulation of this compound. 
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CHAPTER 1 
Introduction 
 
 
 
Regulatory Interest in Perfluorooctanoic Acid 
In April of 2003, the U.S. Environmental Protection Agency (EPA) published a 
notice in the Federal Register [1] stating that health hazards had been identified in association 
with perfluorooctanoic acid (PFOA) exposure, and that a preliminary human health risk 
assessment was being undertaken by the EPA.  This sudden interest of the EPA in a 
compound which had been produced for over 60 years followed close upon work the agency 
had recently been engaged in, concerning perfluorooctane sulfonate (PFOS).  PFOS had been 
a primary component of the popular, spray-on fabric protectant, Scotchgard™, but in 2000 
was voluntarily phased out of use by its sole producer in the U.S., the 3M Company (consent 
agreement with EPA), to be completed by 2002 [2].  At that time, the bioaccumulative and 
persistent nature of the compound had been recognized in humans [3, 4], wildlife [5-9], and 
the global environment [10-17]. and the mammalian toxicity of PFOS was becoming 
apparent in laboratory experiments [18, 19].  Since the phase-out, however, production of 
PFOA has increased to fill the market void left by PFOS.  Given that PFOA was becoming 
recognized as similarly distributed in the natural and biological environment, and of similar 
persistence, these combined observations lead the EPA to publish their formal notice in the 
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Federal Register [1] in 2003, and to produce the resultant risk assessment document drafted 
by the EPA Office of Pollution Prevention and Toxics (OPPT).  In May, 2006 this document 
was reviewed by the EPA-appointed Science Advisory Board (SAB) on PFOA, and it was 
concluded that further research concerning PFOA toxicity was necessary.  In the comments 
provided by the SAB, it was suggested that in order to produce a complete risk assessment of 
PFOA, certain data gaps would need to be filled, including: addressing non-cancer endpoints 
such as those mediated by a possible endocrine-disrupting mechanism of PFOA, elucidating 
the developmental toxicity of PFOA including windows of sensitivity, and addressing the 
role played by the PPAR! pathway in PFOA-induced carcinogenesis and other adverse 
health effects [20].   The research described herein was aimed at addressing these goals of the 
OPPT and SAB by characterizing how gestational PFOA exposure affects the mammary 
gland in the exposed lactating dam and in the subsequent female offspring, and by evaluating 
the human relevance of the mechanism(s) by which these effects are mediated.  
 
PFOA in the Market and the Environment 
Not occurring in nature, PFOA (CAS # 3825-26-1) is an eight-carbon, fully-
fluorinated carboxylic acid, which may be linear or branched.  Structural homology exists 
between PFOA and the dietary eight-carbon fatty acid, caprylic acid (octanoic acid), found in 
coconut, dairy, and breast milk.  PFOA has broad industrial applications, and has likely been 
in industrial use since the late 1940s and early 1950s, when polytetrafluoroethylene (PTFE) 
was first marketed as a non-stick cookware coating, and prior to the establishment of the 
Toxic Substances Control Act (TSCA) of 1976.  Employed for its surfactant properties in the 
emulsion polymerization process necessary to produce the PTFE polymer, PFOA remains a 
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vital ingredient in the production of many consumer products including non-stick cookware 
coatings, all-weather clothing, and paper coatings to repel grease, as well as industrial 
applications such as fire-fighting foams, electrical insulation, and insecticides.  Furthermore, 
PFOA is a waste product in the production of many perfluorinated chemicals (PFC) and may 
be released in the effluent from such facilities [10], as well as a final environmental 
degradation product of many PFC [21-23].  Such environment degradation of PFC may occur 
via aerobic, microbial metabolism [21], or by photolysis in the lower atmosphere [22], the 
latter which mechanism may partially explain the global distribution of PFOA [23].  PFOA, 
however, is a final product of the processes, and resists further degradation.  
The presence of organic fluorine in the serum of employees of PFC-producing plants 
was first reported in 1980 [24], and a correlation between PFC exposure and serum organic 
fluorine concentration, presumed to be predominantly PFOA, was evident, though no adverse 
health effects were observed, when considering blood chemistry, disease patterns, and 
mortality rates [24].  At that time, serum organic fluorine concentrations in non-
occupationally exposed individuals were presumed to fall within the range of 0.0 - 0.13 ppm 
[25].  Since then, multiple epidemiologic studies of occupationally exposed populations have 
been performed.  In 1993, about 3,500 male and female 3M employees at the Cottage Grove 
plant in Minnesota, including about 400 deceased employees, participated in a retrospective 
mortality study [26].  Only a slight increase in prostate cancer among the PFOA-exposed 
male employees was observed, as well as an increased risk of prostate cancer mortality with 
increased length of employment.  In 1997 the study was revisited, however the exposure-
grouping was modified in this follow-up and the cohort was expanded, therefore comparison 
between the two studies is difficult [27].  Again, using standardized mortality ratios to 
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control for biological variables (age, weight, sex), slight increases were observed among 
definitively PFOA-exposed employees for cancers of the pancreas, prostate, and large 
intestine, as well as cerebrovascular disease mortality [27].    
More recently, epidemiologic studies have addressed PFOA concentrations in 
populations from communities environmentally exposed to PFOA, due to their proximity to 
fluoropolymer production plants.  A study was recently conducted in communities near 
Washington, WV (site of a fluoropolymer plant using PFOA), served by the Little Hocking 
water system, which exhibits the highest PFOA concentrations measured in an American 
municipal water supply to date.  This study found that individuals in the community, believed 
to receive PFOA exposure only via this contaminated drinking water, exhibited mean serum 
PFOA concentrations ranging from about 300 to 400 ng/ml, and this value increased with 
increasing likelihood of occupational exposure to PFOA [28].  Only the population drinking 
non-Little Hocking water (i.e. bottled water), exhibited lower serum PFOA concentrations – 
with a mean concentration less than 80 ng/ml [28].  The average PFOA concentration in 
Little Hocking water, presumed to lead to the circulating PFOA concentration of about 400 
ng/ml in humans consuming that water, was 3.55 ppb [28].  Serum PFOA was also higher in 
populations consuming locally produced meat, fish, and fruits and vegetables, and not using 
in-home carbon water filters [28].  Another study performed by this same group examined 
various health parameters with respect to serum PFOA concentration, and found no 
association between PFOA levels and what they considered to be markers for adverse health 
conditions, measured by clinical blood chemistry [29].  However, this study only considered 
individuals with PFOA exposure in recent years, and only those who received adult 
exposures, for the health effects of interest.  Additionally, they observed increased total 
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cholesterol with increasing serum PFOA concentration, suggesting that PPAR!-activation 
(resulting in hypolipidemia) is not occurring [29].        
Recent studies of non-occupationally exposed populations have found that PFOA 
serum concentrations in Japan may have significantly increased over the past 25 years [30, 
31].  The primary source of exposure there may be drinking water, where PFOA was 
measured as high as 40 ng/L (Osaka tap water); this contamination may have resulted from 
pollution by industry of water sources, including one estuarine area where surface water 
PFOA measured 67,000 ng/L [32].  Another study of human serum found that at various 
locations throughout the U.S. between 1990 and 2002, PFOA was present in every serum 
sample and ranged from 2.8 to 23.7 "g/L [33].  However, when the same study addressed 
Peruvian serum, PFOA was not present in every sample, and measured concentrations ranged 
from only 0.1 to 0.3 ug/L, suggesting the influence of the industrialized environment on 
PFOA exposure [33].  Today, in the general American population (non-occupatioanlly 
exposed, etc.), many studies have suggested that the mean serum PFOA concentration is 
approximately 5 ng/ml [34, 35].  Potential sources of exposure of the general population may 
include contact between food and PFC-treated packaging, ingestion of contaminated drinking 
water or household dust (believed due to prevalence of PFOA in consumer products), and 
possibly dietary sources including fish consumption, among other unknown pathways, may 
contribute to human PFOA exposures [36, 37].  Whatever the means of delivery or exposure, 
it is now recognized and accepted that PFOA is widely distributed in the natural environment 
[38, 39] and in biota [40, 41].  
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Toxicity of PFOA 
Acute toxicity of PFOA in laboratory animals was observed as early as 1976, when 
the oral LD50 for Sherman-Wistar rats was determined to be less than 1000 mg/kg [42].  
Then in 1978, the oral LD50 for male and female CD rats was reported as 680 and 430 
mg/kg, respectively [43].  Further other rat strains were later reported on, and in 1997 the 
oral LD50 for male and female Sprague-Dawley rats was reported as greater than 500 mg/kg 
and between 250-500 mg/kg, respectively [44].  Mutagenicity studies performed in 
Salmonella and E. coli found no positive mutation response, and no chromosomal aberrations 
were observed in human lymphocytes [45-47].  Chromosomal aberrations were observed, 
however, in Chinese hamster ovary cells, when tested with metabolic activation [48].  
Chronic exposure studies have also revealed non-human primate toxicity.  In one 90-
day study in rhesus monkeys, all animals in the 30 and 100 mg/kg/day (gavage) groups lost 
body weight after one week, exhibited bone marrow hypocellularity, and atrophy of splenic 
lymphoid follicles, and only one of the eight animals survived [49].  Animals from the same 
study at lower doses showed decreases in heart and brain weight (females, 10 mg/kg/day), 
and increases in pituitary weight (males, 3 mg/kg/day; lowest dose) at necropsy [49].  
Another chronic exposure study, performed in cynomolgus monkeys, found that after 26 
weeks of exposure to 0, 3, 10, or 30 mg/ kg/day body weight and food consumption were 
reduced among the highest exposure group, and liver weight and liver:body weight ratios 
were increased among all exposed animals.  These hepatic effects were believed by the 
authors to be due to hepatocellular hypertrophy, as suggested by decreased hepatic DNA 
content, and hypertrophy was believed to result from mitochondrial proliferation, as 
concluded by the authors, due to increased activity of succinate dehydrogenase.  No changes 
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in estradiol, estrone, estriol, testosterone, thyroid-stimulating hormone, thythyroxine, 
cholecystokinin, bilirubin, or bile acids were observed, though triiodothyronine levels were 
decreased in the highest exposure group during the dosing period.  Liver weight changes 
were reversed at 13 weeks after the end of the dosing period.  
Many studies of the general toxicity of PFOA have been conducted in rodents, and 
some of the most prominent observations in these have been hepatomegaly and hepatic 
necrosis.  Early observations of hepatotoxicity are now understood to occur through 
activation of the peroxisome proliferator-activated receptor alpha (PPAR!), and changes 
observed in liver tissue have been consistent with exposure to PPAR agonists [50].  
Consequences of activation result in a number of metabolic changes including increased fatty 
acid beta-oxidation, and inhibition of hepatic secretion of very low density lipoproteins and 
cholesterol [50].  This explains the previously reported hypolipidemic capacity of PFOA in 
rodents, now believed to be mediated through PPAR! activation, the same means by which 
fibrate drugs enact their pharmacologic activity.  Furthermore, previous feeding studies 
observed a common triad of cancers in the exposed rats, including hepatocellular, Leydig-cell 
and pancreatic acinar-cell tumors [51].  The first of these, like the above-described liver 
changes, is believed to be mediated by PPAR! activation that results in increased cell 
proliferation and decreased apoptosis, thus allowing for the clonal expansion of cells of 
preneoplastic lesions, culminating in full-blown hepatocellular tumors.  Agonism of PPAR! 
by PFOA is thought to also explain the thymic and splenic atrophy observed in exposed 
rodents [52].  The PPAR!-mediated mode of action believed to be responsible for these 
hepatocellular tumors, however, is not believed to be relevant to human health, given the 10-
fold lower expression of PPAR! mRNA in the human liver, as compared to the rodent [50].  
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For this reason, there is some question whether hepatotoxicity, if the observed toxic 
endpoints are demonstrated to be PPAR!-mediated, should be considered relevant to human 
health.  The human relevance of non-hepatic endpoints that are PPAR!-mediated, has not yet 
been determined.    
There are two proposed modes of action responsible for Leydig cell tumor formation.  
The first of these posits that testosterone biosynthesis may be inhibited and lead to an 
imbalance between androgen and estrogen levels, which results in increased luteinizing 
hormone that then promotes the tumor.  Alternatively, estradiol levels -- which may stimulate 
production of growth hormones, encouraging proliferation of these tumors -- may become 
increased in these males because of induction by PFOA of increased hepatic aromatase 
activity.  The mode of action responsible for the observed pancreatic acinar cell tumors, 
however, is unclear, although other peroxisome proliferators have been observed to also 
induce such tumors.  Also of note, the same 2-year feeding study in rats also reported a 
statistically significant increase in mammary fibroadenomas compared to controls, but these 
observations were deemed ambiguous, as tumor rates were considered “comparable to some 
historical background indices” [51, 53].  Nonetheless, beyond its action on PPAR!, PFOA is 
largely considered inert [52].  
 
PFOA Absorption, Distribution, Metabolism, and Excretion in Various Species 
Because the toxicity of PFOA has not been thoroughly characterized, the absorption, 
distribution, metabolism, and excretion patterns across species are not well known.  This 
problem is compounded by the fact that most early toxicological tests were performed as 
internal reports, by industrial labs invested in the safety of PFOA, and the results of such 
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studies were neither published in peer-reviewed journals, nor otherwise made publicly 
available.  In rats, PFOA may be absorbed via dermal, inhalation, or oral exposure; these 
routes are listed in order of increasing absorption [54].  Distribution of PFOA in the rat body 
studied using 
14
C-labelled PFOA found that in male rats PFOA distributed primarily to the 
liver and serum, but in females PFOA was also distributed substantially to the kidney [55].  
Studies in mice have exhibited the same findings in the male rat – partitioning of PFOA 
primarily to the liver and serum.  Furthermore, female rats exhibited rapid urinary excretion 
of PFOA, suggesting a half-life for PFOA of less than one day, compared to the half-life of 
about two-weeks in male rats [55].  It was postulated that PFOA might be metabolized to a 
PFOA-glucuronide or sulfate ester, and that this might explain the rapid urinary excretion, 
but polar metabolites have not been detected in urine [55].  It is now recognized that PFOA is 
eliminated intact, and not metabolized [56].  Later studies in male rats observed an increase 
in the fecal elimination of PFOA, when they were fed cholestyramine resin following 
exposure, suggesting the enterohepatic circulation is involved in elimination [56, 57].  
Because the aim of the research detailed in this proposal is to provide data to inform 
human health risk assessments, differences between experimental animals and humans must 
be considered.  For example, while the rat has historically been the experimental animal of 
choice in toxicologic studies, clear differences between the rat and human appear to exist, 
with respect to PFOA elimination.  Early hepatotoxicity studies of PFOA in rats displayed a 
clear gender difference under hormonal control (alluded to above), whereby female rats did 
not exhibit the pronounced hepatomegaly and peroxisomal beta-oxidation observed in male 
rats [58].  This finding was supported by further study that found PFOA urinary excretion to 
be much more rapid in the female, and that castration or estradiol treatment of males 
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stimulated similar excretion patterns [59].  It has since been determined that this gender 
difference in elimination results from higher renal expression of organic anion transport 2 
(Oat2) in the female rat, which promotes the secretion of circulating PFOA into the urine 
[60].  Recently, PFOA half-lives have also been more accurately calculated as about 2 hours 
in the female and 5.7 days in the male [60].    
This preferential urinary excretion and elevated renal Oat2 is not observed in female 
humans, who display a similar PFOA half-life to that observed in human males [61].  The 
half-life of PFOA in humans is essentially the same for both genders, and has been suggested 
to be 4.37 years based upon occupational observations, though the human toxicokinetics of 
PFOA remain poorly understood [56].  Similarly, mice exhibit no gender difference in the 
elimination of PFOA, nor difference in renal Oat2 expression.  This suggests that the mouse 
would provide a more appropriate model of human health, when considering the reproductive 
and developmental toxicity of PFOA.  That is, when pregnant female rats are employed in 
developmental toxicity studies where PFOA is administered once daily, they do not establish 
steady-state circulating levels of PFOA.  Instead, due to complete elimination of PFOA in a 
few hours, their internal dose becomes episodic rather than constant.  Because this 
physiology is not representative of the human response to PFOA, such developmental studies 
should instead be performed in the more representative mouse model.   
 
PFOA and Developmental Toxicity 
The developmental toxicity of PFOA has only recently been addressed.  Initially, 
these studies were performed in the rat, as many other PFOA toxicity studies had been, but as 
the gender difference in elimination became recognized, it was clear that these studies should 
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be performed in the mouse instead (for reasons described above).  A multigenerational study 
in Sprague-Dawley rats, which addressed various reproductive parameters in P0 and F1 
including estrous cyclicity, fecundity, and litter survival and growth, utilized oral exposures 
prior to F0 mating, and continued over the lifetime of the F1 generation including the period 
between parturition and weaning of F2 litters [63].  Their findings were that doses as high as 
30mg/kg did not adversely affect reproductive function in the P0 and F1 generations, but that 
doses of 10 mg/kg and higher did reduce F1 birth weight, neonatal survival, and sexual 
maturation, and that doses at least as low as 1 mg/kg altered body and organ weights in P0 
and F1 males [63].  These data clearly support the consequences resulting from gender 
elimination differences in rats, on the effects of PFOA toxicity.  Another developmental 
study performed in the rat examined the pharmacokinetics of PFOA transfer via the placenta 
and lactational milk [64].  The measured PFOA by HPLC-MS in tissues pre- and post-
natally, including amniotic fluid, placenta, embryos, fetal blood, neonatal blood, maternal 
blood, and milk.  While this study provided invaluable information about the transmission of 
PFOA from the dam to the offspring, it provided little in the way of hazard information [64].  
Steady-state milk PFOA concentrations, at the single time point evaluated, were determined 
to be about one tenth that of maternal serum, and milk concentrations were generally 
comparable to offspring serum concentrations at mid-lactation.  Offspring serum 
concentrations were also observed to fall between PND 3 and 7, though little change 
occurred between PND 7 and 21, within a treatment group.  The most important finding of 
this paper, however – from the perspective of the research goals described in this proposal -- 
was that PFOA is excreted by the dam, into the milk, demonstrating that prenatally-exposed 
neonates continue to receive exposure to PFOA via breast milk consumption.  And while 
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effects to offspring were not addressed, the pharmacokinetic information produced by the 
study will provide a means to estimating the internal dose received by exposed offspring.  It 
should be noted that neither study followed animals beyond 5 months of age (~160 days, F0 
gen; [63]), nor did they address non-reproductive or developmental endpoints, such as 
possible long-term adverse health effects resulting from early developmental exposure.                   
In general, the findings of these early PFOA development toxicity studies, suggested 
that PFOA posed a weaker threat than PFOS.  However, this observation in rats may have at 
least partly resulted from the gender difference in PFOA elimination, as described above.  A 
more recent study from our own laboratories was performed in mice, in order to examine 
developmental toxicity in a model organism more representative of human health, with 
respect to the endpoints addressed.  The findings of this study suggested much more severe 
developmental toxicity in the mouse compared to the rat. Briefly, this study found reductions 
in percentage of live offspring born and birth weight under a 20 mg/kg exposure, and 
decreased postnatal survival, growth deficits (also in 3mg/kg exposure offspring), and delays 
in eye opening were all observed among offspring under doses of 5mg/kg and higher.  Also, 
liver enlargement was observed at GD 18 in dams exposed throughout gestation (GD 1-17), 
at as low a dose as 1 mg/kg/day [65]; in previous studies, liver enlargement was only 
observed in males [63].  
Little is known about the potential reproductive and developmental toxicity of this 
ubiquitous environmental contaminant, and even less is known in the mouse, the species 
most appropriate for modeling human health, with respect to these endpoints.  Furthermore, 
until recently, no studies existed which addressed the effects of developmental PFOA 
exposures on reproductive tissue.     
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The Developing and Lactating Mammary Gland 
The mammary gland is a reproductive tissue, unique in its development.  That is, 
although mammary gland development begins early prenatally, the tissue does not reach its 
mature form until after the end of puberty.  However, this stage of development cannot be 
said to represent the final, functional tissue, as the mammary gland undergoes a second stage 
of maturation during pregnancy, whereby it differentiates into a milk-secreting, functional 
gland.  Ultimately, the mammary gland is vital to the survival of mammals in nature and, like 
the gonads, is necessary for the continuance and proliferation of a mammalian species.  
Unfortunately, however, the mammary gland has largely been neglected in recent decades as 
a tissue of study, with the exception of breast cancer research, which often does not address 
tissue development or function.  This may be changing, though, as fetal origins of adult 
disease become of greater interest in fields such as breast cancer.  
In the mouse there are 10 individual glands, 5 on either side of the ventral midline of 
the body, with 10 nipples, to support the many offspring born to each litter.  The earliest 
gestational evidence of mammary gland development in the mouse is evident at GD10-11, as 
ventrolateral ectoderm begins to thicken [66].  This thickened tissue is then referred to as the 
mammary streak or band, and in rodents is visible running the length of the ventral surface 
between the fore- and hindlimbs.  The cells comprising this band, at GD 13-14, condense to 
form the mammary buds, each of which is the precursor to an individual mammary gland 
[66].  Invasion of the fat pad by the recognizable ductal epithelium occurs at about GD 15 
[66].  In mammals the primitive mammary buds and germinal ectoderm give rise to the 
epithelium of the mammary gland, a compound alveolar gland.  This early morphogenesis of 
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the tissue occurs largely independently of the hormonal control exerted later in life, though 
hormone receptors may be present and responsive.  In the juvenile gland, the highly 
mitogenic terminal end buds push through to fill the fat pad with ductal epithelium [67].  
Then, during puberty, the gland comes under the control of ovarian estrogens, pituitary 
prolactin, and locally produced epidermal growth factor (EGF) and insulin-like growth factor 
(IGF), thus appropriate receptor expression must exist in the gland, in order to respond and 
mature [67].  In the mature gland, functional units are the lobules, which appear 
peripubertally and persist into adulthood, each composed of clustered alveoli and ducts to 
drain them [67].    
During normal, prepubertal development of the mammary gland, a critical window of 
sensitivity to exogenous signaling is believed to exist.  In mice, this period is thought to 
occur at about GD 12-14, as the primary ducts begin to form at the site of each mammary 
bud [68].  Interference with this process may result in altered structural development of the 
gland, or farther-reaching consequences in the health of the tissue [68].  Multiple studies of 
gestational dioxin exposures, administered as bolus doses to dams during this critical window 
(GD 14-16 in rats), demonstrate that exposures during this period may result in altered gland 
morphology from as early as PND 4 to as late as 11 weeks of age [69-71].  One study even 
found that offspring resulting from these affected females displayed smaller mammary 
glands themselves [71], demonstrating that the effects of this exposure were not limited to 
inconsequential histopathologic changes.  Interestingly, dioxin produces essentially no effect 
on the mammary gland when the exposure occurs in the adult animal [68].     
While secretion from the mammary gland is possible as early as birth in many 
mammals, given the presence of the appropriate lactogenic hormonal cues (circulating in the 
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dam, and transmitted via the milk), true lactation is controlled by a complex and tightly 
regulated series of events.  To produce the functional lactating mammary gland, the epithelial 
parenchyma undergoes extensive differentiation and proliferation to produce true alveoli and 
a dramatic increase in parenchymal cell number [67].  Lobulo-alveolar tissue is formed 
during the second half of gestation in mice, after which time alveoli continue to grow in size.  
Additionally, another surge in proliferation occurs in mice 2-3 days after parturition, further 
increasing the amount of parenchymal tissue in the fat pad.  During pregnancy the gland is 
prepared for lactation by the action of many hormones, including estrogens, progesterone, 
prolactin, EGF, growth hormone, cortisol, and insulin [67].  For lactation to commence, 
however, the influence of estrogen and progesterone must be removed, as they act to inhibit 
terminal differentiation and lactogenesis.  After this occurs, lactation is regulated largely by 
prolactin, as well as cortisol and insulin [67].  At weaning and the cessation of suckling, the 
lactating gland undergoes involution, whereby much of the alveolar epithelium undergoes 
apoptosis, and the entire tissue is remodeled.  This is mediated primarily by a reduction in 
available prolactin (caused by the action of reduced offspring suckling).  
While human and rodent mammary glands are not the same, many developmental and 
morphologic similarities exist, such as the molecular cues and processes described above.  
The critical period described in rodents, above, is a developmental period which corresponds 
in human gestation to embryonic weeks 10-13, when breast bud development is occurring 
[68].  This early in gestation, some mothers may not yet even be aware of their pregnancies, 
thus may not take proper precautions to shield their child from exposures in the workplace or 
the home.  Given the sources of PFOA exposure for non-occupationally exposed populations, 
it is unlikely that gestational exposures would be restricted to any individual window of 
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pregnancy, but rather would occur continuously at low levels, and potentially bioaccumulate, 
throughout pregnancy, including this window of susceptibility.  Thus, it is important that 
environmentally relevant compounds suggested to impact the mammary gland during this 
critical period, be assessed for their potential to produce lasting adverse health effects.     
 
Significance and Goals of the Doctoral Study 
Since 2002, when the perfluoroalkyl acid (PFAA) with similar use patterns, PFOS, 
was phased out of production due to recognized bioaccumulation in human and wildlife 
serum, PFOA has increased in production, rapidly replacing PFOS in consumer products and 
the PFC market.  Now, PFOA is recognized as having widespread and persistent distribution 
in the environment and biota.   Given the structural homology shared by PFOS and PFOA, 
and the documented toxicity of PFOS, there is much interest in characterizing toxicity posed 
by PFOA exposure.  While hepatotoxicity has been associated with PFOA exposure of 
rodents, this may not be relevant to human health because the proposed PPAR!-mediated 
mode of action responsible in rodents likely requires greater hepatic PPAR! expression than 
occurs in humans.  The developmental and reproductive toxicity profile of PFOA is only just 
beginning to be experimentally addressed, in part because the utilized animal model 
necessitated being changed from rats to mice, in order to be more accurately representative of 
human health (given the endpoints addressed).   
To date, developmental toxicity studies in the mouse suggest that prenatal PFOA 
exposure may reduce postnatal weight gain and survival among offspring.  It is hypothesized 
here, that this may be mediated by interference with dam lactation.  The mammary gland 
clearly plays a critical role in all mammalian reproduction, and adverse consequences in this 
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tissue, resulting from toxicologic exposures, have the capacity to greatly diminish the 
reproductive success of the affected individual or species.  Thus, both adult differentiation 
and early-life development of this tissue greatly merit evaluation in toxicologic screens.  
Given the suggested effects of PFOA on the mammary gland and the sensitivity of this tissue, 
combined with the incompletely understood etiology of breast cancer and possible influence 
of environmental factors, a comprehensive assessment of the effects of PFOA on the 
mammary gland is merited. 
The specific goals of this doctoral study include characterizing the effects of 
gestational exposure to PFOA on the MG in the exposed female dam and offspring, 
identifying the precise exposure conditions required for these effects in the mammary gland, 
determining any functional consequences or altered carcinogenesis risk due to these changes 
in the mammary gland, and addressing whether PFOA exposure leads to the observed 
changes in the MG by PPAR!- or non-PPAR!-mediated mode(s) of action.  In doing so, this 
doctoral study should provide extensive, desired data to address the goals set by the SAB to 
perform a complete risk assessment of PFOA, and to determine any necessary regulatory 
action to take concerning PFOA.  
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CHAPTER 2 
Gestational PFOA Exposure of Mice is Associated with Altered Mammary Gland 
Development in Dams and Female Offspring 
 
 
 
Preface 
 
 
 In this chapter, the effects of PFOA on the mammary gland were first investigated.  
This work demonstrated that the effects of gestational PFOA exposure on lactation might 
play a role in the reduced weight gain and increased neonatal mortality previously observed 
in offspring, and it also identified a significant stunting of the mammary epithelium in the 
offspring exposed prenatally and during lactation. These findings paved the way for further 
studies addressing mammary effects of developmental PFOA exposure.  The material in this 
chapter was published previously, under the following citation: 
 
White S.S., Calafat A.M., Kuklenyik Z., Villanueva L., Zehr R.D., Helfant L., Strynar 
M.J., Lindstrom A.B., Thibodeaux J.R., Wood C., Fenton S.E.  Gestational PFOA 
exposure of mice is associated with altered mammary gland development in dams and 
female offspring.  Toxicological Sciences. 2007 Mar; 96(1):133-44. 
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Abstract 
Perfluorooctanoic acid (PFOA), with diverse and widespread commercial and 
industrial applications, has been detected in human and wildlife sera. Previous mouse studies 
linked prenatal PFOA exposure to decreased neonatal body weights (BWs) and survival in a 
dose-dependent manner. To determine whether effects were linked to gestational time of 
exposure or to subsequent lactational changes, timed-pregnant CD-1 mice were orally dosed 
with 5 mg PFOA/kg on gestation days (GD) 1–17, 8–17, 12–17, or vehicle on GD 1–17. 
PFOA exposure had no effect on maternal weight gain or number of live pups born. Mean 
pup BWs on postnatal day (PND) 1 in all PFOA-exposed groups were significantly reduced 
and decrements persisted until weaning. Mammary glands from lactating dams and female 
pups on PND 10 and 20 were scored based on differentiation or developmental stages. A 
significant reduction in mammary differentiation among dams exposed GD 1–17 or 8–17 was 
evident on PND 10. On PND 20, delays in normal epithelial involution and alterations in 
milk protein gene expression were observed. All exposed female pups displayed stunted 
mammary epithelial branching and growth at PND 10 and 20. While control litters at PND 10 
and 20 had average scores of 3.1 and 3.3, respectively, all treated litters had scores of 1.7 or 
less, with no progression of duct epithelial growth evident over time. BW was an 
insignificant covariate for these effects. These findings suggest that in addition to gestational 
exposure, abnormal lactational development of dams may play a role in early growth 
retardation of developmentally exposed offspring.  
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Introduction 
Perfluorooctanoic acid (PFOA), a synthetic perfluorinated eight-carbon organic 
chemical has broad industrial applications, and is also a final, persistent degradation product 
of other perfluorinated materials [1]. The ammonium salt of PFOA has widespread use, 
particularly in the production of fluoropolymers. These fluoropolymers are highly resistant to 
degradation, and since the 1940’s have been employed in the production of consumer and 
industrial goods, including weather- and stain-resistant materials, as well as electrical, 
aeronautic, communications, and other industrial applications.  
Humans may be exposed to PFOA in occupational settings, through environmental 
exposures, or through contact with consumer goods. Confirmation of widespread exposure in 
the general population, and the biological persistence of PFOA, has come by way of survey 
studies of sera from humans [2-4] and wildlife [5]. The chemical persistence of PFOA, its 
widespread presence in humans, and the potential for increased health risk in the 
occupationally exposed have raised regulatory concern, and spurred the addition of PFOA to 
the list of contaminants to be addressed in the 2003–2004 National Health and Nutrition 
Examination Survey [6], and the proposed National Children’s Study [7].  Previously [8], 
evidence of the toxicity of PFOA appeared in the scientific literature, and shortly thereafter 
PFOA was shown to induce hepatic peroxisome proliferation in rats [9]. Today, PFOA is 
characterized as a peroxisome proliferator–activated receptor alpha (PPAR!) agonist [10, 
11]. This mode of action is expected to lead to hepatotoxicity in rodents, however, a PPAR!-
mediated mechanism for this health outcome is not considered to be relevant in humans [12]. 
Nonetheless, a PPAR! mode of action may be relevant for other responses (e.g., during fetal 
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and neonatal development), and it is important to consider that other non-PPAR!-mediated 
modes of action are possible and may lead to health effects in animals and humans.  
Other differences exist between rats and humans with respect to the toxicity of PFOA. 
One primary example is a gender difference in the elimination of PFOA by rats, whereby 
female rats excrete PFOA more rapidly than males [13].  This preferential excretion does not 
occur in humans but in rats is mediated by higher renal expression of organic anion 
transporter 2 (Oat2) in the postpubertal female rat compared to the male rat (or either gender 
of other species), and results in a significantly reduced PFOA half-life in the adult female to 
about 2 h, one seventieth of the 5.7-day half-life exhibited in an adult male rat [13]. Due to 
this rapid elimination rate, daily dosing of adult female rats leads to episodic burden of 
PFOA. Thus, the female rat may not be an appropriate animal model for studies addressing 
the potential reproductive and developmental toxicity in humans posed by PFOA. In contrast, 
expression of Oat2 in the mouse is more consistent with that in humans, and the mouse 
displays no sex-dependent elimination difference [14]. Therefore, these data suggest that the 
mouse may represent a more suitable model than the rat for human health effects, with 
respect to the reproductive and developmental toxicity of PFOA.  
Despite the gender difference in elimination, most PFOA studies have been 
performed in rats. One 2-year feeding study in rats [15] reported a statistically significant 
increase in mammary fibroadenomas compared to controls but these observations were 
deemed equivocal, as tumor rates were considered ‘‘comparable to some historical 
background indices’’ [12]. Additionally, described in this study was an increased occurrence 
of Leydig cell adenomas, suggesting that PFOA may impact a range of reproductive tissues. 
Because the mammary fibroadenoma data were regarded as equivocal by the U.S. EPA 
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Science Advisory Board, there have been recommendations to reconsider the possible impact 
of PFOA on mammary tissue [16]. Recent data from Lau et al. [14] indicated a decrease in 
postnatal weight gain in mouse pups following oral exposure on gestation days (GD) 1–17 to 
5 mg PFOA/kg body weight (BW), without the dramatic effects on postnatal survival that 
were seen with higher doses of PFOA (< 30% survival among 10 and 20 mg PFOA/kg BW 
exposures). Because neonatal BW gain is highly dependent upon the quantity and quality of 
milk received from the dam, these findings may reflect nutritional deficits associated with 
mammary gland alterations in lactating dams, in utero toxicity, or some combination of the 
two.  
These observations led us to examine the specific effects of PFOA on the mouse 
mammary gland. In addition to the direct influence of PFOA on developing maternal 
mammary tissue, the possible role of impaired lactation in PFOA-exposed dams on neonatal 
BW gain and survival was investigated. Furthermore, the impact of prenatal PFOA exposure 
on neonatal mammary gland development in female pups was evaluated as a developmental 
toxicity endpoint. For this purpose, exposure was timed to correspond with known 
gestational windows of sensitivity for offspring mammary gland development (most 
lactational mammary gland development in dams occurs during the second half of gestation 
[GD 9–18], whereas the mammary bud in offspring forms after GD 13 in the mouse; [17]. 
Hence, the effects of PFOA on differentiation and development of mammary tissue were 
determined in both the dam and female offspring, in order to describe the as yet unknown 
effects of PFOA on this important developing tissue, and move toward further characterizing 
the mode(s) of action of PFOA toxicity in tissues other than the liver.  
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Materials and Methods  
Animals.  Timed-pregnant CD-1 mice were acquired from Charles River Laboratories 
(Raleigh, NC). Sperm-positive females were designated GD 0, and delivered on the same day 
to U.S. EPA’S Association for Assessment and Accreditation of Laboratory Animal Care 
facilities. Animals were weighed upon arrival and randomly distributed among four treatment 
groups. Mice were housed individually in polypropylene cages and received food (LabDiet 
5001, PMI Nutrition International LLC, Brentwood, MO) and tap water ad libitum. Animal 
facilities were maintained on a 14:10-h light-dark cycle, at 20–24°C with 40–50% relative 
humidity. All animals were found to be free of infectious diseases prior to beginning the 
study. All animal protocols were reviewed and approved by the U.S. EPA’s National Health 
and Environmental Effects Research Laboratory Institutional Animal Care and Use 
Committee.  
 
Dosing Solution and Procedures.  PFOA as its ammonium salt (> 98% pure) was 
acquired from Fluka Chemical (Steinhiem, Switzerland). PFOA dosing solution was prepared 
fresh daily in deionized water, at a concentration of 0.5 mg/ml. Mice received either water 
vehicle or PFOA at 5 mg/kg BW by oral gavage, once daily over the dosing periods 
described below. The dose of 5 mg PFOA/kg BW/day was chosen based on previous work 
that found this dose to reduce neonatal BW gain [14]. This dose was not meant to reproduce 
average human serum PFOA concentrations in the United States, as the current range of 
mean serum PFOA in humans is between 5.6 ng/ml (general biomonitoring; [4]) and 329 
ng/ml (no occupational exposure, but potential community exposure; [2]).  
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Experimental Design.  Sixty dams, divided equally among two blocks, were treated 
once daily on GD 1–17 (N = 14 dams), 8–17 (N = 16 dams), or 12–17 (N = 16 dams) with 5 
mg PFOA/kg BW, or on GD 1–17 with water vehicle (control, N = 14 dams).  Dams were 
weighed daily throughout gestation. At birth, pups were individually weighed and sexed. 
Pups were pooled and randomly redistributed among the dams of respective treatment 
groups, and litters were equalized to 10 pups (both genders represented). Dams which 
delivered small litters (N < 4 pups) were excluded from the remainder of the study. On 
postnatal days (PND) 5, 10, and 20 the litters were weighed, and average neonatal BWs were 
calculated. Half of the dams and respective litters in each treatment group were randomly 
chosen and necropsied at PND 10. Remaining dams and litters were necropsied on PND 20. 
Figure 2-1 graphically depicts this study design.  In a separate study, timed-pregnant CD-1 
mice (N = 5 per group) were dosed GD 1–17 with 0 or 5 mg PFOA/kg BW/day and 
sacrificed on GD 18 to evaluate, via whole mount, the development of the maternal 
mammary gland prior to parturition and ensuing lactation.  
 
Necropsy.  Dams and pups were sacrificed on PND 10 or 20 by decapitation and 
trunk blood was collected and stored at -80°C in polypropylene tubes for dosimetric studies. 
At the time this study was initiated, no validated protocol for serum PFOA measurements 
was available to us. Therefore, pup blood and unperfused liver (quick frozen under dry ice) 
were collected and maintained at -80°C for use in (at the time undetermined) future studies.  
 46 
 
 
 
 
Figure 2-1. Study design. Time-pregnant CD-1 mice received 5 mg PFOA/kg BW/day for 
different periods of gestation, depicted by bar lengths, ending on GD 17. Stars represent BW 
data collection (for both dams and pups after PND 1). Other data collection time points are 
also shown. 
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Extra pups remaining from individual treatment groups at PND 1 (following equalization of 
litters) were euthanized and livers removed and frozen as stated for future studies. The fourth 
and fifth inguinal mammary glands were collected from dams and female pups on PND 10 
and 20. One side was prepared as whole mounts, and portions of the contralateral glands 
were placed either in TRI Reagent (Sigma-Aldrich Corp., St Louis, MO) for RNA isolation, 
or in 10% neutral buffered formalin for histological preparation. Uteri were dissected from 
dams to determine the number of implantation sites.  
 
Uterine Implantation.  Upon removal, uteri were placed in phosphate-buffered saline. 
The number of uterine implantation sites per dam was visually determined by light 
macroscope (Leica WILD M420 macroscope, Leica, Wetzlar, Germany), to evaluate rates of 
postimplantation loss.   
 
Mammary Gland Preparations.  Mammary glands were removed on PND 10 and 20 
because these time points represent peak lactational output from the dam, and the time that 
pups begin to wean themselves from the dam, respectively. The entire fourth and fifth glands 
were removed from dams and female pups, and mounted flat on glass slides. Whole mounts 
were fixed in Carnoy’s solution, stained in alum carmine stain, and dehydrated and cleared in 
xylene, as previously described [18]. A portion of the contralateral mammary glands was 
removed on PND 10 and 20, placed in a histology cassette, fixed in 10% neutral buffered 
formalin for 48 h, and stored in 70% ethanol. The glands were paraffin-embedded and 5-lm 
sections were prepared and stained with hematoxylin and eosin (H & E). Whole mounts and 
histological sections were visualized by light macroscope (magnification up to 370).   
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Mammary gland whole mounts from female offspring were scored on a 1–4 
subjective, age-adjusted developmental scale (as described in [19]; 1 = poor 
development/structure; 4 = normal development/structure, given age). The developing tissue 
was assessed for number of primary ducts, number of large secondary ducts, and lateral side 
branching, appearance of budding from the ductal tree and longitudinal outgrowth of the 
epithelia. Slides were separated by score as they were evaluated, compared within a score for 
consistency, and then recorded. Two independent scorers, blind to treatment, scored glands 
within the age groups. Mean scores for the two ages, within treatment groups, were 
calculated and analyzed statistically for treatment and time-related differences.  
Maternal mammary gland H & E slides were similarly subjectively scored.  The 
differentiated tissue was assessed for amount of epithelial tissue filling the gland, presence of 
well formed, productive alveoli (lipid/milk), and in the case of the involuting tissue (PND 
20), the normal presence of apoptotic bodies and regressing alveoli. Typical mammary 
glands, representing the mean score for each treatment group, were photographed using the 
above described macroscope and mounted camera (Photometrics CoolSNAP, Roper 
Scientific, Inc., Tucson, AZ).  
 
Real-Time Polymerase Chain Reaction.  Total RNA was extracted from lactating 
glands using TRI reagent according to the manufacturer’s suggestions, employing two 
chloroform extractions, and dissolving the RNA pellet in RNase-free water. Samples were 
digested with DNAse I (Promega M6101; Madison, WI) and quantitated using RiboGreen 
reagent (Invitrogen R11490; Carlsbad, CA) according to the manufacturer’s instructions. 
RNA was then reverse transcribed (ABI complementary DNA [cDNA] Archive kit 4322171; 
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Foster City, CA) and 10 ng (for !-casein and !-lactalbumin [!-Lac]) or 50 ng (for epidermal 
growth factor [EGF] and lactotransferrin [LactoF]) of the corresponding cDNA was 
amplified in a reaction containing 0.4mM deoxy-nucleotide triphosphate, 8mM MgCl2, 13 
Platinum Taq buffer (Invitrogen 10966-034), 1 U Platinum Taq enzyme, 0.24lM forward 
primer, 0.24lM reverse primer, and 0.12lM dual-labeled fluorescent probe. Dual-labeled 
(fluorescein, BHQ) hydrolysis probes were synthesized by IDT (Coralville, IA) according to 
the sequences shown in Table 2-1. PCR cycling conditions were an initial 95°C for 3 min, 
then 40 cycles of 95°C for 15 s, 60°C for 20 s, 72°C for 10 s. Quantitative real-time PCR was 
performed in a BioRad iCycler (LaJolla, CA). All samples were run in duplicate. A cDNA 
standard was synthesized for each gene and quantitated using PicoGreen (Invitrogen P7589). 
Known quantities of this cDNA were diluted and amplified in each plate to generate a 
standard curve for each particular gene. Each RNA sample was compared to the gene-
specific standard cDNA curve to determine relative copy number.  
 
Blood Dosimetry.  After collection, blood specimens were stored at -80°C until 
shipped on dry ice to the Centers for Disease Control and Prevention’s (CDC) National 
Center for Environmental Health, and frozen at -40°C until analysis. PFOA in blood was 
semiquantitatively measured through a multiple reaction monitoring experiment using online 
solid-phase extraction coupled to reversed-phase high-performance liquid chromatography-
tandem mass spectrometry (HPLC/MS), as described [20]. The necessary dilution of blood 
samples was performed in two steps. First, at least 10 "l of blood was diluted to 1 ml with 
water in a 2-ml polypropylene tube, then a second dilution was performed by aliquoting the 
appropriate amount of the diluted sample into an autosampler vial and adding blank calf  
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Table 2-1.  Primer and probe sequences for milk protein gene products.  
Primer and Probe Sequences 
  Forward Reverse Probe 
Gene Transcript    
   ß-Casein GCCAGTCTTGCTAATCTGCACC GAGTCTGAGGAAAAGCCTGAACAA AGTCTCTGGTCCAGCTCCTGGCACA 
   EGF GCAACTGTGTTATTGGCTATTCTGG TGTCATGCTTCTGCCCGTAG TCGAGACCTACGATGGTGGGAGCTG 
   !-Lac TGCATTTCGTTCCTTTGTTCC TTAATGGCATGGGACACCTGG CGTTGCCTGCCTTTCAAGCCACA 
   LactoF ATCCCTTGAGGAAGCGGTATC ACACGAGCTACACAGGTTGGG TGTGTTCCCGGTGCCCAAAAGGA 
EGF, epidermal growth factor;  !-Lac, alpha-lactalbumin; LactoF , lactoferrin.   
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serum (calibration standards also contained blank calf serum). The diluted blood sample was 
further diluted with 0.1M formic acid and injected into a commercial column switching 
system allowing for concentration of PFOA on a C18 solid-phase extraction column.  The 
column was automatically positioned in front of a C8 analytical HPLC for chromatographic 
identification of PFOA.        
Detection and quantification utilized negative-ion TurboIonSpray ionization, a variant 
of electrospray ionization, tandem MS. The isotope-labeled internal standard used for 
quantification was 1,2-
13
C2-PFOA. Quality control (QC) materials, prepared in calf serum, 
were analyzed with the samples to ensure the accuracy and reliability of the data [20]. The 
analytical batch consisted of nine calibration standards and 61 samples (including two high-
concentration QCs [QCH], two low-concentration QCs [QCL], two reagent blanks, and one 
serum blank). The concentrations of the two QCH and the two QCL were evaluated and 
averaged to obtain one measurement of QCH and of QCL per batch, using standard statistical 
probability rules. Because of the high dilution factors and the fact that blood instead of serum 
was used for the measurements (the analytical method is validated for serum), only estimated 
values of PFOA concentration ranges are provided.  
Ranges of PFOA concentration (ng/ml) were reported and were rounded up to create 
five categories, (< 100 = 100;  100–499 = 500;  501-<10x10
3
 = 10x10
3
;  10x10
3
-<20x10
3
 = 
20x10
3
;  >20x10
3
 = 50x10
3
) in order to calculate an estimated mean for each treatment 
group. These values were rounded up so that the values in the lowest concentration range did 
not appear to be 1 ng/ml (near the limit of detection of 0.1 ng/ml). PFOA ranges in dams and 
their pups within this study can be directly compared, and changes in burden over treatment 
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times can be compared but absolute blood concentrations could not be determined in this 
study, and statistical differences were not calculated.  
 
Liver Dosimetry.  Livers from PND 1, 10, and 20 offspring were weighed and 
analyzed at the U.S. EPA National Exposure Research Laboratory for PFOA concentration 
using a method that is a variation of a procedure previously described [21]. 1,2-
13
C2-PFOA 
was purchased from Perkin-Elmer (Wellesley, MA) and used as the internal standard for 
quantitative analyses. Pentadeca-fluorooctanoic acid ammonium salt was obtained from 
Fluka and used as unlabeled standard. Liver samples were homogenized in water. If the 
tissue sample was sufficiently large the proportions were 1 g tissue + 6 ml water.  Smaller 
tissue samples were homogenized as 10 mg tissue + 100 !l of water. Twenty-five microliters 
of the homogenate was added to a 15 ml polypropylene tube along with 1 ml of 0.5 M 
tetrabutylammonium hydrogen sulfate (pH 10) and 2 ml of 0.25 M sodium carbonate. The 
mixture was vortexed for 20 min. Three hundred microliters of this mixture was transferred 
to a fresh 15 ml polypropylene tube and 25 !l of 1,2-
13
C-PFOA (1ng/!l) was added. Five 
milliliters of MTBE [methyl tert-butyl ether] was added and the mixture was vortexed for 20 
min. The tube was centrifuged for 3 min at 3500 rpm. One milliliter of the MTBE layer was 
withdrawn and transferred to a 5-ml polypropylene tube and evaporated to dryness at 45°C 
with a gentle stream of nitrogen. The residue was dissolved in 400 !l 1:1 with 2mM 
ammonium acetate-acetonitrile, placed into an autosampler vial and analyzed by HPLC-
MS/MS. Samples were analyzed using an Agilent 1100 HPLC system coupled with a Sciex 
API 3000 triple quadrupole MS. The HPLC was equipped with a Phenomenex (Torrance, 
CA) Luna C18(2) 50 x 3.0 mm, 5-!m pore size column. Samples were chromatographically 
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separated using an isocratic mobile phase consisting of 1:1 mix of 2mM ammonium acetate 
and acetonitrile at a flow rate of 200 !l/min. The Sciex API 3000 MS was operated in the 
MS/ MS mode using negative-ion TurboIonSprayJ ionization. The transitions monitored 
were PFOA (m/z 413–369) and 
13
C2-PFOA (m/z 415–370). Area counts for each analyte are 
determined automatically using the Analyst software provided with the API 3000. Area ratios 
(AR) of analyte to internal standard were used in the construction of matrix matched 
calibration curves (r
2
 > 0.99). Quantitation of PFOA in unknown samples and quality 
assurance / QC samples were derived from the AR predicted by the calibration curves. The 
lowest standard curve point was 500 ng/g for the PND 20 livers and 250 ng/g for the PND 10 
and 1 liver samples (represents the limit of quantification). The amount of PFOA is presented 
on a liver weight basis.  
 
Statistical Analysis.  Data were evaluated for age and exposure period effects by 
analysis of variance (ANOVA) using a general linear model (Statistical Analysis System 
[SAS] version 9.1, SAS Institute, Inc. Cary, NC). Block effects were not detected in any test 
and therefore block was removed from the model. Means were evaluated and effects of 
exposure periods compared. Treatment group-specific mean BWs were calculated for dams 
daily throughout gestation, and for pups (with litter as the unit of measure) on PND 1, 5, 10, 
and 20. Percentage of postimplantation loss was calculated for the four treatment groups, and 
mean developmental scores for mammary glands were calculated. Differences between 
treatment groups were determined using Dunnett’s t-tests (significance at the level of p < 
0.05), with SAS. Mammary gland scores were analyzed using BW at time of collection (as 
well as litter, for neonatal mammary gland scores) as a covariate. Mean numbers of starting 
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milk protein gene transcripts were calculated and compared to control (via one-way 
ANOVA, SAS), to determine significant changes in expression for the genes described 
(shown as percent difference from control levels). Liver PFOA concentrations were 
compared on a liver weight basis using a factorial ANOVA to detect differences due to 
PFOA exposure periods between age (PND 1, 10, 20).  
 
Results 
Body Weight.  Maternal weight gain during pregnancy was similar between groups, 
and no effect of PFOA exposure or period of treatment was apparent (Table 2-2). Visual 
examination of uteri following necropsy allowed determination of total number of uterine 
implantation sites. No effect of treatment on mean number of implantation sites, live pups 
born, and embryonic/fetal loss rates was observed (Table 2-2). A comparison of pup BW 
over time and exposure period is also shown in Table 2-2. On PND 1, BWs among prenatally 
PFOA-exposed pups were significantly reduced in an exposure duration-dependent manner 
by 3% (GD 12–17), 7% (GD 8– 17), and 12% (GD 1–17), compared to controls (p < 0.001). 
On PND 5, mean BWs for PFOA-exposed pups were further reduced compared to controls 
(by 23, 35, and 40%, respectively; p < 0.001), also in an exposure duration-dependent 
manner. This effect was sustained throughout the lactational period in all PFOA-treated 
groups, as treated offspring remained smaller than controls at both PND 10 (by 25, 31, and 
39%, respectively; p < 0.05) and PND 20 (by 26, 27, and 33%, respectively; p < 0.001). The 
BW deficit compared to controls, within each treated group, was maximal by PND 5. Taken 
together, the lack of effect of PFOA exposure on the mean number of implantation sites, 
numbers of live pups born, percent preimplantation loss, and maternal weight gain suggest  
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Table 2-2.  Maternal indices and offspring body weight.  
PFOA Exposure Periods 
  
Control GD 12-17 GD 8-17 GD 1-17 
Maternal gestational weight gain (g) 
Implants (# per live litter) 
24.8 ± 1.9 
11.7 ± 1.0 
23.5 ± 1.4 
10.9 ± 0.9 
25.6 ± 0.9 
11.8 ± 0.7 
27.1 ± 0.8 
14.0 ± 0.9 
Live fetuses (# per live litter) 10.8 ± 1.0 10.2 ± 0.8 11.1 ± 0.6  11.1 ± 1.0 
Prenatal loss (% per live litter) 7.7 ± 3.0 5.7 ± 2.2 5.9 ± 2.0 20.3 ± 5.1* 
Neonatal body weight (g) at age     
   PND 1 1.65 ± 0.02 1.60 ± 0.01 *** 1.53 ± 0.02 *** 1.45 ± 0.03 *** 
   PND 5 3.8 ± 0.1 2.9 ± 0.1 *** 2.5 ± 0.1 *** 2.3 ± 0.2 *** 
   PND 10 6.8 ± 0.3 5.1 ± 0.4 * 4.7 ± 0.2 ** 4.1 ± 0.4 ** 
   PND 20 11.6 ± 0.2 8.6 ± 0.6 *** 8.4 ± 0.4 *** 7.7 ± 0.4 *** 
Note: Data presented are mean ± SE.  Maternal weight gain is shown for entire period of GD 1-17. 
N = 7-11 litters per treatment group at PND 1 and 5.  
N = 4-6 dams/litters per treatment group at PND 10.  
N = 3-6 dams/litters per treatment group at PND 20.   
GD = gestation day, PND = postnatal day.   
*Significant treatment effect by ANOVA; p < 0.05.   
**Significant treatment effect by ANOVA; p < 0.01.   
***Significant treatment effect by ANOVA; p < 0.001. 
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that the observed reductions in neonatal BW at birth and throughout lactation were not due to 
general maternal toxicity (as defined in [22]) or to a difference in pup number per dam.  
 
Lactating Mammary Gland Development.  Mammary glands from dams on PND 10 
and 20 were examined for morphological differentiation, which included subjective scoring 
of H & E–stained sections, as well as a comparison of mammary whole mounts. On PND 10, 
typically the peak of lactation in rodents, dams treated during GD 8–17 and GD 1–17 
exhibited significant visible delays in epithelial differentiation (Fig. 2-2A; GD 8–17 not 
shown) and developmental scores compared to controls (Table 2-3, p < 0.05 and p < 0.001, 
respectively), and these glands morphologically resembled those of dams days earlier in 
lactation. Altered differentiation was visible in glands of GD 12–17 exposed dams, however, 
these changes were not statistically significant with respect to score. In the affected glands, 
excessive adipose tissue remained, whereas in the control dam the gland was fully occupied 
by well differentiated, extensive milk-filled alveoli. In lactating dams examined at PND 20, 
control glands displayed signs of involution, normally found at this developmental time 
point, immediately prior to weaning. By contrast, glands from dams in all PFOA exposure 
groups at PND 20 had few apoptotic bodies, little visible adipose tissue, and displayed milk-
filled alveoli, appearing quite similar to the glands of control animals at PND 10 (peak 
lactation). Therefore, in addition to a treatment-related effect (p < 0.05), there was also a 
significant effect of time within exposure parameter (p < 0.05, significant time 3 treatment 
interaction) on the postnatal course of mammary gland differentiation and lactation (evident 
from mean scores in Table 2-3). These data suggest a substantial delay (possibly up to 10 
days) in differentiation of the glands from dams exposed to PFOA throughout gestation.  
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Figure 2-2. Development of maternal mammary glands of mice exposed to PFOA on GD 1–
17. Glands were removed and prepared on PND 10 and 20, or GD 18. (A) H & E–stained 
sections of mammary glands at 370 showing significantly (p < 0.001 at PND 10) delayed 
development stemming from PFOA exposure (N = 4– 6 dams per treatment group at PND 
10, N = 3–6 dams per treatment group at PND 20). (B) Whole mount preparations of 
mammary tissue from dams on GD 18 at 320 (N = 4 control dams, N = 3 GD 1–17 PFOA 
dams). Glands shown are representative of mean respective scores (Table 2-2). Arrows point 
to adipose tissue. 
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Table 2-3. Mammary gland developmental scores at PND 10 and 20. 
PFOA Exposure Parameters 
  
Control GD 12-17 GD 8-17 GD 1-17 
Lactating maternal MG at time     
   PND 10 4.0 ± 0.0 3.7 ± 0.1 3.2 ± 0.2 * 1.8 ± 0.5 *** 
   PND 20 2.7 ± 0.2 2.8 ± 0.2 3.2 ± 0.1 3.3 ± 0.2 
Developing neonatal MG at age     
   PND 10 3.1 ± 0.2 1.7 ± 0.1 *** 1.4 ± 0.1  *** 1.6 ± 0.2  *** 
   PND 20 3.3 ± 0.2 1.4 ± 0.1  *** 1.5 ± 0.1  *** 1.8 ± 0.3  *** 
Note: Data presented are mean ± SE.  Scores are on 1-4 scale; criteria adjusted for stage of development and age. 
N = 4-6 dams/litters per treatment group at PND 10.  
N = 3-6 dams/litters per treatment group at PND 20.   
MG = mammary gland, GD = gestation day, PND = postnatal day.   
*Significant treatment effect by ANOVA; p < 0.05.   
***Significant treatment effect by ANOVA; p < 0.001. 
 59 
 
To determine if delayed differentiation of the mammary glands in PFOA-exposed 
dams resulted from their gestational exposure, or from an effect of PFOA on the thriftiness of 
pups -- that is, their ability to suckle and sufficiently stimulate lactation -- glands of GD 1–17 
dams were evaluated on GD 18 by whole mount analysis (mean score ± SE: control = 3.9 ± 
0.1; GD 1–17 = 2.0 ± 0.6; p < 0.015). As shown in Figure 2-2B, control glands were 
saturated with milk-filled alveoli, whereas the PFOA-exposed glands were not, and exhibited 
stunted alveolar development (spiked appearance). These observations suggest that this 
alteration in functional mammary gland differentiation occurs prior to stimulation of the 
gland by offspring.  
 
Milk Protein Gene Expression.  To assess the association of altered milk content with 
reduced weight gain among PFOA-exposed offspring during lactation, and to evaluate 
physiologic aspects of lactation in dams, gene expression profiles of several milk protein 
genes were evaluated at PND 10 and 20 in maternal mammary tissue. Gene expression 
patterns for milk proteins in maternal mammary glands, shown as percentage difference from 
control levels at the same time point, can be seen in Figures 2-3 and 2-4. For comparative 
purposes, the number of molecules of each milk protein transcript is reported in Table 2-4. !-
casein and EGF are proteins normally present in milk, reaching their peak concentrations by 
PND 10 and PND 6, respectively [23, 24]. Although isolated significant differences were 
apparent, there was no clear and consistent pattern of effect of PFOA exposure on gene 
expression levels for these two milk proteins. The differences that were apparent were  
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Figure 2-3.  PND 10 milk protein gene expression in mammary gland tissue of dams exposed 
to PFOA for various periods ending on GD 17. Gene expression is depicted as percent 
difference from mean control tissue expression of respective genes. Statistical significance of 
number of starting molecules (Table 2-3) is depicted by asterisks, where *p < 0.05, and ***p 
< 0.001 (N = 4–6 dams per treatment group). 
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Figure 2-4.  PND 20 milk protein gene expression in mammary gland tissue of dams exposed 
to PFOA for various periods ending on GD 17. Gene expression is depicted as percent 
difference from mean control tissue expression of respective genes. Statistical significance of 
number of starting molecules (Table 2-3) is depicted by asterisks, where ***p < 0.001, and 
where ‡p < 0.055 (N = 3–6 dams per treatment group). 
 62 
 
 
 
 
Table 2-4.  Milk protein gene expression in lactating MG on PND 10 and 20. 
PFOA Exposure Parameters 
  
Control GD 12-17 GD 8-17 GD 1-17 
ß-Casein         
   PND 10 62.3 ± 4.8 E+07 55.1 ± 5.9 E+07 73.3 ± 5.1 E+07 * 68.0 ± 5.9 E+07 
   PND 20 8.7 ± 0.8 E+07 10.7 ± 1.9 E+07 8.2 ± 0.6 E+07 11.2 ± 1.7 E+07 
EGF     
   PND 10 8.0 ± 0.8 E+04 8.4 ± 1.4 E+04   13.6 ± 1.4 E+04 *** 10.7 ± 0.7 E+04 * 
   PND 20 2.0 ± 0.5 E+04 4.0 ± 2.1 E+04 3.0 ± 0.6 E+04 4.4 ± 0.2 E+04 ‡ 
!-Lac     
   PND 10 42.1 ± 2.3 E+06 30.7 ± 4.0 E+06 *** 38.5 ± 4.3 E+06 42.7 ± 3.0 E+06 
   PND 20 2.4 ± 0.3 E+06 2.5 ± 0.8 E+06 1.7 ± 0.2 E+06 2.1 ± 0.4 E+06 
LactoF     
   PND 10 11.8 ± 2.5 E+06 9.4 ± 1.3 E+06 16.6 ± 3.0 E+06 26.3 ± 7.3 E+06 * 
   PND 20 41.1 ± 10.5 E+06    19.4 ± 8.3 E+06 *** 8.6 ± 2.1 E+06 *** 10.4 ± 4.0 E+06 *** 
Note: Data presented are mean ± SE of milk protein transcripts.   
N = 4-6 dams per treatment group at PND 10.  
N = 3-6 dams per treatment group at PND 20.   
MG = mammary gland, GD = gestation day, PND = postnatal day.  
EGF = epidermal growth factor, !-Lac = alpha-lactalbumin, LactoF = lactoferrin.   
*Significant treatment effect by ANOVA; p < 0.05.   
‡ p = 0.055.   
***Significant treatment effect by ANOVA; p < 0.001. 
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greatest between the intermediate-duration treatment exposure group (GD 8–17) and the 
control group, and did not occur in an exposure duration-dependent manner.  
!-Lac is a common whey protein in milk, reaching peak concentrations between PND 
6 and 10 [25]. On PND 10, mammary tissue from dams with the shortest exposures (GD 12–
17) exhibited significantly reduced expression of !-Lac (p < 0.001). On PND 20, however, !-
Lac expression was recovered in this treatment group. LactoF is a protein with antimicrobial 
properties that is commonly present in milk, with highest levels early and late in lactation 
(when the risk of infection is highest; [25]). On PND 10, expression of LactoF was elevated 
in gland extracts from dams with the longest exposures (p < 0.01), suggesting that the early 
lactation peak of this milk protein was delayed in the GD 1–17 treatment group. By PND 20, 
however, this pattern was reversed, and GD 1–17 dams, as well as dams with shorter 
exposures (GD 8–17, GD 12–17), exhibited significantly lower LactoF expression compared 
with control animals, suggesting again that the late lactation peak of this milk protein had not 
yet taken place. While this may initially appear to conflict with the histologic findings, a 
closer examination suggests that LactoF levels on PND 20 in exposed animals are quite 
similar to control levels on PND 10 (Table 2-4), which is consistent with the postulated 10-
day delay in mammary gland development.  
 
Blood PFOA Concentration Range.  At the time the animal experiments were 
conducted, no validated method for measurement of PFOA in blood was available to the 
authors, and thus whole blood and liver were collected at necropsy in order to preserve all 
possible sources of information. Although a validated method for the quantitative 
measurement of PFOA in serum now exists [20], a validated method for blood was not 
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available. Because we felt it was important to compare relative levels of PFOA in the dams 
and offspring within this study, trunk blood, collected at necropsy, was diluted to 
semiquantitatively determine the concentration range of PFOA. PFOA concentration ranges 
on PND 10 and 20 in maternal and neonatal blood are shown in Figure 2-5A. Instead of 
decreasing over time as is seen in the serum of adult, nonlactating females [14], maternal 
blood PFOA concentration ranges remained fairly constant between PND 10 and 20, within a 
treatment group, and increasing duration of gestational exposure was correlated with 
increased blood concentration ranges postnatally. However, a drop in maternal blood PFOA 
in our study may have been disguised by the concentration ranges to which values were 
assigned. On PND 10, offspring consistently exhibited higher blood PFOA concentration 
ranges than dams but by PND 20 dams exhibited similar or higher (for GD 1–17 only) blood 
PFOA concentration ranges than offspring. Therefore, unlike their dams, the offspring in 
these studies decreased their blood PFOA concentrations between PND 10 and 20 by nearly 
half. Our blood PFOA estimations were consistent with the concentrations in mouse serum 
under the same dose and exposure length ([26]; at weaning, 5U+L dam = 36,900 ng/ml and 
pup = 22,114 ng/ml vs. our PND 20 dam = 45,000 ng/ml and pup = 33,000 ng/ml), and 
obtained using the validated serum method [20]. However, we expected that the serum levels 
reported in Wolf et al. [26] would slightly exceed our estimates of PFOA in blood (and they 
did not), in accordance with reports of direct comparisons of those media in humans [27]. 
This may be due not to the matrix but to the high dilution factor involved in obtaining the 
blood PFOA concentrations (making it necessary to group the data, and possibly forcing the 
means slightly higher than they would be if grouping hadn’t been required). 
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Figure 2-5. PFOA concentration ranges in maternal and pup blood (A, mean concentration 
range) and pup liver (B, mean ± SE) following gestational exposure. The semiquantitative 
blood PFOA concentration ranges (ng/ml) were rounded up to create five categories: < 100 = 
100, 100–499 = 500, 501–< 10 x10
3
 = 10 x 10
3
, 10 x 10
3
–< 20 x10
3
 = 20 x 10
3
, > 20 x 10
3
 = 
50 x 10
3
.  Longer duration of exposure consistently increased PFOA levels in blood in both 
dams and pups, as well as pup liver (shown as ng/g liver), at both 10 and 20 days postnatally. 
bValues that were below the level of quantitation are reported as 0 (controls only). Mean ± 
SE PFOA concentrations are shown as significantly lower than PND 1 and 10 concentrations 
(
a
p < 0.05). N = 4–6 litters per treatment group at PND 10, N = 3–6 litters per treatment 
group at PND 20. 
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Due to the semiquantitative nature of the blood data, we also quantitatively analyzed 
the PFOA content in livers of the PND 1, 10, and 20 offspring. This was done to (1) clarify 
the relationship between blood and liver PFOA levels within offspring of a particular 
treatment group and (2) determine that the liver PFOA levels in the offspring followed the 
same trend as the blood PFOA levels within and between treatment groups, thereby lending 
credence to the blood data. Measured accuracy for matrix-matched high QC samples was 
98.1% (cv. 5.8%) and for low QC samples 107.3% (cv. 4.1%). Replicate analysis of 
unknown liver samples (n = 26) over the course of analysis had a cv. of 6.3%.Values that fell 
below the level of quantitation are reported as 0 (controls only). Figure 2-5B graphically 
demonstrates that the liver PFOA concentration in prenatally exposed female offspring was 
very large and higher than the blood concentrations regardless of time since exposure (PND 
1, 10, or 20) or amount of time exposed (exposure period). Further, the liver PFOA 
concentrations on PND 1 and 10 are statistically similar within an exposure group, and 
decreased significantly to nearly ! their original value by PND 20 in all exposure groups. 
The mean liver:blood PFOA concentration ratios were 2.5 at PND 10 (for all exposure 
groups) and varied between 1.9 and 3.0 at PND 20.  
   
Offspring Mammary Gland Development.  To determine if prenatal exposure of pups 
to PFOA, even for only 6 days (1/3 of gestation), resulted in altered mammary gland 
development, whole mounts from female offspring at PND 10 and 20 were prepared and 
analyzed. The effects of exposure duration on morphological development were of particular 
interest. Mean developmental scores for the pups under different exposure parameters at 
PND 10 and 20 are shown in Table 2-3, and Figure 2-6 depicts representative glands that  
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Figure 2-6. Mammary gland development in female pups gestationally exposed to PFOA.  
Whole mount preparations of mammary tissue from female offspring at PND 10 and 20 at 
320. Glands shown are representative of mean respective scores (Table 2-2; N = 4–6 litters 
per treatment group at PND 10, N 3–6 litters per treatment group at PND 20). 
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correspond to the mean scores within each group. Mammary gland epithelial branching and 
longitudinal growth was significantly stunted among all PFOA-exposed offspring at both 
PND 10 and 20, compared to control (Table 2-3, p < 0.001). Normal progression of growth 
was observed in control tissues between PND 10 and 20, with mean developmental scores of 
3.1 and 3.3, respectively. All treated groups lacked this normal progression, and had mean 
scores of 1.7 or less. Despite the growth retardation noted in exposed offspring (Table 2-2), 
BW was not a significant covariate for the observed mammary effects. Furthermore, while it 
was reduced, neonatal growth did occur and BW was gained between PND 10 and 20 in the 
PFOA-exposed pups (weight increased from PND 10 to PND 20 by 1.7-, 1.7-, 1.8-, and 1.9-
fold in controls, GD 12–17, 9–17, and 1–17 PFOA-exposed pups, respectively) but virtually 
no mammary gland development occurred during this period of normally allometric growth 
(there was an insignificant time x treatment interaction). In addition, the relative blood and 
liver levels of PFOA in pups decreased over this time, suggesting that these PFOA 
concentrations were sufficient to significantly affect mechanisms necessary for early 
epithelial outgrowth and branching. 
  
Discussion  
This study demonstrated that a 5 mg PFOA/kg BW/day exposure delivered 
throughout (GD 1–17) or during the second half of gestation (GD 8–17) was sufficient to 
significantly alter normal lactational development of maternal mammary glands in the 
absence of effects on maternal weight gain during the dosing period. Furthermore, this dose 
of PFOA for as short an exposure as the final 6 days of gestation (GD 12–17) was sufficient 
to significantly retard neonatal growth and halt female pup mammary epithelial proliferation. 
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The delay in functional differentiation of the lactating mammary gland may be a direct effect 
of PFOA on the gland or may indicate that offspring are not sufficiently thrifty as to 
stimulate normal lactational development.  
The low PND 1 neonatal BWs observed in this study are in agreement with the 
reports of Lau et al. [14] and Wolf et al. [26]. Reduced PND 1 BWs among PFOA-exposed 
pups suggest that gestational PFOA exposure alone may be sufficient to impair neonatal 
growth and development. This conclusion is supported by the findings of a collaborative 
cross foster study [26], in which pups exposed to 5 mg PFOA/kg BW/day from GD 1–17 and 
fostered to a control dam exhibited significant deficits in total BW gained between PND 1 
and PND 22 (although, female pups born to control dams and fostered to dams exposed to 5 
mg PFOA/kg BW/day from GD 1–17 also exhibited significant BW deficits at PND 2–4 and 
PND 22). The effects of PFOA exposure on neonatal growth may impact the ability of 
offspring to nurse from dams, thus interfering with the feeding stimulation essential for 
optimal lactation, and impacting lactational mammary gland differentiation and nutritional 
transfer to the pups. Support for this idea is provided in this study by the significant delays 
observed in lactational mammary gland development of PFOA-exposed dams by PND 10, 
which is associated chronologically with the period of neonatal life that exhibited the most 
dramatic PFOA- induced growth retardation.  
Conversely, observations of mammary glands isolated from GD 18 dams in on-going 
studies, under the same exposure dose and time, suggest that PFOA exposure induces 
delayed mammary gland differentiation prior to parturition. Thus, altered gland development 
cannot be entirely accounted for by underdeveloped offspring and insufficient stimulation by 
suckling. It is also possible that even with the morphological effects of PFOA on the lactating 
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gland, sufficient functional capacity remains, such that the growth and development of litters 
may be supported. The number of molecules encoding four major milk proteins was not 
different in an exposure duration-dependent manner between control and PFOA-exposed 
animals, suggesting that the normal differentiation of the gland was not physiologically 
altered but that the amount of epithelium producing the proteins (and thus total milk output) 
was diminished due to the delayed process. The present studies have not yet addressed the 
volume of milk produced by PFOA-exposed dams. Unresolved issues regarding the 
mediation of neonatal growth deficits are under study in our laboratory and will include 
examination of the mammary glands from dams in a cross-foster paradigm.  
A novel finding and another factor for consideration with respect to altered lactational 
development is the PFOA blood level of lactating dams, which remains high and relatively 
unchanged between PND 10 and 20. These elevated levels of PFOA may be directly 
involved in delayed differentiation of the dam mammary gland. Maternal grooming practices 
may be responsible for steady state PFOA burden, as it is likely the cleaning of offspring and 
stimulating micturition results in continued maternal reingestion of PFOA excreted in the 
urine of the litter during the first 10–12 days of life. This recycling of PFOA, as suggested by 
dosimetric findings, may keep maternal blood PFOA concentrations in a near steady state, at 
levels correlated with exposure duration.  
A comparison of liver and blood PFOA levels within the exposed pups of this study 
demonstrates a similar trend. High PFOA levels were detected in both on PND 10 and 
dropped by about half by PND 20, even though the liver concentrations were consistently 
higher than those in blood (2.5-fold on PND 10 and ranging from 1.9- to 3.0-fold on PND 
20). These values agree with reports of the mean liver to serum ratio in human samples 
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(mean of 1.3:1 in paired samples, but ranged from 0.2:1 to 3.4:1 in individual samples; [28]). 
It does appear, based on our quantitative data from pup livers, that the levels of PFOA in the 
pup remain elevated and steady between PND 1 and 10, the time during which the offspring 
require maternal assistance in elimination of body wastes. If PFOA does impact lactational 
development through a direct alteration of normal cell-signaling pathways, a constant high 
blood level could provide a substantial contribution to delayed lactational development, in 
addition to the contributions of gestational exposures and impaired stimulation by exposed 
offspring. Importantly, this may explain why delays in lactational development are seen 
primarily in the dams which received the longest exposures -- and thus maintained the 
highest blood levels -- even though all exposed offspring showed significant deficits in 
neonatal weight gain, and potentially thriftiness.  
Since PFOA is a known PPAR! agonist, effects on the mammary gland may involve 
this pathway. Overexpression of PPAR!, using a keratin 5 promoter, causes severe neonatal 
mortality due to a lactational defect in the dam [29]. The effect of this targeted 
overexpression to the myoepithelial cells of the mammary alveoli was most pronounced after 
parturition causing lobulo-alveolar units to be small and malformed, yet had no effect on 
expression of some of the common milk genes. Although there is a fair chance that the mode 
of action mediating the lactational defects seen in the current study may be through activation 
of PPAR!, the similarities to the importance or role of PPAR! in the human breast are 
unknown. Also, it is known that PPAR! is not a critical element of mammary gland 
development in the neonate, as PPAR! null mice exhibit normal mammary gland 
development and function [30]. Therefore, any effects of gestational PFOA exposure on 
neonatal mammary tissue must not be mediated through this pathway.  
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The dose of PFOA used in this study, even for only the final 6 days of gestation, was 
also able to significantly stunt mammary gland development in female offspring. Most 
interestingly, development of mammary tissue between PND 10 and 20 in these offspring did 
not appear to be simply delayed but rather altogether arrested during a window of 
development where the gland should be growing at least isometrically with the body. The 
observation of these notable mammary gland alterations in pups under all exposure periods 
suggests that a critical window of sensitivity in mammary gland development may exist after 
GD 12 and possibly postnatally. Furthermore, because PFOA can transfer to the milk [31], 
exposure of pups is presumed to continue after dosing ceases and lactation begins. Therefore, 
the respective contributions of late gestational and lactational PFOA exposures to these 
mammary alterations cannot be discerned from these data but are currently being pursued. 
Whether this stunting of the neonatal gland is compensated for at the conclusion of puberty, 
or has lasting effects on either the ability to maintain a litter or on the risk of mammary gland 
pathologies, are important issues being addressed in on-going studies (in collaboration with 
Wolf et al.; [26]).  
While previous studies have observed effects on the mammary gland and other 
reproductive tissue following adult PFOA exposure [15], no one has yet reported effects of 
PFOA on reproductive tissues following gestational exposures. Further, this study is the first 
to report findings of PFOA-induced toxicity in mouse reproductive tissues. Additionally, this 
study identified that the developmental stage at the time of exposure -- both in dams and 
offspring -- determines the tissue toxicity (nonpregnant adult females that received PFOA for 
up to 17 days showed no changes in mammary tissue; S. Fenton, data not shown). This 
toxicity is not specific to females in general but is specific to lactating mothers and the 
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developing fetus, which represent susceptible subpopulations. These findings corroborate 
other reports, which have identified a critical window in mammary gland development 
during the final 6 days of gestation, and possibly into lactation. Such studies have identified a 
susceptibility of the gland during this window to pollutants including high-dose atrazine [19, 
32], a low-dose atrazine metabolite mixture (Enoch, R. R., Stanko, J. P., Greiner, S.N., 
Youngblood, G. L., Rayner, J. L., and Fenton, S. E. Mammary Gland development as a 
sensitive end-point following acute prenatal exposure to a low dose atrazine metabolite 
mixture in female long evans rats. Environ. Health Perspect. Submitted), as well as other 
environmental contaminants [18, 33, 34].  
Our current challenge is to identify the mechanisms by which PFOA affects this 
dynamic tissue. As the present study has shown, gestational exposure of the mouse to PFOA 
clearly alters normal differentiation of the lactating gland in the dam, and the early branching 
and migration in the female offspring (with the latter being the more prominent in this study). 
However, the processes which regulate these two stages of development differ, and therefore 
PFOA may not mediate the observed changes by the same mechanism. Once the mechanisms 
which mediate these alterations in the murine mammary gland are further elucidated, the 
influence of PFOA on the human breast and ultimately functional lactation, may be better 
estimated.  
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CHAPTER 3 
Effects of Perfluorooctanoic Acid on Mouse Mammary Gland Development and 
Differentiation Resulting from Cross-Foster and Restricted Gestational Exposures 
 
 
 
 
Preface 
 
 
 The following chapter was aimed at understanding the relationship between the 
timing and route of exposure to PFOA, and the subsequent effects in the lactating or 
developing mammary gland, observed in the previous chapter.  This work provided 
dosimetry data associated with the physiological outcomes, in order to understand the 
pharmacokinetic relationship between internal dose and the observed effects. This chapter 
has been accepted for publication, under the following citation: 
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Abstract  
The adverse consequences of developmental exposures to perfluorooctanoic acid 
(PFOA) are established in mice, and include impaired development of the mammary gland 
(MG).  However, the relationships between timing or route of exposure, and consequences in 
the MG have not been characterized. To address the effects of these variables on the onset 
and persistence of MG effects in female offspring, timed pregnant CD-1 dams received 
PFOA by oral gavage over various gestational durations.  Cross-fostering studies identified 
the 5mg/kg dose, under either lactational- or intrauterine-only exposures, to delay MG 
development as early as postnatal day (PND) 1, persisting beyond PND 63.  Intrauterine 
exposure during the final days of pregnancy caused adverse MG developmental effects 
similar to that of extended gestational exposures.  These studies confirm a window of MG 
sensitivity in late fetal and early neonatal life, and demonstrate developmental PFOA 
exposure results in early and persistent MG effects, suggesting permanent consequences. 
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Introduction 
Perfluorooctanoic acid (PFOA) is a broadly used industrial compound, as well as a 
final environmental degradation product of many other perfluorinated compounds.  
Numerous applications of PFOA arise from its capacity to resist extreme temperatures and 
stresses, and include industrial production of fire-fighting and flame retardant materials, 
water- and oil-repellant coatings for fabrics and food packaging, surfactants, paint additives, 
and electrical insulation, among many others.   However, the chemical properties of PFOA, 
which lend so well to these commercial applications, result also in its environmentally 
persistent nature [1].  Given its commercial and environmental ubiquity in conjunction with 
its persistence, it is not surprising that PFOA has been detected in the sera of humans and 
wildlife, and found to be widely distributed by a number of survey studies [2-9].  Recent 
estimates suggest that the non-occupationally exposed American exhibits an average serum 
PFOA concentration of 3.9 ng/ml, which is down from the national average two years prior 
(5.2 ng/ml) [10].  While sources of exposure are poorly characterized, this may result from 
ingestion of contaminated food or water, as compared to the presumed inhalational route 
among the occupationally exposed.  This average serum PFOA concentration, to date, has not 
been associated with adverse health effects in humans.  However, occupationally relevant 
levels, higher than those observed in the average American, have been observed in animal 
studies [11, 12].  Toxicologic studies of carcinogenesis in animals have indicated the 
potential for high-dose (generally, >10mg/kg/day in rodents, chronically), adult PFOA 
exposures to result in hepatotoxicity marked by extreme hypertrophy, as well as a common 
tumor triad consisting of hepatocellular carcinomas, pancreatic acinar-cell tumors, and 
Leydig cell tumors [13, 14].   
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Recent developmental toxicity studies in an outbred mouse strain have identified the 
capacity for PFOA to hinder early life body weight gain in gestationally-exposed offspring 
[11, 15, 16], as well as delay mammary gland (MG) development in female offspring [17] 
independent of body growth retardation.  Treatment of pregnant dams with 5 mg/kg PFOA 
on gestation days (GD) 12-17 was demonstrated as sufficient to produce developmental 
delays in the 10- and 20-day old offspring MG [17]. Whether this response is dependent on 
use of this relatively high exposure compared to that received by humans, is specific to late-
pregnancy timing, or requires both in utero and lactational exposures, is not known.  
Nevertheless, these routes of exposure have immediate relevance to human health, as PFOA 
has been detected in both the cord blood and breast milk of humans [18-24].  Given these 
potential human exposures, understanding how these changes in the MG are mediated by 
PFOA exposure conditions in the mouse will be critical in interpreting mode of action and 
health risk in human populations.  
In the three studies described herein, the persistence of the MG effects present in 
PFOA-exposed offspring is addressed, as is the timing and route of exposure sufficient to 
produce these effects.  Utilizing concurrent animals from previously reported studies [11], 
adult and late-life consequences of PFOA exposure with respect to MG tissue were 
examined.  Then, to determine the timing of the appearance of the MG phenotype, another 
similar experiment was performed, addressing multiple early time points not included in the 
prior studies.  Using the resulting data, this paper discusses the onset and duration of 
impaired MG development resulting from early-life PFOA exposures, the persistence of this 
impairment, and the subsequent late-life MG phenotype.    
 
 82 
Materials and Methods 
PFOA.  Perfluorooctanoic acid (PFOA, ammonium salt; >98% pure) was purchased 
from Fluka Chemical (Steinhiem, Switzerland).  NMR analysis, kindly provided by 3M 
Company (St. Paul, MN, USA), indicated that approximately 98.9% of the chemical was 
straight-chain and the remaining 1.1% was branched isomers.  For all studies, PFOA was 
dissolved by mild agitation in de-ionized water and prepared fresh daily, immediately prior to 
administration.  
 
Animals.  All animal studies were conducted in accordance with guidelines established 
by the National Health Effects and Environmental Research Laboratory Institutional Animal 
Care and Use Committee.  Procedures and facilities were consistent with the recommendations 
of the 1996 NRC “Guide for the Care and Use of Laboratory Animals”, the Animal Welfare 
Act, and Public Health Service Policy on the Humane Care and Use of Laboratory Animals.  
Timed pregnant CD-1 mice were obtained from Charles River Laboratories (Raleigh, NC, 
USA), where females were bred overnight, and the sperm positive females, defined as GD 0, 
were shipped on the same day for use in these studies.  Upon arrival, mice were housed 
individually in polypropylene cages with Alpha-dri (Shepherd Specialty Papers, Kalamazoo, 
MI, USA) bedding and provided pellet chow (LabDiet 5001, PMI Nutrition International LLC, 
Brentwood, MO, USA) and tap water (containing PFOA at concentrations below the level of 
detection) ad libitum.  Animal facilities were controlled for temperature (20-24°C) and relative 
humidity (40-60%), and kept under a 12-h light-dark cycle. 
 
Late-Life Effects Cross-Foster Study.  The study was performed in two blocks, spaced 
4 weeks apart, with 56 timed pregnant mice per block (112 total).  Upon arrival at the animal 
facility on GD 0, mice were weighed and randomly assigned to one of three treatment groups, 
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vehicle control which received de-ionized water (n=48), 3 mg PFOA/kg body weight (n=28), or 
5 mg PFOA/kg body weight (n=36).  On GD1-17, mice were weighed daily and dosed by 
gavage at a 10 ml/kg volume.   On GD18-19, dams were monitored at 4-hour intervals, and 
litters of similar ages and exposures were mixed, then fostered to yield the following 7 exposure 
groups shown in Figure 3-1A:  1) Control pups nursed by control dams (control); 2) control 
pups nursed by dams dosed during gestation with 3 mg PFOA/kg (3L, lactational exposure); 3) 
control pups nursed by dams dosed during gestation with 5 mg PFOA/kg (5L, lactational 
exposure); 4) pups exposed in utero to 3 mg PFOA/kg nursed by control dams (3U, 
intrauterine exposure); 5)  pups exposed in utero to 5 mg PFOA/kg nursed by control dams 
(5U, intrauterine exposure);  6) pups exposed in utero to 3 mg PFOA/kg nursed by dams 
dosed during gestation with 3 mg PFOA/kg (3U+L, intrauterine and lactational exposure);  7) 
pups exposed in utero to 5 mg PFOA/kg nursed by dams dosed during gestation with 5 mg 
PFOA/kg (5U+L, intrauterine and lactational exposure).  Foster litters included 10 pups with 
equal representation of males and females (where possible). All pups were either assigned to 
foster litters or were euthanized. 
 
Early-Life Effects Cross-Foster Study.  This study was performed in a single block of 
112 timed-pregnant CD-1 mice.  Upon arrival at the animal facility on GD 0, mice were 
weighed and randomly assigned to one of two treatment groups, either vehicle control which 
received de-ionized water (n=56) or 5 mg PFOA/kg body weight (n=56), received by oral 
gavage.  Pregnant dams were weighed daily and dosed by gavage at a 10 ml/kg volume on 
GD8-17, as this treatment window was previously demonstrated as sufficient to impair 
offspring MG development without profound offspring growth deficits or postnatal loss [17]. 
On GD18-19, dams were monitored at 4-hour intervals, and litters of similar ages and 
exposures were mixed, then fostered to yield the following 4 exposure groups shown in Figure  
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Figure 3-1.  Schematic of study design and implementation.  Shown for (A) the late-life 
effects cross-foster study, (B) the early-life effects cross-foster study, and (C) the restricted 
exposure study. 
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3-1B: 1) Control pups nursed by control dams (control); 2) control pups nursed by dams dosed 
during gestation with 5 mg PFOA/kg (5L; lactational exposure of offspring); 3) pups exposed 
in utero to 5 mg PFOA/kg nursed by control dams (5U, intrauterine exposure of offspring);  4) 
pups exposed in utero to 5 mg PFOA/kg nursed by dams dosed during gestation with 5 mg 
PFOA/kg (5U+L, intrauterine and lactational exposure of offspring).  Foster litters included 10 
pups with equal representation of males and females (where possible).  All pups were either 
assigned to foster litters or were euthanized.  
 
Restricted-Exposure Study.  Sixty-four timed pregnant CD-1 mice were received on 
GD 0.  Mice were weighed and randomly assigned to treatment groups, and dosed orally by 
gavage as follows:  vehicle control dosed with de-ionized water at 10 ml/kg on GD7-17 
(n=12); 5 mg PFOA/kg on GD7-17 (n=14), GD10-17 (n=14), GD13-17 (n=12), or GD15-17 
(n=12), as shown in Figure 3-1C.  The study did not include the GD1-17 dosing window, as 
this was addressed in the 5U+L dose group in the late-life effects cross-foster study, 
performed within weeks of this study.  On GD18-19, mice were monitored at frequent 
intervals until parturition and the date and time of birth, number of live and dead pups, and 
number of pups of each sex were recorded and litters were weighed by sex.  Litters were culled 
to 10 pups with equal representation of male and female (where possible). 
 
Postnatal Observations and Necropsy.  For the early-life effects cross-foster study, 
litters were observed, weighed, and euthanized on PND 1, 3, 5, and 10 (n = 4 litters per 
treatment group, per time point).  All dams and offspring in this study were euthanized on or 
before PND 10.  In the late-life effects cross-foster and restricted exposure studies, litters 
were observed as previously described [11].  On PND 22, pups from the two latter studies 
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were weighed and weaned, and males and females were housed separately.  From these 
studies, female offspring were necropsied on PND 22, 29, 32, 42, and 62, as well as at 18 
months postnatally.  At necropsy in all studies, body and liver weight measurements were 
made, and whole livers and blood samples were collected.  Serum was prepared from blood 
samples and stored frozen for PFOA analysis (due to limited volume, female pup blood was 
pooled by litter at necropsies which occurred prior to weaning). The fourth and fifth inguinal 
MG were collected from dams in the early-life effects cross-foster study and female offspring 
in all three studies.  MG tissue from one side of the animal was prepared as a whole mount, 
and the contralateral glands were prepared for histological analysis.  
 
Mammary Gland Preparations.  MG tissues isolated at necropsy for whole mount 
purposes were mounted flat on glass slides. Whole mounts were then fixed in Carnoy’s 
solution, stained in carmine alum stain, and dehydrated and cleared in xylene, as previously 
described [25]. A portion of the contralateral MG was removed, placed in a histology cassette 
and fixed in 10% neutral buffered formalin for 48 h, then stored in 70% ethanol. These 
histologically prepared glands were paraffin-embedded and 5!m sections were prepared and 
stained with hematoxylin and eosin (H & E).  
Whole mounts were visualized by light macroscope (Leica WILD M420 macroscope, 
Leica, Wetzlar, Germany; magnification up to x70).  MG whole mounts from female 
offspring between PND 1 and PND 63 were scored on a 1–4 subjective, age-adjusted, 
developmental scale (as described in [26]; 1 = poor development/structure; 4 = normal 
development/structure, given age). Briefly, the developing tissue was assessed for the gross 
presence and appropriate timing of several histological criteria, including primary ducts and 
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large secondary ducts, lateral side branching, appearance of budding from the ductal tree, 
longitudinal outgrowth of the epithelium, terminal end buds, differentiated ends, and contact 
inhibition between glands. Slides were separated by score as they were evaluated, compared 
within a score for consistency, and then recorded. Two independent scorers, blind to 
treatment, scored glands within the age groups. Mean scores for the time points, within 
treatment groups, were calculated and analyzed statistically for treatment and time-related 
differences.   
Whole mounts from 18-month old offspring and lactating dams were qualitatively 
examined with respect to concurrent controls.  Areas of unusual, darkly-staining foci in 18-
month old tissues were counted.  Lactating glands were assessed for differentiation, amount 
of epithelial tissue filling the gland, and presence of well-formed, productive alveoli.  
Representative tissues from these assessments, as well as those scored by the above-
described methods were photographed using the Leica macroscope and mounted camera 
(Photometrics CoolSNAP, Roper Scientific, Inc., Tucson, AZ).  Histological sections were 
visualized by light microscope (Nikon Eclipse E600, Nikon, Tokyo, Japan), and were 
assessed by a pathologist for inflammation, preneoplastic lesions, and areas of hyperplasia, 
which might contribute to the aforementioned unusual foci.  Magnifications are shown in 
figures.  Photographs were taken using a Nikon FDX-35 scope-mounted camera. 
 
Serum PFOA Determination.  Serum samples from the dams and pups of the early-
life effects cross-foster study (at PND 1, 3, 5, and 10), pups of the restricted exposure study 
(at PND 22, 29, and 32), and 18-month old female offspring from both the late-life effects 
cross-foster study were prepared at the Environmental Protection Agency.  All serum 
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samples were stored frozen in polypropylene vials, shipped on dry ice to the Centers for 
Disease Control and Prevention’s National Center for Environmental Health laboratory, and 
then kept at or below -40ºC until analysis. Measurement of the concentrations of PFOA in 
serum was performed through a multiple reaction monitoring experiment using a 
modification of the online solid-phase extraction (SPE) coupled to reversed-phase high-
performance liquid chromatography (HPLC)-tandem mass spectrometry previously described 
[27].  A Surveyor HPLC pump (ThermoFinnigan, San Jose, CA, USA) was used, coupled 
with a ThermoFinnigan TSQ Quantum Ultra triple-quadrupole mass spectrometer equipped 
with a heated electrospray ionization (HESI) interface.  The HPLC pump operated at a 300 
!l/min flow rate with 20mM ammonium acetate (pH 4) in water (mobile phase A) and 
acetonitrile (mobile phase B).  Necessary dilution of the serum samples was performed in 
two steps. First, at least 10 !l serum was diluted to 0.5 ml with water in a 2-ml Eppendorf 
tube, then a second dilution was performed by aliquoting the appropriate amount of the 
diluent into an autosampler vial, adding 0.1M formic acid, and injected into a commercial 
column switching system allowing for concentration of PFOA on a C18 SPE column. The 
column was automatically positioned in front of a Betasil C8 analytical HPLC column (2.1 x 
50 mm, 5 !m; ThermoHypersil-Keystone, Bellefonte, PA, USA) for chromatographic 
identification of PFOA. Detection and quantification utilized negative-ion HESI, a variant of 
electrospray ionization, tandem mass spectrometry. The isotope-labeled internal standard 
used for quantification was 
13
C2-PFOA.  Blanks and quality control materials, prepared in 
calf serum, were analyzed along with each batch of samples to ensure the accuracy and 
reliability of the data across time [27].  
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Statistical Analysis.  Data were evaluated for age and exposure period effects using 
mixed-model analysis of variance (ANOVA) in SAS 9.1 (SAS Institute, Inc. Cary, NC). 
Block effects were not detected in any test and therefore block was removed from the model.  
For all measurements, means were evaluated and effects of dose and exposure periods 
compared.  Statistical analysis of body weight and maternal effects for the late-life effects 
cross-foster study and restricted exposure study were performed as previously described [11].  
In the early-life effects cross-foster study, treatment-specific mean body weights were 
calculated for dams at GD 1 and GD 17, and for pups, with litter as the unit of measure, on 
PND 1, 3, 5, and 10.  For all three studies, mean MG developmental scores were calculated.  
MG scores were analyzed using body weight at time of collection as a random effect, with 
litter as the unit of measure for neonatal scores. Differences between treatment groups were 
determined using Dunnett’s or Tukey’s t-tests (significance at the level of p < 0.05 for all 
comparisons, in text and figures), with SAS. 
 
Results 
Late-Life Effects Cross-Foster Study.  As previously reported, all exposed groups 
exhibited lower body weight compared to controls at PND 22, except Con-3 (3L) [11].  
These deficits were overcome within one week subsequent, except among the 5U and 5U+L 
groups which did not recover until as late as PND 85 [11].  Additionally, all exposed groups 
exhibited increased liver to body weight ratios at weaning [11], presumed to result from liver 
hypertrophy, as observed in adult-treated animals.  In the present study, at PND 22, 42, and 
63 (that is, 3, 6 and 9 weeks old) all cross-fostered offspring that received PFOA exposure, 
regardless of route or dose, exhibited reduced MG developmental scores, as compared to 
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controls, except for the 3L group at PND 22, and the 3 U+L group at PND 42 (Table 3-1).  
This abnormal development was characterized by delays in ductal elongation, delays in 
timing of terminal end bud (TEB) appearance, and reduced secondary and tertiary branching 
(Figure 3-2A).  Reduced branching was particularly pronounced among the combined 
exposure groups (3U+L, not shown; 5U+L), which exhibited mammary fat pads with greatly 
reduced parenchymal density (not reflected in 3U+L at PND 42, due to inter-individual 
variance and the multiple criteria used to arrive at the final score).  While PFOA-exposed 
groups at most time points exhibited lower MG developmental scores compared to controls, 
there was no consistent trend that suggested that any one exposure route (5L vs. 5U), or dose 
given via an exposure route (3L vs. 5L) negatively affected MG development more than the 
others.   
In female offspring from this study at 18-months postnatally, MG development could 
not be assessed using the scoring criteria described.  However, as seen in Figure 3-2B, the 
epithelial density within a gland appeared to be reduced in PFOA-exposed animals, 
particularly among the combined exposure groups (3U+L, not shown; 5U+L).  Ostensibly, 
this arose due to a smaller starting population of parenchymal cells, and thus the subsequent 
reduced branching and proliferation of that ductal network resulted in sparser epithelial 
arborization of the fat pad.  Additionally, among PFOA-exposed groups there was a tendency 
to exhibit higher densities of unusual, darkly-staining foci in an individual gland than 
observed among controls (Figure 3-2B; mean number of foci per gland: controls = 6.9, 
3mg/kg exposure groups = 34.3, 5mg/kg exposure groups = 38.6).  In histopathologic MG 
sections, as shown in Figure 3-2B, these darkly-staining areas appear to result from one or 
more of the following: hyperplasia of the ductal epithelium, infiltration by inflammatory cells  
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Table 3-1.  Mammary gland developmental scores. 
 
Female offspring age in postnatal days 
 
 
 
 
PND1 
 
PND3 
 
PND5 
 
PND10 
 
PND22 
 
PND29 
 
PND32 
 
PND42 
 
PND63 
Restricted Exposure     
Study Dose Groups 
        
    Control -- -- -- -- -- 3.6 ± .1 3.6 ± .1 -- -- 
    GD7-17 -- -- -- -- -- 2.1 ± .1* 1.9 ± .1* -- -- 
    GD10-17 -- -- -- -- -- 2.0 ± .2* 2.2 ± .2* -- -- 
    GD13-17 -- -- -- -- -- 2.2 ± .1* 2.5 ± .1* -- -- 
    GD15-17 -- -- -- -- -- 2.0 ± .2* 2.3 ± .3* -- -- 
Early Cross-Foster       
Study Dose Groups 
    
 
    
    Control 3.3 ± .2 3.5 ± .2 3.0 ± .1 2.8 ± .2 -- -- -- -- -- 
    5 L 1.7 ± .4* 1.8 ± .2* 1.5 ± .1* 2.3 ± .2* -- -- -- -- -- 
    5 U 1.9 ± .2* 1.9 ± .3* 2.0 ± .2* 1.4 ± .1* -- -- -- -- -- 
    5 U+L 1.5 ± .2* 1.7 ± .3* 1.1 ± .1* 1.5 ± .2* -- -- -- -- -- 
Late Cross-Foster         
Study Dose Groups 
        
    Control -- -- -- -- 3.7 ± .1 -- -- 3.2 ± .2 3.1 ± .2 
    3 L -- -- -- -- 3.0 ± .2 -- -- 2.5 ± .2* 2.6 ± .2* 
    5 L -- -- -- -- 2.1 ± .2* -- -- 2.5 ± .1* 2.4 ± .2* 
    3 U -- -- -- -- 1.8 ± .2* -- -- 2.2 ± .1* 2.6 ± .2* 
    5 U -- -- -- -- 2.1 ± .3* -- -- 2.2 ± .2* 1.9 ± .2* 
    3 U+L -- -- -- -- 1.8 ± .2* -- -- 2.7 ± .2 2.6 ± .3* 
    5 U+L -- -- -- -- 1.2 ± .2* -- -- 1.9 ± .2* 1.9 ± .2* 
Note.  Data are presented as mean ± SE.  Scores are on a 1-4 scale; criteria adjusted for stage 
of development and age.  Due to the outbred nature of the CD-1 mouse strain, the mean score 
for controls was less than 4.  Dashes (--) signify time points where no measure was taken 
within the given study.  N = 10-21 adult females per treatment group per time point for the 
restricted exposure study.  N = 4 litters (3 pups per litter) per treatment group per time point 
for the early-life effects cross-foster study.  N = 9-18 adult females per treatment group per 
time point for the late-life effects cross-foster study.  Statistical comparisons made are with 
controls within a given study; inter-group comparisons can be found in Results.  *Significant 
treatment effect compared to control; p < 0.05. 
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Figure 3-2.  MG development of female offspring in the late-life effects cross-foster study.  
(A) Whole mount preparations of mammary tissue from female offspring are shown at PND 
22 (25x; a lymph node appears as a large darkly-staining object), PND 42 (50x), and PND 63 
(50x).  Glands pictured are representative of mean respective scores (given in Table 3-1; N = 
10-13 adult females per treatment group at PND 22, N = 9-18 per group at PND 42, N = 9-17 
per group at PND 63.)  *Significant treatment effect by ANOVA, compared to control; p < 
0.05.  (B) On the left, whole mounts from representative adult female offspring at 18-months 
of age (16x). Large arrows indicate unusual, darkly-staining foci; one small arrow in 5U 
indicates peripheral, localized increases in epithelial density observed in some PFOA-
exposed animals at 18 months.  On the right, histopathologic images from contralateral 
glands in the same animal show ductal areas that might account for darkly staining foci 
observed on whole mounts (400x; N = 5-12 females per group at 18 months). The arrow in 5 
U identifies an area of inflammation.  In 5U+L the large arrow identifies an area of increased 
stromal density; the small arrow points to a potentially hyperplastic region of ductal 
epithelium.  These ductal pathologies were observed in all treatment groups; some ductal 
inflammation was also seen in controls. 
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into ductal regions, increases in stromal density surrounding the ducts, or inappropriate 
differentiation of MG ductal epithelium (Figure 3-2B).  These histologic analyses utilized a 
single section of the contralateral gland, not that used for whole mounts.  As such, the 
observations described in histopathologic sections were not in the same tissue in which 
whole mount observation were made, and therefore may not explain individual darkly-
staining foci.  In whole mounts, the composition and etiology of these foci can not be 
determined, but it is presumed that histopathologic MG sections are representative, and 
therefore reveal what produces the appearance of these foci.   In addition, peripheral, 
localized increases in epithelial density were visible in whole mounts of some 18-month-old 
PFOA-exposed offspring; however, there was not a consistent effect of dose or route of 
exposure on the extent of the pathology.  Furthermore, these increases were strictly 
peripheral, and did not represent an achievement of ideal epithelial organization and content, 
which early time points revealed to be delayed and diminished.  This study was not designed 
to address these histological changes in the tissue, and therefore these observations are noted, 
but not interpreted.   
 
Early-Life Effects Cross-Foster Study.  Maternal and early neonatal indices were 
assessed and no effect of treatment was observed on either litter size or pup birth weight 
(data not shown).  However, dam weight gain during pregnancy was significantly higher 
among dams treated with 5 mg/kg PFOA on GD 8-17 (29.2 ± 0.8 g) compared to controls 
(25.7 ± 1.0 g).   
Among all PFOA-exposed offspring significant delays in MG developmental 
morphology were observed as early as PND 1 (Figure 3-3), similar to that seen at later time  
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Figure 3-3.  MG development of female offspring in the early-life effects cross-foster study.  
Whole mount preparations of mammary tissue from female offspring at PND 1, 3, 5 (64x), 
and PND 10 (50x).  The arrow in 5 U+L on PND 1 identifies ductal epithelium. Glands 
pictured are representative of mean respective scores (Table 3-1; N = 4 litters per treatment 
group at each time point; 3 pup glands scored per litter).  *Significant treatment effect by 
ANOVA, compared to control; p < 0.05. 
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points in the late-life effects cross-foster study.  The lactation-only exposure group nursed on 
treated dams and thus were exposed to PFOA for at least 12 hours after parturition before the 
PND 1 necropsy, a period which is marked by very rapid elongation and branching of the 
early ductal epithelium, and may be particularly susceptible to insult by circulating PFOA.  
These effects persisted through the duration of the study, from PND 1 to 10, among the three 
exposed groups as compared to controls (Table 3-1).  Differences in severity of 
developmental delays between PFOA exposure groups were only evident at PND 5 when 5U 
and 5U+L differed significantly from one another, and at PND 10 when 5L development, 
despite being worse than controls, was significantly greater than either 5U or 5U+L, which 
were both determined to be severe (defined as a developmental score ! 1.5; Table 3-1).     
None of the PFOA-exposed groups exhibited reduced body weight compared to 
controls on PND 1, the age at which both intrauterine-exposed groups exhibited highest 
circulating PFOA levels (Table 3-1; Figure 3-4B).  While this result differs from that 
previously reported for the late-life effects study [11], it is important to note that gestational 
treatment in the early-life study did not start until GD 8, as compared to GD 1 in the late-life 
effects study (Figure 3-1A, 3-1B).  On PND 3 the combined exposure females (5U+L) 
weighed less than controls, and by PND 5 the other exposure groups also weighed less than 
controls (5L, 5U).  It should be noted that MG developmental scores were consistently lower 
among PFOA-exposed offspring over PND 1-10, in the absence of consistent body weight 
disparities.  
Liver to body weight ratios were elevated among intrauterine-exposed pups (5U, 
5U+L) on PND 1, when their serum levels were highest (Table 3-2; Figure 3-4B), suggesting 
that liver hypertrophy may be initiated occur prior to birth.  Lactationally-exposed pups also  
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Figure 3-4.  Serum PFOA concentrations in dams and female offspring from the early-life 
effects cross-foster study (offspring from the late-life effects study also shown on right for 
comparison; reported in [14]).  Data are shown as mean ± SEM bars; numerical values are 
shown for non-zero controls, and for control dams nursing treated pups at PND1.  (A) 
Among the dams, direct treatment with PFOA consistently yielded higher serum level than 
nursing treated pups (5U).  (B) Among offspring, lactationally-exposed females (5L) 
exhibited serum concentrations that increased until PND 10, when they converged upon 
concentrations observed in the intrauterine (5U) and combined exposure (5U+L) groups. At 
PND 1, treated pups (5U, 5U+L) exhibited higher serum PFOA concentrations than treated 
dams (nursed 5L, 5U+L pups).  By PND 10 all exposed offspring groups were becoming 
similar to one another in serum concentrations, and were becoming increasingly similar in 
serum concentrations to their paired dams.  In the late-life effects study (right), by PND 63 
serum from female offspring in all treatment groups were near background levels, at less than 
1,000 ng/ml. Statistical comparisons are provided in the text. 
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Table 3-2.  Body weights and relative liver weights in dams and female offspring in the 
early-life effects cross-foster study. 
 
PND 1 PND 3 PND 5 PND 10 
 
 
Body          
weight (g) 
Relative 
liver weight 
Body          
weight (g) 
Relative 
liver weight 
Body          
weight (g) 
Relative 
liver weight 
Body          
weight (g) 
Relative 
liver weight 
Dam          
Control,  
  Control Pups  
37.4 ± 1.7 6.5 ± 0.4 39.5 ± 1.6 6.4 ± 0.1 41.8 ± 1.2 6.9 ± 0.2 45.3 ± 0.9 7.2 ± 0.2 
Control,  
  5U Pups   
33.9 ± 1.2 6.1 ± 0.3 39.1 ± 2.5 6.1 ± 0.1 38.0 ± 1.8 7.2 ± 0.2 42.6 ± 0.9 7.6 ± 0.2 
Treated,  
  5L Pups   
38.2 ± 0.4 12.0 ± 0.4* 37.3 ± 2.8 13.4 ± 0.4* 43.7 ± 0.7 13.1 ± 0.2* 46.4 ± 1.5 10.2 ± 0.5* 
Treated,  
  5U+L Pups  
37.4 ± 2.1 12.5 ± 0.7* 41.2 ± 1.1 14.1 ± 0.5* 43.3 ± 2.2 12.6 ± 0.4* 48.2 ± 1.3 12.9 ± 0.2* 
Female Pups 
        
 Control   1.77 ± .06 4.1 ± 0.2 2.29 ± .10 3.3 ± 0.1 3.65 ± .10 3.0 ± 0.1 6.07 ± .29 2.7 ± 0.02 
 5U Pups   1.65 ± .01 6.8 ± 0.1* 2.07 ± .10 6.6 ± 0.1* 2.73 ± .13* 6.1 ± 0.3* 4.51 ± .09* 5.8 ± 0.1* 
 5L Pups   1.69 ± .04 4.4 ± 0.2 2.25 ± .13 3.6 ± 0.2 3.03 ± .11* 3.9 ± 0.3* 5.64 ± .08* 4.3 ± 0.1* 
 5U+L Pups  1.60 ± .06 6.9 ± 0.2* 1.85 ± .05* 6.8 ± 0.1* 2.43± .11* 6.0 ± 0.1* 4.34 ± .09* 6.4 ± 0.2* 
Note.  Data presented are mean ± SE. The relative liver weight means are calculated as the 
average of each dam’s liver weight divided by their body weight, multiplied by 100.  Pup 
body weight means are calculated as the average of the litter averages (of 3 female pups). As 
with pup body weight means, relative liver weight means were calculated by averaging the 
litter averages for relative liver weight.  N = 4 dams or litters (N = 3 female pups per litter) 
per treatment group per time point for the early-life effects cross-foster study.  N = 9-18 adult 
females per treatment group per time point for the late-life effects cross-foster study.  
*Significant treatment effect compared to control; p < 0.05 
 
 
 98 
exhibited a significant elevation in this ratio by PND 5, when their circulating PFOA reached 
approximately 15,000 ng/ml.  By this time point, all PFOA-exposed offspring exhibited 
increased relative liver weight, which persisted through PND 10. Considering the effect of 
this increased liver weight, adjusted body weights were calculated by subtracting the liver 
weight from the body weight of each neonate.  Using this adjusted body weight as a random 
effect, statistics on MG scores were reevaluated and determined to be unaffected by potential 
growth deficits not reflected in whole body weight (data not shown).  
Morphological examination of lactating dam MG tissue suggested profoundly altered 
differentiation in treated dams (nursed 5L, 5U+L pups) at PND 1, when lobulo-alveolar units 
appeared neither distended nor differentiated to the degree of control tissues, and a large 
population of adipocytes remained discernable (Figure 3-5).  Qualitatively, these glands 
appeared immature, similar to that seen in late pregnancy, prior to parturition and the 
initiation of nursing.  Because this phenotype was present in dams nursing controls pups, it 
may be presumed that this effect is a direct action of PFOA on the differentiating lactating 
dam, rather than a result of possible poor suckling and stimulation by smaller, and 
presumably weaker, PFOA-treated pups (as discussed in [17]).  While these treated groups 
continued to exhibit diminished lactational morphology until PND10, alveolar units filled the 
fat pad more completely by PND 3 though they did not catch up with control dam 
morphology before the end of the study (data not shown).  Reduced alveolar filling of the fat 
pad was visible among control dams nursing treated offspring (5U) as early as PND 3 (data 
not shown), at which time point these dams exhibited serum PFOA levels of roughly 2,000 
ng/ml (Figure 3-4A), presumably as a result of dam behaviors that including grooming the 
litter and stimulating micturition, thereby ingesting PFOA eliminated from the offspring.  
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Figure 3-5.  MG differentiation of lactating dams in the early-life effects cross-foster study.  
Whole mount preparations of mammary tissue from lactating dams are shown on PND 1, the 
first day of lactation (40x).  Glands pictured are representative of lactating dams in respective 
groups at LD 1 (body weights given in Table 3-2; N = 4 dams per treatment group at each 
time point). 
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The precipitous drop in circulating PFOA in 5U pups suggest that the compound, primarily 
lost through the urine, is being excreted at a high rate, and could therefore readily be ingested 
through normal maternal behaviors.    Delays in lactational morphology persisted to PND 10 
among these three exposed groups of dams, with combined-exposure dams in the 5U+L 
group exhibiting the most profound delays (data not shown). 
 
Restricted-Exposure Study.  In the restricted-exposure study, treatment with PFOA 
under even the shortest duration treatment, GD 15-17, was sufficient to consistently lower 
MG scores at PND 29 and 32 as compared to controls (Table 3-1).  These delays, observed in 
all treatment groups, were similar to those observed in both cross-foster studies, in that they 
were marked by reduced ductal elongation and branching, as well as delays in timing and 
density of TEBs (Control, GD 15-17, and GD 10-17 shown, Figure 3-6A).  Because all 
treated groups except for GD 10-17, recovered from body weight deficits within one week of 
weaning (previously reported in [11]), the observed MG delays again occurred in the absence 
of body weight deficits, which might otherwise have been a factor in MG growth impairment 
(except in the GD10-17 group, when body weight was still below that of controls).  
At 18-months postnatally, MG development was not scored in the fully mature gland, 
due to the absence of developmental indices integral to scoring criteria.  However, among 
PFOA-exposed groups, as with the late-life cross-foster study, there was a tendency for 
PFOA-exposed females to exhibit higher densities of unusual darkly-staining foci, which 
were originally suspected to be areas of ductal hyperplasia (Figure 3-6B; mean number of 
foci per gland: controls = 1.5, GD 15-17 exposure = 29.8, GD 13-17 exposure = 17.9, GD 
10-17 = 32.8, GD 7-17 = 25.5).  Identical to that noted in the late-life effects cross-foster  
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Figure 3-6. MG development of female offspring in the restricted exposure study. (A) Whole 
mount preparations of mammary tissue are shown at PND 32 (16x).  Glands pictured show 
morphology representative of respective treatment groups at given time points (Table 3-1; N 
= 10-20 females per treatment group at PND 32). *Significant treatment effect by ANOVA, 
compared to control; p < 0.05.  (B) On the left, whole mount preparations of mammary tissue 
at 18-months of age are shown (16x). Large arrows identify unusual, darkly-staining foci; 
small arrows identify peripheral, localized increases in epithelial density observed in some 
PFOA-exposed animals at 18 months. On the right, histopathologic images from contralateral 
glands in the same animal show ductal areas that might account for darkly staining foci 
observed on whole mounts (400x; N = 4-11 females per treatment group at 18 months). The 
large arrow in GD 15-17 identifies an area of increased stromal density; the small arrow 
points to a focus of inflammation.  In GD10-17 the arrow identifies a large, potentially 
hyperplastic region of ductal epithelium.  These ductal pathologies were observed in all 
treatment groups; some ductal inflammation was also seen in controls. 
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study, observations in histopathologic MG sections (Figure 3-6B) suggest these darkly-
staining foci result from one or more of the following: hyperplasia of the ductal epithelium, 
infiltration by inflammatory cells into ductal regions, increases in stromal density 
surrounding the ducts, or inappropriate differentiation of MG ductal epithelium.  To a greater 
degree than the late-life effects study, peripheral, localized increases in epithelial density 
were visible in whole mounts from many 18-month-old PFOA-exposed animals.   
Serum PFOA levels were not measured in these animals, though the serum data from 
the late-life effects cross-foster study at 18-months demonstrate that serum PFOA are at 
background levels.  Mean body weights, liver weights, and liver to body weight ratios were 
similar between all treatment groups and controls at 18-months postnatally. 
 
Serum PFOA Dosimetry.  The serum PFOA concentrations previously reported by 
Wolf et al. [11] for the late-life effects cross-foster study should be considered when 
evaluating the MG scores.  Therefore, the control, 5L, 5U, and 5U+L group means at 3, 6, 
and 9 weeks [11] are presented in Figure 3-4B (3L, 3U, and 3U+L are not shown, but were 
consistently lower than the 5 mg/kg equivalent exposure groups).  These data appear 
alongside serum PFOA concentrations measured in the early-life effects cross-foster study 
(vide infra) to illustrate the potential pattern of PFOA serum load over time, based on 
exposure parameters.  However, the early-life effects study exposure period was about 60% 
the duration of the late-life study, and therefore these data cannot be directly compared.  
Most importantly, in the late-life effects study the persistent nature of the MG developmental 
delays was evident at 9 weeks postnatally, when the circulating PFOA concentrations had 
returned to near-background levels, on the order of hundreds rather than tens of thousands of 
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ng/ml.  As presumed, based on the 16-19d half-life of PFOA in mice [28], mean serum 
PFOA concentrations were similar to controls and had reached background levels in all 
PFOA-exposed females, 18 months after their last treatment (data not shown). 
In the early-life effects cross-foster study, serum PFOA concentrations in female 
offspring were highest at the earliest time point assessed, PND 1, among those with 
intrauterine exposure (5U, 5U+L; Figure 3-4B).  Conversely, among the lactationally-
exposed (5L) offspring, levels rose steadily after birth and through PND 10, demonstrating 
substantial postnatal lactational transfer of PFOA.  This transfer was evident also by the 
decline in serum PFOA observed in the treated dams that nursed these pups, which exhibited 
the highest serum concentrations at PND 1, falling steadily during lactation.  Interestingly, at 
PND 1 the intrauterine-exposed offspring (5U, 5U+L) exhibited significantly higher serum 
levels than treated dams, a surprising observation given previous assumptions about 
gestational transfer [29].  This trend appeared to diminish with time, and by PND 10 dam and 
pup serum levels were similar.  Among lactating dams in this study, serum PFOA 
concentrations decreased over time between PND 1-10, among the two treated groups.  
Control dams that nursed intrauterine-only exposed pups exhibited increasing serum PFOA 
over the course of the study (vide supra), and significantly higher serum PFOA 
concentrations than controls as early as PND 1, which persisted through the study. 
In the restricted exposure study, serum PFOA concentrations for all treated groups at 
PND 29 and 32 (previously reported in [11]) were consistently higher than controls even 
under the shortest duration exposure of GD 15-17.  While serum PFOA concentrations were 
not measured in 18-month old females from this study, one may presume -- given PFOA 
pharmacokinetics in the CD-1 mouse [28] -- that the serum concentrations for the 18-month 
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old 5U+L females in the late-life effects study represent conservative estimates for 
circulating PFOA concentrations in females of the same age, strain, and environmental 
conditions in the restricted exposure study, where PFOA dose and route of exposure were the 
same, only exposure periods were shorter (Figure 3-1A, 3-1C).  Furthermore, serum PFOA 
reported previously for these two studies [11] consistently showed lower serum PFOA 
concentrations among all PFOA-treated groups in the restricted exposure study, as compared 
to 5U+L offspring in the late-life effects cross-foster study at PND 22.    
 
Discussion 
   These studies have demonstrated the capacity for both short duration prenatal and 
exclusively postnatal, lactational PFOA exposure to delay development of the proliferating 
MG in offspring from as early as PND 1, to as late as or later than 9 weeks postnatally.  
Furthermore, these delays remain apparent even as the internal PFOA dose drops, 
approaching background levels.  These data, in conjunction with sparse epithelial filling of 
the MG fat pad observed in 18-month old PFOA-exposed offspring, suggest that early life 
exposure may result in permanent effects in the mammary tissue. 
In the late-life effects study, lactational-only exposure at 5 mg/kg was sufficient to 
produce delays in MG development that persisted from 3 weeks until at least 9 weeks of age, 
when sexual maturity has been attained, even though PFOA serum concentrations were 
relatively low (<350 ng/ml at 9 weeks), and of the same order of magnitude as concentrations 
reported in humans exposed to PFOA occupationally or accidentally, by ingestion of 
contaminated drinking water [12].  In this group, body weight deficits were overcome after 
PND 22 [11], yet MG developmental deficits persisted, and appeared evident even at 18 
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months postnatally.  These effects were observed in this group despite receiving exclusively 
postnatal exposure.  The 3/5U and 3/5U+L groups also exhibited these delays, and although 
body weight deficits among these groups persisted longer, serum PFOA concentrations in 
3/5U females were less than or equal to that in 3/5L females for the entire 3-9 week age 
window [11].  Even at 18 months postnatally, filling of the gland by epithelium was visibly 
different in density and organization, from controls in lactational exposure-only females, as 
well as the intrauterine exposure groups.   
The early-life effects cross-foster study supported these findings, and all PFOA-
exposed female offspring – 5L, 5U, and 5U+L – exhibited delayed MG development as early 
as PND 1, or 24 hours after parturition, during which time the MG parenchyma normally 
undergoes rapid growth and development [30].  These delays were maintained, and persisted 
through PND 10.  These studies taken together suggest that MG deficits resulting from 
intrauterine, lactational, or combined exposures to PFOA develop at least as early as PND 1, 
and persist into sexual maturation.  The observations in the early-life effects study also 
specifically point to a window of sensitivity for the MG during late fetal and early neonatal 
life.  Interestingly, among the 3 mg/kg lactationally exposed group in the late-life effects 
study, body weight was never reduced compared to controls, yet MG morphology revealed 
growth deficits at PND 42 and PND 63 in the absence of any body growth retardation over 
life.  This suggests that the threshold for effect may be lower for MG developmental delays 
as compared to that for body growth deficits, and that the mechanisms responsible for these 
effects may differ.       
In the restricted exposure study, similar persistence of MG morphological deficits 
was observed, with as short a treatment window as the final three days of gestation (GD 15-
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17) producing delays visible at PND 29 and PND 32, and persistent morphological changes 
visible at 18 months. These findings are consistent with those of the cross foster-studies, 
demonstrating the late gestation and early lactation periods as most sensitive for the effects of 
PFOA on the MG.    
These findings support previous work [17] that reported delays in MG development 
resulting from developmental PFOA exposure, independent of body weight deficits.  This 
work is also in agreement with work on other environmental agents, which indicate that late 
fetal and early neonatal MG development is particularly sensitive to environmental insult 
(reviewed in [31], where the rodent MG is illustrated to be a suitable model for the human 
tissue).  Furthermore, this is the first work to the authors’ knowledge that reports effects of 
developmental PFOA exposure occurring as late as the postnatal period -- via the presumed 
lower transmission route of nursing -- that persist into adulthood and late-life.  An important 
finding was also illuminated in the dosimetry data, specifically that offspring with 
intrauterine PFOA exposure exhibited higher serum PFOA concentrations on PND 1 than did 
the treated dams they nursed on, an observation not previously reported, and vital to the 
understanding of the pharmacokinetics of PFOA in the fetus and neonate.  It deserves 
mention that the reduced MG epithelium phenotype reported here was also recently observed 
following postnatal, peripubertal exposure of C57BL/6 (at the dose of 10 mg/kg, only) and 
Balb/c mice to PFOA [32, this issue].  The finding of this similar study, that the response in 
the MG seems to differ between inbred strains, is noteworthy and merits further 
investigation.      
At the conclusion of these studies, numerous questions remain unanswered.  
Understanding the no observable adverse effect level (NOAEL) and the lowest observable 
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adverse effect level (LOAEL) in conjunction with internal dosimetry would be beneficial in 
reducing uncertainties in the relationship between dose and health effects.  Using the data 
presented here and elsewhere, pharmacokinetic models may be able to anticipate these doses.  
Characterizing the long-term adverse effects of MG perturbations in PFOA exposed animals, 
including possible impaired lactational support of litters or altered cancer susceptibility also 
remains to be understood.  Finally, how these morphological delays and subsequent 
persistent deficits are mediated remains unclear, but will be important in determining the 
human health hazard posed by PFOA.   
PFOA is a known agonist of the peroxisome proliferator-activated receptor (PPAR) ! 
isoform (PPAR!). Knockout and transgenic mice have provided some clues as to possible 
modes of action for PFOA in the MG.  In transgenic mouse dams exhibiting constituitively 
activated PPAR!, normal differentiation of lobular-alveolar units was so profoundly 
impaired during lactation, that no offspring survived until weaning [33], suggesting that 
altered PPAR!-signalling has the potential to greatly interfere with proper functional 
differentiation of the lactating gland.   
The mode of action responsible for the general growth deficits observed in 
gestationally PFOA-exposed mice was recently examined using PPAR! knockout mice.  
These effects – including impaired postnatal body weight gain, delayed eye opening among 
pups, and postnatal mortality – were found to be dependent upon PPAR! expression [16].  
Interestingly, early prenatal loss did not appear to require PPAR! expression.  This study did 
not examine dam lactation or MG morphology of female offspring, however, studies 
addressing these tissues in PPAR! knockout mice are currently underway.   Of note is the 
fact that the PPAR! knockout mice do seem to reproduce normally and exhibit normally 
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developed MG tissue.  It is noteworthy that MG effects have been observed to occur in the 
absence of growth deficits, which have been identified as PPAR!-dependent effects.  
Furthermore, because these delays in body weight gain and developmental indices were 
shown not to result from lactational exposure only, while MG effects were, there is evidence 
that MG developmental effects may not be mediated by a similar mechanism and may 
represent a more sensitive endpoint. 
While the observations reported here and in previous publications [17] concerning 
impaired lactational development of lobular-alveolar units among PFOA-treated dams, agree 
with similar observations in publications examining the impact of PPAR! agonists on 
lactation [33], the authors do not rule out the potential for an upstream event or an entirely 
PPAR!-independent pathway to be responsible for the MG effects in either the treated dam 
or the exposed offspring.   
This work has identified the MG as a tissue that is sensitive to developmental 
perturbation by PFOA, and may be among the most sensitive endpoints studied to date.  In 
these studies, when internal dose was examined with respect to effect, a circulating serum 
concentration of about 2,000 ng/ml appeared sufficient to stimulate the inhibition of 
developing and differentiating MG tissue.  This is approximately four times the circulating 
PFOA concentration found in some non-occupationally exposed populations [12], suggesting 
that epidemiologic studies focused on the health effects of PFOA exposure may want to 
evaluate women’s ability to exclusively breast feed.  With respect to animal studies, 
knowledge of the lowest effective doses and the mode of action for the PFOA-induced MG 
effects will allow comparison with health results in epidemiological studies that are currently 
on-going, including that done by the Breast Cancer and Environment Research Centers [34] 
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and by the C8 Science Panel [35] on the human health effects of PFOA. This type of 
research, in conjunction with internal dosimetry, should result in less uncertainty in risk 
assessment.   
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CHAPTER 4 
 
Investigating the Multigenerational Effects of Prenatal PFOA Exposure on Mouse  
Mammary Gland Development, Function, and Tumor Susceptibility. 
 
 
 
Preface 
 
 This chapter was aimed at characterizing functional consequences with respect to 
lactation, as well as altered susceptibility to carcinogenesis, which might result in the 
affected mammary gland of developmentally PFOA-exposed offspring, observed in previous 
chapters.  In addition, the possibility of transgenerational effects was also investigated.  This 
chapter is being prepared as a manuscript for submission to Environmental Health 
Perspectives at the end of 2008, under the same title and with the following author list: White 
S.S., Kato K., Jia L.T., Basden B.J., Calafat A.M., Wolf D.C., Hines E.P., Stanko J.P., and 
Fenton S.E.  
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Abstract 
Background:  Prenatal exposure to perfluorooctanoic acid (PFOA), a ubiquitous 
industrial pollutant, has previously been reported to delay mammary gland (MG) 
development in female mouse offspring and the treated (P0) lactating dam.  Objective:  The 
aim of this study was to determine the consequences of PFOA-induced MG developmental 
delays on F1 lactational function and MG tumor susceptibility, and subsequent development 
of F2 offspring.  Methods:  We treated P0 dams with 0, 1, or 5 mg PFOA/kg/day on gestation 
days 1-17.  Resulting adult F1 females were bred to generate F2 offspring, whose 
development was monitored over postnatal days (PND) 1-22.  F1 MG function was assessed 
on PND10 by timed-lactation experiments.  MG tissue was isolated from P0, F1, and F2 
females throughout the study and histologically assessed for age-appropriate development.  A 
subset of F1 females were challenged with the carcinogen, 7,12-dimethylbenz[a]anthracene, 
at 1 mg once weekly between 4 and 10 weeks of age, and monitored for MG tumor 
formation.  Results:  F1 dams exhibited delayed lactational differentiation, though no effect 
of treatment on milk volume or maternal behavior was detected. Body weights of F2 pups 
were not reduced by maternal exposure. Interestingly, MG developmental scores were 
reduced among F2 offspring of 5mg/kg dams.  While developmental PFOA exposure did not 
increase MG carcinogenesis incidence, latency to tumor formation was delayed in PFOA-
exposed adult F1 females.  Conclusions:  Our findings demonstrate that PFOA-induced 
delays in early life translate to delayed lactational MG differentiation, but suggest this has 
little detectable effect on the F2 offspring early in life.  Furthermore, these delays in MG 
development are so severe at the doses tested, that they impart a delay in induced-tumor 
formation. 
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Introduction 
Perfluorooctanoic acid (PFOA) is a fully-fluorinated eight-carbon chain with a single 
carboxylic acid functional group, which displays structural homology with the naturally 
occurring fatty acid caprylate.  PFOA is a member of the perfluoroalkyl acid (PFAA) family 
of compounds.  Like many other PFAAs, PFOA is used in the polymerization production of 
fluoropolymers and fluoroelastomers, which have extensive industrial applications [1].  
Furthermore, PFOA is a final breakdown product of many such fluorinated compounds, and 
resists degradation in the ambient environment by biota or physical processes [2].  The 
combined ubiquity of fluorinated products and the persistence of PFOA in the environment 
may be responsible for what is now recognized as widespread contamination of human and 
wildlife tissues with PFOA [3-5]. 
In humans, occupational exposure to PFAAs or their manufacture has long been 
known to result in increased organic fluorine in serum [6].  More recently, it has been 
recognized that the average non-occupationally exposed American has measurable PFOA in 
their blood serum, on average at a concentration of 3.9ng/ml [7].  Under occupational 
exposure settings, however, this internal dose can jump to more than 200 times this [8].  
Furthermore, communities near perfluorinated chemical plants, specifically in the Little 
Hocking district of West Virginia, where the municipal drinking water supply has been 
contaminated with PFOA at 3.55 ppb, yield individuals with serum PFOA concentrations at 
an average of 423 ng/ml [8].  Thus, there exists the potential for non-occupationally exposed 
Americans to receive substantial unanticipated exposures to PFOA. It is not known, however, 
if adverse health effects result from such exposures in these communities.  The potential 
toxicity of PFOA, and the dose threshold for toxic of effects in humans is still under study.    
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A number of studies in rodents have demonstrated the potential for gestational PFOA 
exposure to result in developmental toxicity [9-11].  The mammary gland, specifically, has 
proven to be a sensitive tissue with respect to the developmental endpoints addressed, 
including functional lactation, milk protein gene expression, and developing neonatal 
mammary gland structures [12].  Despite the observation of these changes to the mouse 
mammary gland that result from developmental exposures, precisely whether they represent 
adverse health outcomes is not known.   
To understand the consequences of altered mammary gland development, we 
performed a multigenerational study to examine the ability of the affected females to provide 
lactational support for their litters.  This study design also allowed us to examine other 
potentially adverse consequences of prenatal and early neonatal PFOA exposure, and to 
evaluate such endpoints as F1 susceptibility to mammary carcinogen-induced tumorigenesis, 
F1 lactatogenesis and lactational morphology, F2 body growth as a proxy for F1 milk 
nutritional and caloric content, and F2 mammary gland morphologic development.     
 
Materials and Methods 
Animals.  We acquired timed-pregnant CD-1 mice from Charles River Laboratories 
(Raleigh, NC). Sperm-positive females were designated GD 0, and delivered on the same day 
to U.S. EPA’S Association for Assessment and Accreditation of Laboratory Animal Care 
facilities.  Animals were weighed upon arrival, housed individually in polypropylene cages, 
and received food (LabDiet 5001, PMI Nutrition International LLC, Brentwood, MO) and 
tap water ad libitum.  Animal facilities were maintained on a 14:10-h light-dark cycle, at 20–
24°C with 40–50% relative humidity. Animals were found to be free of infectious diseases 
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prior to beginning the study. Animal protocols were reviewed and approved by the U.S. 
EPA’s National Health and Environmental Effects Research Laboratory Institutional Animal 
Care and Use Committee in advance of our undertaking these studies. 
 
Dosing solutions.  PFOA as its ammonium salt (> 98% pure) was acquired from 
Fluka Chemical (Steinhiem, Switzerland).  PFOA dosing solution was prepared fresh daily in 
deionized water (known to contain trace PFOA), at a concentration of 0.5 mg/ml.  
 
Study design.  A schematic of the study timeline is shown in Figure 4-1.  One hundred 
fifteen dams, randomly divided amongst three groups, were treated once daily on GD 1–17, 
with 0 (control; N = 43 dams), 1 (N = 42 dams), or 5 mg PFOA/kg BW (N = 30 dams).  The 
dose of 5 mg PFOA/kg BW/day was chosen based on previous work that found this dose to 
significantly alter offspring mammary gland development [12], and was not meant to 
reproduce average human serum PFOA concentrations previously discussed.  Additionally, a 
subset of control (control + 5ppb PFOA; N = 13) and 1mg/kg (1mg/kg + 5ppb PFOA; N = 
12) dams received PFOA in their drinking water at a concentration of 5ppb throughout 
gestation and for the lifetime of the study, as did their subsequent F1 and F2 offspring.  
Weekly water consumption per cage was tracked, and on-going PFOA exposure was 
calculated with this information.  This value of 5ppb was chosen based by on epidemiologic 
studies that suggest the potential for human drinking water exposures at 3.55ppb [8]. 
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Figure 4-1.  Study timeline.  The schedule of treatment, breeding, and observation for the 
three generations, P0, F1, and F2, are plotted along the timeline for the study. 
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Dams were weighed daily throughout gestation. At birth, pups were individually 
weighed and sexed. Pups were pooled and randomly redistributed amongst the dams of 
respective treatment groups, and litters were equalized to 12-13 pups, with equal gender 
representation where possible.  On PND 22 the offspring were weaned, and the dams and one 
female offspring per litter were necropsied.  Adult F1 females were additionally sacrificed at 
6 and 9 weeks postnatally (PND 42 and 63).  A subset of adult F1 females from each of the 
five treatment groups received once weekly 1mg/dose treatments with 7,12-
dimethylbenz[a]anthracene (DMBA) between 4 and 10 weeks of age, to induce mammary 
gland tumors (N = 16 females per treatment group).  A subset of the remaining adult F1 
females were bred to age-matched control males on the night of proestrus, at 7-8 weeks 
postnatally.  Plug-positive females were designated GD 0, housed individually, and weighed 
daily over gestation (N = 8-10 dams per treatment group).  Females receiving chronic PFOA 
drinking water exposures (control + 5ppb PFOA, 1mg/kg + 5ppb PFOA) were maintained 
under these conditions during breeding, gestation, and nursing.  A lactational challenge 
experiment was performed with F1 dams on PND 10, whereby dams were separated from 
offspring for three hours, then returned to their litters and allowed to nurse for 30 minutes.  
The time between reunion and initiation to nurse was recorded, as was the weight of the 10-
pup litter before and after precisely 30 minutes of nursing, in order to determine the volume 
of milk produced in the set period.  F1 dams and one F2 female offspring per litter were 
sacrificed at either PND 10 or 22.  Weaned F2 females were necropsied on either PND 42 or 
63.   Remaining virgin F1 females were necropsied at 6-months, as matched controls for the 
DMBA-treated F1 females.  
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Necropsy.  P0 and F1 dams at weaning (PND 22), F1 and F2 offspring at PND 22, 42 
and 63, and F1 adults at 6-months postnatally were sacrificed by decapitation and trunk 
blood was collected and stored at -80°C in polypropylene tubes for dosimetric studies. The 
fourth and fifth inguinal mammary glands were collected from all females at necropsy. One 
side was prepared as whole mounts, and portions of the contralateral glands were placed in 
10% neutral buffered formalin for histological preparation. Uteri were dissected from P0 and 
F1 dams to determine the number of implantation sites.  Upon removal, uteri were placed in 
phosphate-buffered saline. The number of uterine implantation sites per dam was visually 
determined by light macroscope (Leica WILD M420 macroscope, Leica, Wetzlar, Germany), 
to determine rates of postimplantation loss. 
 
Mammary gland preparation.  Mammary glands were removed from dams on PND 
10 and 22 because these time points represent peak lactational output from the dam, and the 
time that pups begin to wean themselves from the dam, respectively.  In offspring, the ages 
of PND 10, 22, 42, and 63 were chosen because normal development of the gland at these 
time points is well understood.  The entire fourth and fifth glands were removed from dams 
and female pups, and mounted flat on glass slides. Whole mounts were fixed in Carnoy’s 
solution, stained in alum carmine stain, and dehydrated and cleared in xylene, as previously 
described [13]. A portion of the contralateral mammary glands was removed, as was any 
palpable tumourous tissue in DMBA-treated adult F1 females, then placed in a histology 
cassette, fixed in 10% neutral buffered formalin for 48 h, and stored in 70% ethanol. The 
glands were paraffin-embedded and 5-!m sections were prepared and stained with 
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hematoxylin and eosin (H & E). Whole mounts and histological sections were visualized by 
the aforementioned light macroscope. 
Mammary gland whole mounts from female offspring were scored on a 1–4 
subjective, age-adjusted developmental scale (as described in [14], 2004; 1 = poor 
development/structure; 4 = normal development/structure, given age). The developing tissue 
was assessed for number of primary ducts, number of large secondary ducts, and lateral side 
branching, appearance of budding from the ductal tree and longitudinal outgrowth of the 
epithelia. Slides were separated by score as they were evaluated, compared within a score for 
consistency, and then recorded. Two independent scorers, blind to treatment, scored glands 
within the age groups. Mean scores for the two ages, within treatment groups, were 
calculated and analyzed statistically for treatment and time-related differences. Lactating 
mammary gland H&E-stained sections were similarly scored on a 1-4 subjective scale, a 
value of 4 representing well-differentiated tissue with extensive epithelial tissue filling the 
gland, and presence of well-formed, productive alveoli, all seen in optimally functioning 
lactating tissue at the peak of lactation (as previously described in [15]).  A value of 1 would 
represent little or diminishing presence of lobuloalveoli and extensive involution of the 
tissue, with the normal presence of apoptotic bodies and regressing alveoli, as would be 
expected at observed at weaning (PND22).  Histological sections of normal and tumorous 
tissue were visualized by light microscope (Nikon Eclipse E600, Nikon, Tokyo, Japan), and 
were assessed for malignancies, preneoplastic lesions and areas of hyperplasia, excessive 
inflammation, and localized lymphoma.  Magnifications are shown in figures.  Typical 
mammary glands, representing the mean score or observation for each treatment group, were 
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photographed using the described scope and mounted camera (Photometrics CoolSNAP, 
Roper Scientific, Inc., Tucson, AZ).   
 
Measurement of PFOA in serum.  Serum samples from the P0 and F1 dams at PND 
22, F1 and F2 pups at PND 22, 42, and 63, and F1 females at 6-months postnatally were 
prepared at the Environmental Protection Agency.  All serum samples were stored frozen in 
polypropylene vials, shipped on dry ice to the Centers for Disease Control and Prevention’s 
(CDC) National Center for Environmental Health laboratory, and then kept at or below -40ºC 
until analysis. Measurement of the concentrations of PFOA in serum was performed by the 
CDC using the HPLC-tandem mass spectrometry methodology as previously described [16]. 
 
Data analysis.  Data were evaluated for dose effects using mixed-model analysis of 
variance (ANOVA) in SAS 9.1 (SAS Institute, Inc. Cary, NC).  For all measurements, means 
were evaluated and effects of dose compared. For both generations, treatment-specific mean 
body weight gain was calculated for dams (P0 and F1) between GD 1 and 17, and for F1 and 
F2 pups, with litter as the unit of measure, on PND 22, 42, and 63.  F2 offspring body weight 
means were calculated also at PND 1, 3, 5, 10, 14, and 17, based on whole litter weights.  For 
all three generations, mean mammary gland lactational or developmental scores were 
calculated.  Scores were analyzed using body weight at time of collection as a random effect, 
with litter as the unit of measure for neonatal scores.  For both P0 and F1 dams, mean 
implant number, percentage of postimplantation loss, and percentage of postnatal survival 
was calculated.  Differences between treatment groups were determined using Dunnett’s or 
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Tukey’s t-tests (significance at the level of p < 0.05 for all comparisons, in text and figures), 
with SAS. 
 
Results 
P0 dams and F1 offspring.  As previously observed, the dose of 5mg/kg PFOA over 
gestation was sufficient to reduce postnatal growth and survival, though no such effect was 
observed with the lower dose of 1 mg/kg PFOA, nor either of the chronic low-dose drinking 
water groups (Table 4-1).  No effect on P0 gestational weight gain or implant number was 
observed at any dose.  As such, and consistent with prior studies [10, 11], maternal toxicity 
among P0 dams was not deemed directly responsible for F1 growth deficits.  The same 
observations in treated dams were made in these previous studies, and in conjunction with 
increases in neonatal mortality among 5mg/kg PFOA-exposed offspring, as replicated here, 
further support the role that altered lactation in the dam may play in postnatal offspring 
survival.   
Lactational morphology was compromised among all PFOA-treated P0 dams at PND 
22, and these affected glands appeared structurally similar to dam mammary tissue earlier in 
the lactational period, including the presence of functional lobuloalveolar units in the absence 
of extensive gland regression seen in control dams.  This is consistent with prior work that 
suggested that gestational PFOA exposure delayed lactational differentiation in the dam [12], 
but is observed here at as low a dose as only 5ppb PFOA in drinking water for a total of 40 
days. 
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Table 4-1.  Maternal and developmental indices of P0 and F1 generations, respectively. 
 
PFOA exposure parameters 
 
 
Control 
Control + 
5ppb PFOA 
 
1 mg/kg 
1 mg/kg + 
5ppb PFOA 
†
 
 
5 mg/kg 
 
Maternal indices, F0 (n = 7-11) 
    
   Gestational weight gain (g) 24.8 ± 1.2 25.0 ± 1.2 26.0 ± 1.2 27.0 ± 1.2 27.7 ± 1.2 
   Implants (# per live litter) 12.8 ± 0.5 12.7 ± 0.4 13.5 ± 0.7 14.0 ± 0.4 13.7 ± 0.6 
   Live fetuses (# per live litter) 12.0 ± 0.5 11.7 ± 0.4 12.9 ± 0.7 13.3 ± 0.5 10.0 ± 0.8* 
   Prenatal loss (% per live litter) 6.1 ± 1.8 7.8 ± 1.7 4.5 ± 1.7 5.1 ± 1.6 25.8 ± 5.6* 
   Postnatal survival (% per live litter) 96.1 ± 1.3 100 ± 0.0* 98.8 ± 0.8 89.5 ± 6.4 72.7 ± 5.8* 
   Mammary gland score (1-4 scale)      
      PND 22 2.4 ± 0.2 3.4 ± 0.1* 3.0 ± 0.2* 3.2 ± 0.2 3.9 ± 0.1* 
 
Developmental indices, F1 females (n = 4-10) 
     
   Body weight (g) at age      
      PND 22 12.70 ± 0.69 12.69 ± 0.87 13.40 ± 0.49 13.20 ± 0.37 11.28 ± 0.45 
      PND 42 25.65 ± 0.43 24.28 ± 0.57 24.24 ± 0.74 24.90 ± 0.62 22.28 ± 0.60* 
      PND 63 28.77 ± 0.96 26.23 ± 1.81 29.93 ± 0.97 26.35 ± 0.84# 27.88 ± 1.25 
   Mammary gland score (1-4 scale)      
      PND 22 3.8 ± 0.1 2.5 ± 0.2* 2.3 ± 0.2* 2.2 ± 0.1 1.6 ± 0.1* 
      PND 42 3.8 ± 0.1 3.3 ± 0.2* 2.6 ± 0.4* 2.2 ± 0.3 2.3 ± 0.2* 
      PND 63 3.8 ± 0.2 2.6 ± 0.4* 2.9 ± 0.2* 2.0 ± 0.3# 2.2 ± 0.2* 
   Liver: body weight ratio (x100%)      
      PND 22 5.56 ± 0.16 5.29 ± 0.13 6.35 ± 0.08* 5.96 ± 0.12 7.81 ± 0.34* 
      PND 42 5.19 ± 0.24 5.75 ± 0.22 5.32 ± 0.10 5.26 ± 0.13 5.79 ± 0.09* 
      PND 63 4.85 ± 0.17 4.99 ± 0.12 4.97 ± 0.13 4.82 ± 0.15 5.24 ± 0.28 
* p < 0.05 compared to Control;  # p < 0.05 when 1mg/kg + water compared to 1mg/kg. 
†  Comparison of 1 mg/kg + water group made only with 1 mg/kg group (not control group). 
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During observation between PND 22 and 63, F1 offspring body weights were not 
consistently reduced by any PFOA treatment.  However, liver-to-body weight ratios were 
elevated at PND 22 amongst F1 females exposed to either 1 or 5 mg/kg, and at PND 42 in 5 
mg/kg F1 females.  This effect, likely the result of transient hepatomegally due to 
hepatocellular hypertrophy under high internal PFOA dose, was overcome by 9 weeks 
postnatally in these animals, though, as circulating PFOA concentrations fell [16].  
Developmental mammary scores among F1 offspring, however, were reduced among all 
treatment groups, and these developmental delays persisted to at least 9 weeks of age (PND 
63), when observation concluded (Figure 4-2).  At 6 months of age, PFOA-exposed adult F1 
females exhibited altered mammary gland morphology and increased frequency of darkly-
staining foci apparent in whole mount preparations (not scored on developmental scale), 
suggesting permanent effects in the gland similar to that reported previously in 18-month old 
animals [16], but resulting at the lower doses of 1 mg/kg PFOA on GD 1-17, or 5ppb 
chronically in drinking water.  
 
F1 dams and F2 offspring.  As anticipated, no maternal toxicity was observed in F1 
dams with developmental or chronic, low-level PFOA exposure.  Interestingly, the number of 
uterine implants was reduced among dams in the 5mg/kg group, resulting in litters with 
fewer pups.  However, no effect of F1 developmental exposure was observed on postnatal 
survival of F2 offspring, suggesting sufficient lactational competency of the gland in these 
exposed F1 females to be able to support litters.  In the lactational challenge, neither milk 
volume nor nursing behavior was affected by developmental or chronic, low-level PFOA 
exposure of these F1 dams.  Nevertheless, F1 lactational morphology was compromised 
among all treatment groups at PND 10 (Figure 4-3).  By PND 22, these morphological delays  
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Figure 4-2.  F1-female offspring mammary gland development of over life.  Carmine-stained 
whole mount preparations of mammary tissue. Glands pictured show morphology 
representative of respective treatment groups at given time points (N = 6-7 females per 
treatment group per time point). *Significant treatment effect by ANOVA; p < 0.05.  ND = 
no statistics determinable. †  Comparison of 1 mg/kg + 5ppb PFOA group made only with 
1mg/kg group (not control group); # p < 0.05 when 1mg/kg+5ppb PFOA compared to 
1mg/kg.  
 129 
 
 
 
 
Figure 4-3. F1-dam lactating mammary gland differentiation.  H&E-stained histological 
sections of lactating F1 dam mammary tissue are shown at 200X. Glands pictured show 
morphology representative of respective treatment groups at given time points (N = 4 dams 
per treatment group per time point). *Significant treatment effect by ANOVA; p < 0.05. †  
Comparison of 1 mg/kg + 5ppb PFOA group made only with 1mg/kg group (not control 
group). 
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were overcome, and only F1 dams with the highest developmental exposure, 5 mg/kg PFOA, 
still exhibited delayed lactational differentiation, showing few signs of normal regression.  
For reference, it should be noted here that at the same time these F1 dams were pregnant and 
undergoing lactational differentiation, their virgin counterparts were still exhibiting stunted 
mammary gland development (PND 63, Figure 4-2).    
Despite morphological changes in the lactating F1 gland, diminishments in nutritional 
support provided by these dams were not detected, as F2 body weights were similar to 
controls.  Interestingly, between PND 14 and 22, F2 offspring of dams with an intermediate 
PFOA exposure (1mg/kg) exhibited higher body weights compared to controls.  However, 
this effect appeared to be driven by larger males in the 1mg/kg F2 litters, as no increases in 
body weight compared to controls were observed when the body weights of female offspring 
in the 1mg/kg and control groups were considered independent of males.  
Unlike F1 females, developmental mammary gland scores in F2 females were largely 
unaffected by maternal exposure, however, control F2 females exhibited unusually low 
scores at PND 10 and 22 which might have resulted in reduced power to detect effects in 
other groups at these time points (Table 4-2). At weaning mammary gland scores were 
reduced among F2 offspring from dams with the highest developmental exposure, 5 mg/kg 
(Figure 4-4).  Then at PND 63, F2 offspring from dams with the intermediate developmental 
exposure, 1 mg/kg PFOA, exhibited developmental scores statistically lower than controls.  
Chronic, low-dose PFOA in drinking water alone did not reduce mammary gland scores at 
any time point.  However, at PND 42, 5ppb PFOA in F2 females from dams with 1 mg/kg 
PFOA produced reduced gland scores as compared to F2 females from dams with only 1 
mg/kg developmental exposure (Table 4-2).  While not statistically identifiable, a  
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Table 4-2.  Maternal and developmental indices of F1 and F2 generations, respectively.  
 
 PFOA exposure parameters  
 
 
Control 
Control   + 
5ppb PFOA 
 
1 mg/kg 
1 mg/kg  + 
5ppb PFOA
†
 
 
5 mg/kg 
 
Maternal indices, F1 (n = 4-10) 
 
  
  
  Implants (# per live litter) 14.9 ± 0.4 14.6 ± 0.5 14.1 ± 0.4 13.4 ± 0.9 12.3 ± 0.2* 
  Live fetuses (# per live litter) 13.6 ± 0.6  13.1 ± 0.6 12.8 ± 0.6 12.1 ± 0.9 12.0 ± 0.3* 
  Prenatal loss (% pre live litter) 8.6 ± 2.5 9.8 ± 3.2 10.0 ± 3.2 6.7 ± 2.5 2.7 ± 1.4 
  Postnatal survival (% per live litter) 100 ± 0.0  100 ± 0.0 98.1 ± 1.4 97.9 ± 1.5 100 ± 0.0 
  Lactational challenge      
      Milk produced in 30 min (g) 2.10 ± 0.20 1.80 ± 0.35 2.08 ± 0.25 1.40 ± 0.44 1.73 ± 0.51 
      Time to initiate (s) 267 ± 38 384 ± 55 307 ± 114 351 ± 86 279 ± 30 
  Mammary gland score (1-4 scale)      
      PND 10 4.0 ± 0.0 2.8 ± 0.5* 2.5 ± 0.2* 2.0 ± 0.2 2.5 ± 0.2* 
      PND 22 2.1 ± 0.3 2.2 ± 0.2 1.9 ± 0.4 1.5 ± 0.2 3.2 ± 0.3* 
 
Developmental indices, F2 (n = 4-10) 
 
  
  
  Body weight (g) at age       
      PND 1 1.71 ± 0.03 1.61 ± 0.03* 1.63 ± 0.05 1.68 ± 0.05 1.65 ± 0.04 
      PND 3 2.27 ± 0.05 2.22 ± 0.05 2.25 ± 0.09 2.30 ± 0.09 2.22 ± 0.06 
      PND 5 3.24 ± 0.07 3.35 ± 0.10 3.38 ± 0.11 3.42 ± 0.15 3.34 ± 0.09 
      PND 10 5.69 ± 0.22 5.83 ± 0.23 6.00 ± 0.19 5.96 ± 0.18 5.87 ± 0.20 
      PND 14 6.26 ± 0.06 6.34 ± 0.05 7.30 ± 0.25* 7.54 ± 0.33 6.85 ± 0.26 
      PND 17 6.64 ± 0.13 7.05 ± 0.06 8.15 ± 0.31* 8.19 ± 0.39 7.42 ± 0.37  
      PND 22 10.80 ± 0.28 11.41 ± 0.26 13.00 ± 0.50* 13.29 ± 0.61 11.60 ± 0.54 
 Mammary gland score  (1-4 scale)      
      PND 10 2.8 ± 0.3 3.0 ± 0.2 1.9 ± 0.3 2.6 ± 0.2 2.0 ± 0.2 
      PND 22 3.1 ± 0.4 2.0 ± 0.3 2.3 ± 0.1 2.3 ± 0.3 1.9 ± 0.2 
      PND 42 3.5 ± 0.2  2.7 ± 0.4 3.4 ± 0.2 2.7 ± 0.2
# 
3.4 ± 0.3 
      PND 63 3.4 ± 0.2  3.5 ± 0.2 2.4 ± 0.2* 2.6 ± 0.5 2.8 ± 0.3 
 Liver: body weight ratio  (x100%)      
      PND 10 2.94 ± 0.15 2.94 ± 0.12 3.08 ± 0.14 2.73 ± 0.14 2.91 ± 0.09 
      PND 22 5.43 ± 0.14 5.25 ± 0.25 5.10 ± 0.21 5.18 ± 0.23 5.11 ± 0.15 
      PND 42 5.43 ± 0.13  5.47 ± 0.10 5.78 ± 0.12 5.36 ± 0.19 5.63 ± 0.21 
      PND 63 5.28 ± 0.25 5.13 ± 0.19 5.05 ± 0.11 5.10 ± 0.15 4.79 ± 0.25 
 * p < 0.05 compared to Control;  # p < 0.05 when 1mg/kg + 5ppb PFOA compared to 1mg/kg. 
 †  Comparison of 1 mg/kg + 5ppb PFOA group made only with 1 mg/kg group (not control group). 
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Figure 4-4. F2-female offspring mammary gland development of over life.  Carmine-stained 
whole mount preparations of mammary tissue. Glands pictured show morphology 
representative of respective treatment groups at given time points (N= 4-5  females per 
treatment group per time point). *Significant treatment effect by ANOVA; p < 0.05. †  
Comparison of 1 mg/kg + 5ppb PFOA group made only with 1 mg/kg group (not control 
group); # p < 0.05 when 1mg/kg+5ppb PFOA compared to 1mg/kg. 
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morphological trend of reduced branching was observed in F2 mammary tissue from both 
chronic, low-dose drinking-water groups, and is evident in Figure 4-4. 
 
Serum dosimetry.  As can be seen in Figure 4-5, the gestational doses of 1 and 5 
mg/kg resulted in the highest circulating PFOA levels – in P0 dams and early F1 offspring – 
nearest in time to the cessation of PFOA administration.  Furthermore, dosimetry in both 
treated P0 dams and exposed F1 offspring consistently support a factor of five difference 
exhibited in the dosimetry of 1 and 5 mg/kg treatment groups, suggesting that no threshold is 
reached where PFOA is either accumulating or being eliminated via altered kinetics.  In F1 
offspring at 9 weeks postnatally, serum PFOA concentrations in the 5 mg/kg group are nearly 
down to levels exhibited in the chronic drinking water exposure groups.  By the time bred F1 
females are weaning their litters, at approximately 13-weeks of age, serum PFOA 
concentrations in the drinking water exposure groups have surpassed those of the 1 and 5 
mg/kg groups, which are continuing to eliminate PFOA from earlier exposures.  The control 
+ 5ppb PFOA group is particularly interesting, as averaged over their lifetimes the F1 and F2 
generations exhibit nearly identical mean serum PFOA concentrations, at 59.5 and 50.8 
ng/ml, respectively.  Furthermore, because the final measurement taken on the F1 generation 
is at 13-weeks postnatally, as compared to only 9-weeks postnatally for the F2 generation, 
the average may be skewed higher in the F1 generation only because of the additional time in 
which PFOA was allowed to accumulate.     
 
Mammary tumor susceptibility.  Of the detectable masses collected from mammary 
tissue, the exclusive tumor type arising from mammary gland parenchymal cells was 
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(A) 
(B)  
        
Figure 4-5. Serum PFOA dosimetry over three generations.  (A) Serum PFOA concentrations 
are shown for P0 dams at weaning (PND 21) and F1 offspring serum over time, at 3, 6, and 9 
weeks postnatally.  (B) Serum PFOA concentrations are shown for F1 dams at weaning 
(PND 21) and F2 offspring serum over time, at 3, 6, and 9 weeks postnatally.  F1 dams are 
13-14 weeks of age at weaning.  Note scale is about 1/100th that shown in (A). (N= 4-8 
females per treatment group per time point). 
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adenocarcinoma (Table 4-3; Figure 4-6).  Animals receiving DMBA were weighed and 
palpated weekly, starting four weeks after cessation of DMBA treatment.  Once a palpable 
mass was identified, it was closely monitored for size and location, and for interference in 
animal quality of life.  If the mass interfered with survival, the animal was euthanized and the 
mass was collected for histology.  All palpable tumors as well as unusual growths in the 
mammary tissue visible at final necropsy (6-months postnatally) were sectioned and 
pathologically assessed for mammary tumorigenesis.  The only discrete mammary tumor 
type observed was adenocarcinoma, independent of PFOA exposure.  The incidence of 
adenocarcinoma was not affected by developmental PFOA exposure, nor was multiplicity 
(Table 4-3).  However, latency to appearance of palpable tumors was extended under 
developmental PFOA exposure, as well as chronic, low-dose exposure, by up to 4 weeks 
(Table 4-3).  This suggests that had the duration of the study been extended, incidence of 
adenocarcinoma of the gland may have increased in PFOA-exposed animals, over the levels 
reported here.  Alternatively, adenocarcinoma incidence may not have increased with time, 
as the number of DMBA mutagenesis targets may have been inherently smaller in the PFOA-
exposed F1 adults, which might be reflected in apparent decreases in the total epithelial 
population as is measured by the histological scores applied in this paper.  The appearance of 
lymphomas, independent of mammary carcinomas and metastatic disease, in PFOA-exposed 
animals may have resulted from the combined assault on the immune system by PFOA and 
DMBA, as both are known to have deleterious effects on immune response and tissues [17]. 
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Table 4-3.  Incidence and observations of histological changes in the mammary gland of 
DMBA-treated F1 females. 
  
PFOA Exposure Parameters 
 
 
 
Control 
Control   + 
5ppb PFOA 
 
1 mg/kg 
1 mg/kg  + 
5ppb PFOA
†
 
 
5 mg/kg 
Incidence of mammary-specific effects       
     Adenocarcinoma 7 / 11 4 / 9  2 / 11  1 / 13 2 / 6 
     Dysplasia  3 / 4 1 / 5 5 / 9  7 / 12 2 / 4 
     Metastatic disease 3 / 7 2 / 4 0 / 2 1 / 1 2 / 2 
Multiplicity      
     Mean tumor number in animals      
     with adenocarcinomas  
1 1.5 1.5 1 2 
Latency to appearance       
     Mean time until first palpable mass (wks) 10.9 14.8 13.6 14.1 12.3 
Incidence of mammary-independent effects      
     Lymphoma 0 / 4 2 / 5 4 / 9 1 / 12 1 / 4 
The denominator for the first measure (adenocarcinoma incidence) defines N for each group.  The term 
“dysplasia” is used as an umbrella term to refer to a number of abnormal changes in parenchymal cells 
including hyperplasia and preneoplasia.  Multiplicity is calculated as total number of observed adenocarcinomas 
observed divided by the number of affected animals.  Latency is calculated as the average time per group, in 
number of weeks after the final treatment with DMBA, before the first palpable tumor appears.   
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Figure 4-6. H&E stained histological sections of mammary gland masses.  Examples of 
adenocarcinomas in control and 5 mg/kg PFOA treated animals are shown at 250X. 
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Discussion 
Our previous studies identified morphological delays in mammary gland development 
that resulted from PFOA exposure during development, but did not determine whether those 
morphological effects translated to functional consequences or altered carcinogenesis risk.  
Here, we have shown that the effects on offspring mammary development, that result from 
treatment of dams with PFOA during development, persist and translate to morphological 
delays in lactational differentiation.  However, delayed lactational morphology did not 
appear to reduce the nutritional value of the milk produced, as F2 offspring survived 
postnatally and gained weight normally.   
The degree to which this altered F1 mammary gland morphology that persists from 
the neonatal period represents an adversity, is difficult to precisely determine with respect to 
functional consequences, as these studies considered only impaired ability to lactationally 
support litters as the measure of adversity.  The effects in the F1 glands did not result in the 
significant decreases in body weight and postnatal survival seen with the first generation, 
however, this does not rule out other, less profound effects in the F2 generation that are not 
detectable at the gross levels of size and mortality.  Future studies might address lactational 
function at the level of milk quality and content, via gene and protein expression assessment 
and lipid profile analysis.  In our lab we are continuing to address the changes induced by 
PFOA in the mammary gland, by examining gene expression profiles in the developing and 
lactating gland following PFOA administration, in order to better characterize the potential 
modes of action by which PFOA acts in this tissue.   
These data suggest that developmental exposure to PFOA may not interfere with the 
capacity for the female mammal to lactate, but may delay lactation initiation and latency to 
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peak milk output.  In the case of humans, where viable alternatives to breast milk are 
available, low-level functional effects in lactation that cause even a short delay in substantial 
milk output may translate to formula-feeding instead of breast-feeding.  Because the health 
benefits of breast-feeding over formula-feeding are well established, if an increase in 
formula-feeding were to result from the exposure of a population to PFOA, it might easily 
represent an adverse consequence with respect to the increased economic costs placed on the 
medical system, albeit far in the future.  In wildlife species, critically reliant upon lactation to 
raise their offspring, differential responsiveness of the gland to PFOA, might leads to delays 
in milk production that could result in starvation of the offspring.  An alternative perspective, 
however, might be that it seems plausible that reduced but not entirely diminished lactation 
in the dam might induce offspring to suckle with greater intensity, potentially resulting in 
greater prolactin release and increased milk production with more rapid letdown, thereby 
compensating for impaired lactational function.  
With respect to carcinogenesis risk, as opposed to solely functional consequences, 
some effect of developmental PFOA exposure was apparent.  While no change was apparent 
in the type of mammary tumor induced by DMBA exposure, developmental PFOA exposure 
substantially increased the latency time to the appearance of palpable tumors.  Presumably, 
this reflects a reduction in the total epithelial population, and therefore fewer targets for 
DMBA-induced mutagenesis.  Such consequences of developmental PFOA exposure should 
not be deemed a protective effect, however, as the mammary glands of these animals are not 
without effect at either the functional lactating level, or the tumorigenic level.  
It is important to note that these studies did not address consequences on lactation 
with the second or later litter, nor did they address carcinogenesis risk in the non-virgin, 
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previously lactationally-functional gland.  Such studies might have reached different 
conclusions than did ours, as we know that the former lactational state of the mammary gland 
can alter risk, and tumorigenesis risk decreases with increasing number of lactational events.  
One of the most interesting findings of this study was that chronic, low-dose PFOA 
exposure in drinking water at human-relevant levels (5ppb) was sufficient to produce 
developmental mammary gland delays.  In an epidemiological study by Emmett et al. [8], 
non-occupationally exposed humans that were exposed to PFOA in municipal supply 
drinking water at 3.55 ppb exhibited a mean serum PFOA concentrations of 423 ng/ml 
compared to the national average of 3.9 ng/ml [7].  In these studies, we found that chronic 
exposure to slightly higher levels of PFOA – administered via the same route and across a 
similar temporal distribution – resulted in lower circulating PFOA concentrations in serum 
(life averages: F1 females = 59.5 ng/ml, F2 females = 50.8 ng/ml) than seen in humans.  This 
suggests that either the pharmacokinetics of low-dose PFOA in the mouse differ from that in 
the human, or that the non-occupationally exposed humans are receiving exposure to PFOA 
via additional, uncharacterized sources.   
It is interesting to note that at the 5ppb level, there was little difference in lifetime 
average serum PFOA concentration between F1 and F2 generations.  This demonstrates that 
the resultant internal dose in F1 females during pregnancy does not lead to altered 
programming of F2 tissue, with respect to expression of transporters that might increase 
elimination.  This tells us nothing, however, about potentially altered expression patterns of 
the nuclear receptor activated by PFOA, peroxisome proliferator-activated receptor alpha.  
Nor does it illuminate the specific mechanism that might underlie the effects observed in 
multiple generations.    
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Our findings suggest that chronic, low-level exposure to only 5ppb PFOA in drinking 
water results in increasing PFOA in circulation, which plateaus in the mouse at 50-100 
ng/ml.  Furthermore, such low internal doses were associated with alterations in mammary 
gland morphology.  As humans with lower-dose, chronic exposures under similar conditions 
exhibit even higher circulating PFOA, the data that we collected on these animals may 
actually under-represent human-relevant exposure conditions.  However, it is not known how 
the mammary gland-specific effects of PFOA will translate to the human, and more research 
will be needed to illuminate the mode of action of PFOA in the mammary gland, and the 
relevance of that mode of action to human breast health.  
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CHAPTER 5 
 
Potential Modes of Action by Which PFOA May Alter  
Mammary Gland Differentiation and Development 
 
 
 
Preface 
 
 This chapter was aimed at determining whether PPAR! activation – the only 
identified mode of action for PFOA-induced toxicity – is the mode of action by which PFOA 
affects the developing and differentiating mammary gland.  Additional data is currently being 
collected for inclusion in this manuscript, before it is submitted to a peer-reviewed journal.  
The final manuscript will be submitted to Toxicological Sciences, under the same title with 
the following author list: White S.S., Woods C.R., Hines E.P., Stanko J.P., Wolf C.J., Abbott 
B.D., and Fenton S.E.    
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Abstract 
 Perfluorooctanoic acid (PFOA) is a recognized activator of the peroxisome 
proliferator-activated receptor alpha isoform (PPAR!), and is believed to induce hepatic 
tumorigenesis in rodents via this mechanism.  Developmental PFOA toxicity, including 
reduced postnatal growth and survival of neonates, has been identified as dependent upon 
PPAR! expression.  Because developmental PFOA exposures may interfere with 
development of the mammary gland (MG), in the absence of PPAR!-mediated reductions in 
postnatal growth, an alternate mode of action might be responsible.  To determine whether 
PFOA-induced alterations in the lactating or developing MG are enacted through PPAR! 
signaling, pregnant 129S1/SvlmJ wild-type (WT) and PPAR! knock-out (KO) mice received 
0, 0.1, 0.3, or 1 mg/kg PFOA on gestation days 1-17.  MG tissue was collected at weaning 
from dams and offspring, and at 18-months from offspring, to evaluate tissue morphology.  
In a separate study, pregnant CD-1 mice were treated with 0 or 5 mg/kg PFOA, and MG gene 
expression in dams and offspring was examined.  In lactating dams, PFOA treatment 
diminished lactational differentiation in WT but not KO dams.  In offspring, however, effects 
of PFOA exposure were apparent in both WT and KO offspring at 22-days postnatally, 
suggesting an alternate, non-PPAR! mode of action may be responsible for offspring 
mammary effects, unlike dam lactational effects.  Gene expression in CD-1 mammary tissue 
did not reveal an alternative mode of action to PFOA, nor did it provide support for PPAR! 
activation in the gland.  These data suggest that to elucidate other modes of action that might 
be acting in the mammary gland -- independent of, or in tandem with PPAR! activation -- a 
global analysis of gene expression at multiple time points, in mammary tissue from all three 
mouse strains examined here, would be most informative for future studies. 
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Introduction 
PFOA is an industrial emulsifier and surfactant, utilized in the production of 
perfluorinated chemicals that have extensive commercial applications.  Though human 
sources of PFOA exposure are incompletely characterized, it has been recognized that in the 
US and other developed countries PFOA is an extremely prevalent human serum 
contaminant [1-4].  The average American exhibits a non-zero serum PFOA concentration, 
most recently measured at 3.9 ng/ml and detectable in 99.7% of the more than 2,000 tested 
individuals, representing a true cross-section of the American population [2].  
In communities surrounding perfluorinated chemical production plants, where 
drinking water has been contaminated with PFOA, non-occupationally exposed individuals 
have exhibited serum levels over 100 times the average American, with measured mean 
serum PFOA concentrations of 423ng/ml [3].  The individuals in this study were believed to 
receive exposure to PFOA exclusively or almost entirely via consumption of municipal water 
contaminated with 3.55ppb PFOA.  In a companion study, the same research group examined 
associations between adverse health effects, or biomarkers of health effects, and serum 
PFOA.  The endpoints they addressed largely focused on clinical chemistry in serum samples 
and hematological measures in blood samples.  That is to say, their biomarkers of adverse 
health effect were largely limited to disease endpoints that impact standard blood or liver 
indices, with the exception of their measure of thyroid-stimulating hormone.  Unfortunately, 
such measures would fail to identify many disease endpoints, including many cancers, prior 
to metastasis.  Furthermore, this study strictly drew associations between biomarker and 
PFOA measures at a single, matched time point, therefore this study would not be able to 
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draw any conclusions about exposures prior in life or disease states achieved later in life.  As 
some developmental toxicity studies of PFOA are now suggesting there is a potential for 
early life PFOA exposures to result in adverse health effects in the adult animal model, and at 
a time when serum PFOA is essentially absent [5, 6].         
PFOA is a ligand for PPAR!, and the identified toxicities of PFOA have largely been 
attributed to activation of this receptor [7, 8].  However, the common triad of tumors 
resulting from chronic PFOA exposure – hepatocellular, Leydig cell, and pancreatic acinar 
cell tumors – have not been demonstrated to arise strictly via this mode of action.  In the 
liver, activation of PPAR! by PFOA is believed to increase cell proliferation and decrease 
apoptosis, generating preneoplastic foci.  As these foci undergo clonal expansion, any 
mutations present are amplified across the new cell population, potentially giving rise to true 
liver tumors.  EPA’s draft risk assessment for PFOA considers this mode of action to not be 
relevant to human health, given the lower hepatic expression of PPAR! in humans compared 
to rodents.  In the testis, however, tumors are hypothesized to be generated indirectly, 
through PFOA-induced increases in hepatic expression of aromatase (CYP 19), which 
converts testosterone to estradiol, leading to chronic elevations in estradiol.  Interestingly, 
some occupational studies have suggested a positive association between circulating PFOA 
and estradiol levels.  Finally, pancreatic acinar cell tumors are believed to arise from changes 
in bile flow or bile composition, that give rise to increased cholecystokinin, sustained high 
levels of which are believed to produce these tumors.  The relevance of these latter two 
tumor types to human health has mostly been dismissed due to their infrequent appearance in 
humans.  Nonetheless, because PPAR! activation is currently the only recognized mode of 
action for the toxicity of PFOA, and this mode of action is deemed not human-relevant (with 
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respect to liver tumorigenesis), determining whether PPAR! activation is responsible for the 
observed changes in the mammary gland may have profound consequences on any decisions 
concerning the regulation of PFOA 
 The alterations in mammary gland development in the neonate and differentiation in 
the lactating dam have consistently been observed in developmental toxicity studies of PFOA 
in the mouse [5, 9].  How these effects are mediated is not known, though it has been 
presumed that, consistent with other toxicities observed in association with PFOA exposure, 
PPAR! agonism is the likely mode of action.  Here, PPAR! knock-out mice are utilized to 
determine whether PPAR! is strictly required for PFOA-induced MG changes.  In addition, 
CD-1 mice are utilized for gene expression studies to help reveal whether PPAR!-induced 
gene changes can be identified as occurring in tandem with altered MG development and 
differentiation.      
 
Materials and Methods  
PFOA.  Perfluorooctanoic acid (PFOA, ammonium salt; >98% pure) was purchased 
from Fluka Chemical (Steinhiem, Switzerland).  NMR analysis, kindly provided by 3M 
Company (St. Paul, MN, USA), indicated that approximately 98.9% of the chemical was 
straight-chain and the remaining 1.1% was branched isomers.  For all studies, PFOA was 
dissolved in de-ionized water and prepared fresh daily.  
 
Animals.  All animal studies were conducted in accordance with guidelines 
established by the National Health Effects and Environmental Research Laboratory 
Institutional Animal Care and Use Committee.  Procedures and facilities were consistent with 
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the recommendations of the 1996 NRC “Guide for the Care and Use of Laboratory Animals”, 
the Animal Welfare Act, and Public Health Service Policy on the Humane Care and Use of 
Laboratory Animals.  For gene expression studies, timed pregnant CD-1 mice were obtained 
from Charles River Laboratories (Raleigh, NC, USA), where females were bred overnight, 
and the sperm positive females, defined as GD 0, were shipped on the same day for use in 
these studies.  For mammary gland morphology studies, male and female 129S1/SvlmJ WT 
(stock #002448) and PPAR! KO (Ppara-tm1Gonz/J, stock #003580) mice were obtained 
from Jackson Laboratories (Bar Harbor, MA).  The PPAR! KO mice were produced by 
targeted mutation of exon 8, encoding the ligand-binding domain, in the laboratory of F. J. 
Gonzalez and are a viable, fertile strain [10]. Strain 129S1/ SvImJ is recommended as the 
best approximate match to the 129S4/SvJae background of the KO strain. Breeding colonies 
of WT and KO mice were established in the EPA Reproductive Toxicology Facility in 
Research Triangle Park, NC. Genotypes of the mice were confirmed by PCR analysis 
(method provided by Jackson Laboratories) using genomic DNA prepared from tail biopsies 
taken from at least one pup from every litter.  Upon arrival, mice were housed individually if 
pregnant, with Alpha-dri (Shepherd Specialty Papers, Kalamazoo, MI, USA) bedding.  
Animals were provided pellet chow (LabDiet 5001, PMI Nutrition International LLC, 
Brentwood, MO, USA) and tap water (known to contain PFOA at concentrations below the 
level of detection) ad libitum.  Animal facilities were controlled for temperature (20-24°C) 
and relative humidity (40-60%), and kept under a 12-h light-dark cycle. 
 
Gene expression study design.  As a part of a larger, previously reported study [5], 
sixteen timed pregnant CD-1 mice were received on GD 0.  Mice were weighed and 
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randomly assigned to treatment groups, and dosed orally by gavage at a volume of 10ml/kg, 
as follows:  vehicle control dosed with de-ionized water (n=4) or 5 mg PFOA/kg (n=4) on 
GD 1-17, or vehicle control dosed with de-ionized water (n=4) or 5 mg PFOA/kg (n=4) on 
GD 8-17.  On GD18-19, mice were monitored at frequent intervals until parturition and the 
date and time of birth, number of live and dead pups, and number of pups of each sex were 
recorded and litters were weighed by sex.  Litters were culled to 10 pups with equal 
representation of male and female (where possible). 
 The first two treatment groups, 0 and 5 mg PFOA/kg over GD 8-17, were utilized as 
previously described [5], and litters were observed and weighed on PND 1, 3, 5, and 10 
(described in Chapter 3), then dams and offspring were euthanized on PND 10.  The 
remaining two treatment groups, 0 and 5 mg PFOA/kg over GD 1-17 were euthanized at 
weaning, on PND 21.  At necropsy for both time points, body and liver weight measurements 
were made, and livers and serum samples were collected (reported in [5]).  The fourth and 
fifth inguinal MG were collected from dams in the early-life effects cross-foster study and 
female offspring and prepared as a whole mount (reported in [5]).  Contralateral glands were 
immediately submerged in TRI reagent (Sigma-Aldrich Corp., St Louis, MO) and frozen on 
dry ice for, for RNA isolation. 
 
Strain-specific mammary gland effects study design.  As a part of a larger, previously 
reported study [8], male and female mice of the same strain (either 129S1/SvlmJ WT or 
PPAR! KO strains) were bred overnight and plug positive females were randomly assigned to 
treatment groups.  On GD 1– 17 dams were weighed and dosed by oral gavage with either 
deionized water or PFOA at 0.1, 0.3, or 1 mg/kg/day at a volume of 10 ml/kg body weight.  On 
PND22, all dams and one pup per litter was sacrificed.  Remaining pups were weaned and 
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housed separately, for further late-life study, and sacrificed at 18 months postnatally.  At 
necropsy, body and liver weight measurements were made, and livers and serum samples 
were collected (reported in [8]).  The fourth and fifth inguinal MG were collected from dams 
and female offspring at PND 22, and from 18-month old female offspring and prepared as a 
whole mount.  To complement these observations, exposed CD-1 offspring described above, 
were ovariectomized prior to first estrous, to determine the role played by ovarian hormones 
in PFOA-induced alterations in mammary gland morphology.  At 18-months postnatally, 
these ovariectomized CD-1 offspring were necropsied and the fourth and fifth inguinal 
mammary glands were prepared as a whole mount.   
 
Reverse-Transcription Real-Time Polymerase Chain Reaction.  Total RNA was 
extracted from lactating or developing glands using TRI reagent according to the 
manufacturer’s suggestions, employing two chloroform extractions, and dissolving the RNA 
pellet in RNase-free water.  2 µg total RNA was initially digested using 2 units DNaseI 
(#M6101, Promega Corporation, Madison, WI) for 30 min at 37°C followed by 10 min at 65°C 
in a buffer containing 40 mM Tris (pH 8.0), 10 mM MgSO4, and 1 mM CaCl2. The RNA was 
then quantified using a Quant-iT RiboGreen RNA assay kit according to the manufacturer's 
protocol (#R11490, Invitrogen Corporation, Carlsbad, CA) and approximately 1.5 µg RNA 
reverse transcribed using a High Capacity cDNA Archive Kit according to the provided 
protocol (#4322171, Applied Biosystems). Amplification was performed on an Applied 
Biosystems model 7900HT Fast Real-Time PCR System in duplicate using 25 ng cDNA and 
TaqMan Universal PCR Master Mix (#4304437, Applied Biosystems) in a total volume of 12 
µl. Beta-2-microglobulin (B2m, Entrez #12010), which was uniformly expressed among all 
samples (cycle threshold standard deviation less than 0.5), was used as an endogenous 
reference gene. The following TaqMan assays (Applied Biosystems) were included in the 
study: B2m (#Mm00437762_m1), Acox1 (#Mm00443579_m1), Ccnd1 (#Mm00432359_m1), 
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Ltf (#Mm00434787_m1), Stat5a (#Mm00839861_m1), Ppara (#Mm00440939_m1), Pparg 
(#Mm01184322_m1), Cyp2b10 (#Mm00456591_m1), and Cyp3a11 (#Mm00435123_m1).  
Fold change was calculated using the 2–CT method of Livak and Schmittgen [11]. 
 
Mammary Gland Preparations.  Mammary glands were removed on PND 21 because 
this time point represents the time that pups begin to wean themselves from the dam, and 
because this time point for the lactating dam and developing offspring mammary gland was 
previously assessed in the CD-1 mouse strain following PFOA exposure.  The entire fourth 
and fifth glands were removed from dams and female pups, and mounted flat on glass slides.  
Whole mounts were fixed in Carnoy’s solution, stained in alum carmine stain, and dehydrated 
and cleared in xylene, as previously described [12].  Whole mounts were visualized by light 
macroscope (Leica WILD M420 macroscope, Leica, Wetzlar, Germany).  Mammary gland 
whole mounts from female offspring were scored on a 1–4 subjective, age-adjusted 
developmental scale (as described in [13]; 1 = poor development/structure; 4 = normal 
development/structure, given age).  The developing tissue was assessed for number of primary 
ducts, number of large secondary ducts, and lateral branching, appearance of budding from the 
ductal tree and longitudinal outgrowth of the epithelium. Slides were separated by score as they 
were evaluated, compared within a score for consistency, and then recorded.  Two independent 
scorers, blind to treatment, scored glands within the age groups.  Mean scores for the two ages, 
within treatment groups, were calculated and analyzed statistically for treatment and time-related 
differences.  Lactating dam whole mounts were similarly, though non-quantitatively, assessed.  
The differentiated tissue was assessed for amount of epithelial tissue filling the gland, presence 
of well-formed, productive alveoli (containing lipid/milk), and in the case of the involuting tissue 
(PND 21), the normal presence of apoptotic bodies and regressing alveoli.  Typical mammary 
glands, morphologically representative each treatment group, were photographed using the 
above described macroscope and mounted camera (Photometrics CoolSNAP, Roper Scientific, 
Inc., Tucson, AZ).  
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Data analysis.  Data were evaluated for dose effects using mixed-model analysis of 
variance (ANOVA) in SAS 9.1 (SAS Institute, Inc. Cary, NC).  For all measurements, including 
mammary gland developmental scores and gene expression delta-Ct values, means were 
evaluated and effects of dose compared. Differences between treatment groups were determined 
using Dunnett’s or Tukey’s t-tests (significance at the level of p < 0.05 for all comparisons, in 
text and figures), with SAS. 
 
Results 
Strain-specific mammary gland effects.  In the lactating WT (PPAR! +/+) control dam, 
mammary gland morphology revealed regressing alveoli, as normally seen as the growing 
litter weans itself and milk production decreases.  As PFOA dose increased, the number of 
dams within a treatment group exhibiting partial or complete regression decreased (Figure 5-
1).  At the lowest dose of 0.1 mg/kg PFOA, regression was visible in two of the six dams 
assessed, and in portions of the gland of one other dam.  The remaining three dams in this 
group exhibited full, round lobuloalveolar units, still apparently producing milk, though in 
places ducts were visible suggesting that the entire gland had potentially not achieved peak 
lactational output. At 0.3 mg/kg PFOA only one of four dams exhibited any regression of the 
gland, and all dams exhibited some to extensive presence of full, active lobuloalveolar units, 
suggesting that milk was still being extensively produced and that pups were not being 
weaned.  In the highest dose of 1 mg/kg PFOA, no regression could be seen in any dam 
whole mount. While three of the six dams in this dose group displayed large, full, active 
lobuloalveoli, the remaining three dams displayed poor louloalveolar devlopment, suggesting 
not only delays, but actual diminishments in total lactational competence.    
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Figure 5-1. PND 22 mammary gland differentiation of PPAR WT and KO lactating dams 
under different PFOA exposure conditions.  The carmine-stained whole mounts of lactating 
mammary tissue pictured show morphology representative of respective treatment groups at 
the given time point.  Note that in PPAR! +/+ dams under 1mg/kg treatment are more 
densely filled and exhibit larger, more extensive lobulo-alveoli compared to control PPAR! 
+/+.  Among PPAR! -/- dams, however, little effect of PFOA treatment is seen (N = 4-7 
dams per treatment group). 
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  In lactating KO (PPAR! -/-) glands, control dams exhibited similar morphology to 
that seen in WT control dams, including regression appropriate to weaning.  Because these 
dams did not exhibit as well developed morphology as was observed in WT animals, it 
appeared that lactational differentiation might be slightly altered, though not functionally 
impaired, by the absence of PPAR!.  There was no observable effect of PFOA on 
differentiation of the lactating gland of KO dams, at any dose, suggesting that PFOA-induced 
impairments in lactation are driven by PPAR! activation (Figure 5-1). 
 With respect to development, mammary gland morphology in the WT, 129S1/SvlmJ 
mouse offspring appeared responsive to PFOA treatment in a manner similar to that seen 
previously in CD-1 mice [5, 9].  That is, with increasing PFOA dose, the developing 
parenchymal epithelial network appeared increasingly diminished.  At the high dose of 1 
mg/kg PFOA this was most apparent in the PND 22 WT offspring mammary gland, when 
mean development scores were statistically lower than for controls, primarily with respect to 
longitudinal growth and branching (Figure 5-2).  Mammary gland whole mounts from KO 
pups actually appeared more responsive to PFOA than did WT glands, exhibiting lower 
developmental scores and poorer development at only 0.1 mg/kg, a dose that did not statistically 
reduce gland development in WT offspring.  This suggests that a non PPAR!-mediated mode 
of action may be partially responsible for delays in development of this tissue.   
At 18 months postnatally, KO offspring exhibited persistent effects of PFOA treatment 
as evidenced by decreases in secondary and tertiary epithelial branching and total parenchymal 
filling of the fat pad (Figure 5-3).  In WT whole mounts, the effects of PFOA on gland 
morphology were still apparent at both the 0.3 and 1 mg/kg PFOA doses, manifesting as 
increases in fibrosis and stromal density at this late age (Figure 5-3).  This is consistent with 
previously reported observations in 18-month old CD-1 mice [5]. 
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Figure 5-2. PND 22 mammary gland development of PPAR! WT and KO mice under 
different PFOA exposure conditions.  Carmine-stained whole mounts of developing 
mammary tissue pictured show morphology representative of respective treatment groups at 
given time points (N = 1-6 per treatment group per time point). *Significant treatment effect 
by ANOVA; p < 0.05. 
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Figure 5-3. 18-month old mammary gland morphology of PPAR WT and KO mice under 
different PFOA exposure conditions.  The carmine-stained whole mounts of mammary tissue 
pictured show morphology representative of respective treatment groups at the given time 
point (N = 7-21 per treatment group). 
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 Ovariectomy.  In a separate study, examining the potential modes of action for PFOA-
induced toxicity in non-mammary tissue, timed pregnant CD-1 dams received PFOA at 0 and 5 
mg/kg over GD 1-17.  A subset of the resulting female offspring were ovariectomized at PND 
26, prior to first estrous, in order to determine whether ovarian hormones might mediate the 
effects of PFOA exposure.  Figure 5-4 shows mammary gland whole mounts from 
ovariectomized CD-1 mice at 18-months of age, with either 0 or 5 mg/kg PFOA exposure 
during gestation.  As can be seen, ovariectomy stunts branching of the epithelium, under either 
control or PFOA treatment, though what little epithelium is present does grow longitudinally to 
fill most of the length of the fat pad.  However, ovariectomy does not save the phenotype.  The 
PFOA-exposed animals exhibited a profoundly diminished ductal network, even compared to 
that of the ovariectomized control animals.   This is not surprising given that this stunted-type 
mammary epithelial phenotype was observed in exposed CD-1 offspring in previous studies [5, 
9] as early as PND 1 when ovarian hormones are not yet controlling the mammary gland, and 
persisted to late-life despite internal PFOA dose diminishing to near or below the level of 
detection.  These observations together suggest that late gestational and early neonatal life 
represent a window of sensitivity for the mammary gland with respect to PFOA exposure.  That 
is, insult by PFOA exposure during this period seems to result in a smaller population of cells, 
potentially the adult stem cell population, that will give rise to all subsequent parenchymal 
tissue.  Alternatively, a permanent change in these cells, such as altered responsiveness to 
growth and developmental signaling molecules possibly at the level of receptor expression, 
might be transmitted to all future cells and might be responsible for the permanent delays and 
diminishments in development and differentiation. 
 
 Mammary gland gene expression.  The genes of interest assessed in the lactating and 
developing mammary gland included acyl CoA oxidase (Acox1) and cyclin D1 (Ccnd1), which 
are hallmarks of PPAR! activation [14]. These genes have previously and consistently been 
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Figure 5-4. 18-month old mammary gland morphology of ovariectomized CD-1 mice under 
different PFOA exposure conditions.  The carmine-stained whole mounts of mammary tissue 
pictured show morphology representative of respective treatment groups at the given time 
point (N = 3-4 per treatment group). 
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shown to be upregulated in the liver by PFOA treatment [14]. However, the mammary gland is 
expected to exhibit a differential gene expression profile than that of the liver.  Expression of 
PPAR! itself, was also examined, given that the PPAR! gene contains a peroxisome 
proliferator response element in its upstream promoter region, and that agonism of the 
receptor can result in positive feedback that upregulates expression of the receptor.  
Lactoferrin (Ltf) was previously shown, following PFOA exposure, to exhibit delayed 
expression in tandem with morphologic delays in the mammary gland [9].  Interestingly, Ltf has 
also been shown to be downregulated in the liver by other PPAR! agonists [15].  Because this 
gene product is a primary milk protein that serves an immunologic role in the naïve neonate, 
alterations in its expression during lactation could result in profound health effects in offspring, 
not measurable at the level of growth and survival.  The “signal transducer and activator of 
transcription 5A” (Stat5a) gene product is required for both mammopoiesis and lactogenesis, 
because prolactin is a primary lactogen in the mammary gland, particularly during lactation, and 
the prolactin receptor is a cytokine receptor which induces transcription through the Jak/Stat 
signaling pathway.  PPAR signaling (! and "), however, is known to modulate signaling 
through the Jak/Stat pathway, and therefore clearly represents a potential means of interference 
directly with lactogenesis [16, 17].  In assessing Stat5a gene expression, a better understanding 
of the possible action of PPAR signaling on the Jak/Stat pathway, which might be responsible 
for the consistently observed impairments in lactogenesis, was investigated.  
In addition to genes directly or potentially related to PPAR! activation, expression of 
PPAR" was also examined, as this receptor is particularly important in tissues with high 
adiposity, such as the mammary gland, and is also weakly bound by PFOA.  Gene markers of 
CAR and PXR activation, Cyp2b10 and Cyp3a11respectively, were also assessed, to determine 
the activation and transcriptional activity of these receptors. 
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No consistent pattern of altered expression in PPAR!-mediated or related genes was 
observed (Table 5-1).  In fact Acox1 and cyclin D1, which should be upregulated by PPAR!-
activation, were almost entirely downregulated, but rarely with statistical change from controls 
(all expression normalized to the endogenous control gene Beta-2-microglubulin).  Ltf, while 
appearing consistently downregulated (though not significantly), as predicted in liver tissue 
[15], did not replicate the pattern of expression in treated dams reported previously [9] (though 
different methods were utilized). Stat5a was expressed at significantly lower levels in treated 
PND 10 offspring mammary tissue, however, Stat5a plays little role in the tissue at this time 
point, as compared in the lactating gland, when decreases in expression were hypothesized.  
Expression data for PPAR", and the CAR and PXR mediated cytochromes provided little 
information (Table 5-2).  PPAR" generally appeared downregulated, but never was this change 
significant.  Expression of the two cytochromes could not be addressed as a fold change of the 
treated group over the control group as expression was undetectable in either the controls or 
both the control and treated groups.        
 
Discussion 
 The work described here supports the thesis that effects of gestational PFOA-
treatment on lactating dam mammary gland morphology, and any nutritional consequences to 
offspring that stem from it, likely result from agonism of PPAR!, as treatment of WT dams 
produces a delayed-type lactational phenotype that was observed in outbred CD-1 mice, but 
not in PPAR! KO mice.  However, because there is some effect of PFOA treatment apparent 
in mammary gland morphology of PPAR! KO offspring, PPAR! agonism is doubtful the 
only target of PFOA for this particular end point.  The gene expression work presented here 
suggests some potential increases in PPAR! activity, but neither does it exclusively identify 
this as the sole target responsible for the observed phenotype, nor does it exonerate PPAR!-
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Table 5-1.  Gene expression of PPAR!-regulated and potentially-regulated genes, in MG 
tissue from PND 10 and 21 lactating dams and developing female offspring.  
  
 Genes of Interest 
 Ppara Acox1 Ccnd1 Ltf Stat5a 
PND 10 Pups      
   5 mg/kg PFOA -2.68* -2.04* -1.31 -1.44 -1.81* 
PND 21 Pups      
   5 mg/kg PFOA 2.68* 1.11 -2.24 -3.65 -1.22 
      
PND 10 Dams      
   5 mg/kg PFOA -1.88 -1.62 -1.32 -1.03 -1.74 
PND 21 Dams      
   5 mg/kg PFOA 2.04 1.16 -2.18* -2.21 1.51 
Note. Transcript number expressed as fold-change difference from control tissue under the same conditions.   
* p < 0.05 compared to control expression. 
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Table 5-2. Gene expression of non-PPAR!-regulated genes, in MG tissue from PND 10 
and 21 lactating dams and developing female offspring. 
  
 Genes of Interest 
 Pparg Cyp2b10 Cyp3a11 
PND 10 Pups    
   5 mg/kg PFOA -1.27 NA UD 
PND 21 Pups    
   5 mg/kg PFOA 3.52 NA UD# 
    
PND 10 Dams    
   5 mg/kg PFOA -1.47 NA UD# 
PND 21 Dams    
   5 mg/kg PFOA -1.07 NA UD 
Note. Transcript number expressed as fold-change difference from control tissue under the same conditions.   
* p < 0.05 compared to control expression.  # Expression evident in some treated samples, but fold change 
could not be calculated due to lack of signal in control samples. NA = not applicable because no expression 
detected. UD = undeterminable because expression not consistently measured within and between groups. 
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mediated effects in the gland.  Microarray work utilizing mRNA isolated from PFOA-treated 
and control dams and offspring of all three mouse strains examined here – CD-1, 
129S1/SvlmJ (WT), and PPAR! KO – would be most useful for determining specific genes 
and gene pathways for continued RT-PCR work, in order to understand non-PPAR!-
mediated mammary effects. 
The mode of action responsible for PFOA effects in the mammary gland is not known, 
but its elucidation will be important in determining the relevancy of mammary health effects in 
animal models of human health.  To date, the predominant toxicity associated with PFOA 
exposure in animal models has been hepatotoxicity, resulting from agonism of the PPAR! 
receptor.  It is generally believed that hepatotoxicants that act through this mode of action do not 
pose a health hazard to humans due to lower hepatic mRNA expression of PPAR! in humans 
as compared to rodents (5-10% of rodent expression; [18].  It is clear that hypolipidemic 
pharmaceuticals that target PPARs, such as clofibrate, in human hepatocytes do not elicit the 
peroxisome proliferation observed in rodent hepatocytes.  Yet, these drugs do effectively 
produce the desired triglyceride-lowering results in human patients, suggesting that PPARs 
do play a role in lipid metabolism in humans despite potentially lower basal expression of 
PPARs in the liver.  That is, PPAR! agonists in humans appear to stimulate gene expression 
along pathways associated with lipid metabolism, but in contrast to what has been seen in 
rodents, they do not upregulate genes involved in apoptotic (decreased) and proliferative 
(increased) pathways, or genes involved in actual peroxisome proliferation.  For this reason, 
humans are believed refractory to the adverse effects of peroxisome proliferating compounds 
observed in rodents.  Some of the suggested factors that might explain species difference in 
response to PPAR! activators include species-specific elements of the PPAR-retinoid X 
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receptor (RXR) heterodimer transcriptional machinery, specifically co-activators such as 
steroid receptor co-activator (SRC-1) and integrator protein p300 [18]. 
 Unfortunately, the efforts to characterize interspecies PPAR! variation have been 
largely isolated to hepatic tissue, and strictly at the level of mRNA [19].  While nuclear 
receptors are bound to undergo turnover and require new synthesis, it seems difficult to 
accept that transient and intermediate mRNA levels at any instant in time could give a true 
approximation as to the basal levels of the function receptor protein in a given tissue and 
species at that time, or averaged over time.  It seems that if regulation of peroxisome-
proliferating compounds is going to be based strictly on quantitative expression of the 
receptors on which they act, a thorough confirmation of this at the level of protein expression 
might be a more precise determinant.   
 Independent of differential hepatic PPAR! expression across species, PPAR! 
expression in other tissues, both human and rodent, is not well characterized.  For this reason 
alone, peroxisome-proliferating compounds should not be regulated solely on differential 
hepatic PPAR! expression, because of the potential for these compounds to activate PPAR! 
in other tissues, resulting in as yet unknown cascades of events.  If, for example, PPAR! 
locally mediates the effects of PFOA in the mammary gland, differential expression in the 
liver should not be the determinant of human health risk for mammary specific effects.  
Ideally, PPAR! expression at both the protein and mRNA levels could be assessed in both 
humans and respective animal models, in order to properly characterize differential 
expression, and on a tissue-specific basis (including human mammary tissue that might be 
isolated from breast-reduction patients).  Furthermore, the specific activity of PPAR! – 
including ligand affinity, heterodimerization efficiency, transcriptional machinery attraction, 
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and DNA binding properties – across species may co-modulate toxicity resulting from a 
given “dose” of PPAR!-agonism, in which case, receptor expression alone may play less of a 
role than formerly held true.  It is important to remember that PPAR!-targeted drugs are 
effective in humans for their hypolipidemic properties, in the absence of peroxisome 
proliferation, and this might not mean solely fewer receptors, but might mean differential 
gene regulation by this nuclear receptor across species and tissues, and thus peroxisome 
proliferation might not necessarily be the sole determinant of whether a PPAR! agonist has 
the potential to induce human disease. 
 Interestingly, peroxisomes have been identified as present in both normal and 
neoplastic mammary epithelium from humans, and their number does not appear to change 
with neoplasia [20].  However, in the same study Acyl CoA oxidase, which PPAR! can also 
regulate, was significantly lower in neoplastic tissue as compared to control tissue, and 
decreased with increasing tumor grade.  In rats, during pregnancy, expression of genes 
associated with lipid oxidation, including acyl CoA-oxidase, is increased in both the liver and 
the mammary gland, though genes involved in cholesterol synthesis exhibit opposing signals 
in the two tissues, increasing in the liver, but decreasing in the mammary gland, compared to 
the virgin animal [21].  The roles for peroxisomes and enzymes involved in lipid oxidation in 
the lactating mammary gland seem plausible, given the extensive metabolism occurring 
locally during lactation. 
 At the level of tissue function, it is clear that PPAR! activity has the potential to 
profoundly interfere with the mammary gland, given that transgenic mice expressing 
constitutively activated PPAR! exhibit such profoundly impaired lactational differentiation 
as to result in the complete loss of litters [22].  In the same study, the authors were able to 
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replicate this mammary gland phenotype in a wild-type mouse strain through treatment with 
the classic PPAR! agonist, Wy-14,643.  The same treatment of a PPAR! knock-out mouse 
strain, however, did not result in altered mammary gland function or morphology, thereby 
confirming the actions of PPAR! activation during pregnancy and lactation.  In multiple 
studies, treatment of pregnant and lactating rats with the PPAR! agonist and pharmaceutical 
agent, ciprofibrate, resulted in increased hepatic expression of peroxisomal enzymes in 
offspring, demonstrating both that the compound is reaching the offspring via amniotic fluid 
or milk, and that PPAR! is both present and functional in the neonate, though not whether 
the compound has the potential to behave similarly in the human [23, 24]. 
 Because PFOA-induced hepatic gene expression profiles are not precisely identical to 
those of the classic, high-specificity PPAR! agonists, Wy14,643 [14], and because PFOA 
can also induce some developmental toxicity and altered hepatic gene expression profiles in 
PPAR! KO (-/-) mice [8], it is evident that a component of the activity of PFOA is 
independent of PPAR!, and alternate targets for PFOA need to be identified.   
A recent paper demonstrated the potential for PFOA to reduced appetite and feeding 
behavior through PPAR! activation, as this effect was not reproducible in PPAR! -/- mice 
[25].  In fact, PFOA was as effective as an anorexigen as was the endogenous PPAR! ligand, 
oleoylethanolamide (OEA).  OEA is a lipid, known to regulate weight and feeding behaviors.  
Structurally, however, OEA is dissimilar to PFOA in its longer chain length as well as its 
branching.  Nonetheless, these structurally disparate compounds both activate the nuclear 
receptor, PPAR!.  Interestingly OEA shares extensive structural homology with anandamide, 
or arachidonoyl ethanolamide, which is the endogenous ligand for cannabinoid receptor 1 
(CB1).  Activation of this G-protein-coupled receptor by anandamide results in increased 
feeding.  Antagonism of CB1, however, results in an anorexic feeding response, making CB1 
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a desirable drug target in the development of anti-obesity drugs, and thus a recent focus of 
study. 
Interestingly, anadamide, the primary endocannabinoid ligand for CB1, has been 
shown to bind and activate PPAR!, presumably as a result of its extensive structural 
homology with OEA, and for the biological purpose of redundancy in the face of exogenous 
cannabinoid molecules, which may increase demand for neuroprotection [26].  In fact, there 
is a growing body of literature that suggests that PPARs, in addition to cannabinoid 
receptors, may be targets for cannabinoids.  Indeed, there seems to be close relationship 
between the two primary ligands for PPAR! and CB1, OEA and anandamide, respectively, 
as they both play vital roles in the regulation of lipid metabolism and feeding behavior, 
however, they have opposing actions – whereby OEA increases lipid metabolism and 
decreases feeding, and anadamide increase lipogenesis and increases feeding [27].  Despite 
the evidence of agonism of PPARs by anandamide, there does not appear to be any evidence 
that OEA can bind or activate CB1.  Nonetheless, the suggestion of this ligand promiscuity 
begs the question of whether there is any potential for PFOA to act on CB1. 
 Utilizing an existing database of array data generated at the EPA on adult and fetal CD-
1 mouse liver RNA following developmental PFOA exposure, a casual Ingenuity® search on 
some genes implicated as responsive to hepatic CB1 activation proved inconsequential.  The 
genes, Cnr1 (cannabinoid receptor 1), Srebf1 (sterol regulatory element binding transcription 
factor 1), Acaca (acetyl-CoA carboxylase 1), and Fasn (fatty acid synthase) had all been shown, 
in a single study, to exhibit increased hepatic expression following treatement with a CB1 
activator [28].  Existing data from microarrays run on fetal hepatic RNA from control and 
5mg/kg PFOA treated CD-1 mice, as well as on hepatic RNA from control and PFOA-treated 
adult WT and PPAR! KO, did not suggest any clear increases in expression of these genes.  
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However, this is a small sampling of gene products that might reflect signaling through CB1.  
Furthermore, the downstream effects of PPAR signaling in lipid metabolism pathways may 
affect expression of these particular genes, despite their involvement in lipogenesis rather than 
lipolysis.  
 Irrespective of the precise signaling pathway disrupted by late gestational or early 
neonatal PFOA exposure – which results in the permanent diminishments of glandular 
parenchyma – it seems that this early insult consistently yields an adult phenotype of less total 
epithelial tissue in the mammary gland.  This might result from impaired early signaling that 
permanently reprograms the tissue to express altered populations of various receptors over life.  
It seems however, that this single early exposure seems only to diminish the total tissue, 
suggesting that potentially the pool of adult stem cells might be smaller in the mammary glands 
of these treated animals compared to controls.  This might explain the suggested delay and 
global reduction in productive lobuloalveoli seen in the bred F1 generation that resulted from 
PFOA-treated P0 dams (Chapter 4).  This might also explain findings in the same paper, that 
latency to carcinogen-induced mammary tumors was increased among PFOA-treated animals 
because there are simply fewer targets for carcinogenesis in these animals, compared to normal 
adult females with presumably larger pools of target cells, in tandem with their larger total 
number of epithelial cells (Chapter 4).       
 These findings demonstrate that a PPAR!-mediated response to PFOA is not the only 
signaling event occurring in the PFOA exposed mammary gland, and that with respect to the 
developing tissue, some other mode of action is clearly at work.  Continued study of these 
PPAR! KO and WT, as well the outbred CD-1 strain, should aim to evaluate gene 
expressions changes common to the three strains, including the PPAR! KO strain, under 
same PFOA exposure conditions in order to isolate a non PPAR!-mediated mode of action 
that might account for morphological changes in the developing PPAR! KO mammary 
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gland.  If such a mode of action is identified as potentially relevant to human health, 
regulatory decisions concerning PFOA will likely be made more rapidly, and with more 
consideration of potential unknown and unpredicted health risks.  
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CHAPTER 6 
 
Conclusions and Perspectives 
 
 
 The research presented in this dissertation represents an effort to characterize the 
nature of the effects of PFOA on the mammary gland.  PFOA is used extensively in the 
production of commercial and industrial goods, and has been released from production 
facilities via effluent air and water.  It is likely that contact with these contaminated materials 
is responsible for the majority of humans in the developed world exhibiting low-level, but 
ever-present PFOA in their blood serum.  For most people the circulating serum 
concentration appears to be low, less than 10 ng/ml, but for those with occupational 
exposures to PFOA, or who live in communities where PFOA is manufactured, the internal 
dose climbs much higher, even a thousand-fold.  Little is known about the health effects of 
these exposures, though, particularly those incurred in early life. 
 Prior to the initiation of this research, developmental toxicity studies at the EPA 
found that treatment of pregnant CD-1 mice with PFOA throughout gestation resulted in 
reduced postnatal survival and weight gain (at 3, 5, 10, 20 mg/kg), with comparatively little 
prenatal loss and no reductions in maternal weight gain.  The fact that offspring effects 
appeared limited to the postnatal period suggested that PFOA might not be acting as a strict 
developmental toxicant, but rather, indirectly by interfering with postnatal maternal support, 
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including the quality and quantity of milk produced, as well proper maternal nesting and 
nursing behavior.     
Thus, the first study in this research was originally initiated to test whether impaired 
dam lactation might be responsible for the neonatal growth deficits and reduced survival that 
resulted from gestational PFOA treatment, in the absence of similar prenatal outcomes.  This 
first study (Chapter 2, [1]) demonstrated that indeed PFOA held the potential to impair 
lactation in the dam, resulting from as short an exposure as the final six days of gestation, 
when the mammary gland is undergoing rapid lactational differentiation.  Furthermore, we 
found that the offspring also exhibited mammary gland effects at both PND 10 and PND 20.  
In fact, both lactating dam MG tissue and developing offspring MG tissue exhibited a 
delayed-type phenotype, where gland morphology in treated animals appeared to be earlier 
in the stage of differentiation of development, respectively, than their chronology would 
imply.  That is, lactational or developmental maturity of the tissue appeared to be delayed in 
time among treated female dams and offspring, respectively. 
In the subsequent studies (Chapter 3, [2]), we pursued the precise exposure 
parameters necessary to produce this phenotype, by examining the effects of exposure via 
intrauterine- and lactational-only routes, at the same and lower doses of PFOA (1 and 5 
mg/kg).  The thoughts behind this pursuit were that we might isolate the effects of PFOA on 
the dam from the direct effects of PFOA on the pup, as well as determine whether effects on 
dam milk production resulted from PFOA exposure during lactational differentiation, or from 
weak suckling by the small PFOA-exposed pups.  We found that both intrauterine- and 
lactational-only routes (and timing, GD 8-17 and PND1-21, respectively) were sufficient at 
the 5 mg/kg dose to reduce MG development among offspring from as early as PND 1, with 
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morphological consequences that persisted throughout a 9 week period (into adulthood), and 
were still apparent at 18 months postnatally. Importantly, these effects were evident at a time 
when the circulating serum PFOA concentrations had returned to nearly baseline levels.  The 
effects were not reversible. Dams that received direct treatment with PFOA exhibited the 
previously described delay in lactational morphology, independent of whether suckling 
offspring received PFOA during gestation.  This observation indicates the direct action of 
PFOA on the differentiation of the lactating mammary gland.  Nonetheless, untreated dams 
that nursed treated pups exhibited increasing serum PFOA concentrations between parturition 
and weaning, and by PND 3 these dams exhibited reduced alveolar filling of the gland.  
Though their exposure to PFOA was not via direct treatment, but by experimentally-
unintended ingestion as a result of maternal grooming practices, they exhibited a non-zero 
PFOA burden, and thus the alterations in lactational differentiation cannot entirely be 
attributed to the smaller, gestationally PFOA-exposed offspring that they nursed.  However, 
as these dams were morphologically similar on PND 1 to control dams nursing control pups, 
initial milk letdown was not likely altered in these dams, therefore evidencing that the 
suckling by the intrauterine-exposed offspring was not so weak as to entirely block initial 
milk production.  This supports the hypothesis that changes in the lactating dam mammary 
gland are almost entirely due to direct action of PFOA at some point in the signaling 
pathways involved in lactogenesis, rather than due to a synergistic effect between direct 
biochemical toxicity of PFOA and diminished pituitary signaling as a result of reduced 
suckling by weak offspring.   
Our next goal was to determine whether the morphological changes observed in the 
mammary gland, specifically in the developing offspring represented an adverse effect 
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(Chapter 4).  That is, we were interested in whether the phenotypic morphological alterations 
in the developing mammary tissue were multi-generational, or translated to either impaired 
lactation when challenged to support a litter, or to altered susceptibility to carcinogenesis 
when challenged with a known mammary-specific carcinogen.  To that end, we performed 
studies similar to those previously described, administering 0, 1, or 5 mg/kg PFOA to time 
pregnant CD-1 dams over gestation (GD 1-17).  Additionally, subsets of dams receiving 0 or 
1 mg/kg PFOA also received chronic PFOA exposure in their drinking water at a human-
relevant dose of 5ppb.  Offspring from these treated dams were then bred to control males, 
and the growth and survival of the resulting F2 litters was considered a proxy for lactational 
support and mammary function of the F1 dams that were exposed early in their own 
development.  While delays in lactogenesis were apparent at a histological level, all of the F2 
offspring grew and survived normally, irrespective of dam developmental exposure, 
illustrating the sufficient nutritional and caloric content of milk.  Interestingly, the chronic 
low-dose of PFOA in drinking water alone appeared to have some effect, particularly at the 
level of ductal branching, in both the lactating F1 dam gland morphology and the developing 
F2 offspring gland morphology, despite resulting in the very low average internal dose of 
only ~55ng PFOA/ml serum in both generations. Although effects of this low dose PFOA 
exposure were present in multiple generations, the internal PFOA dosimetry suggest that 
these effects were likely driven by the exposure, evident in both the F1 dam and the F2 pup 
at the time of weaning of the second generation. Because of the decreased severity and 
inconsistency of effect present in the F2, unlike that seen in the F1 generation, we have no 
reason to believe that changes in the mammary glands of two generations of animals were 
due to epigenetic changes, such as altered DNA methylation status, or other such heritable 
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mechanisms. At the level of altered carcinogenesis susceptibility, developmental PFOA 
exposure did not increase susceptibility, as neither frequency nor multiplicity of mammary 
gland tumors was increased in any PFOA-treated group.  In fact, latency to palpable tumor 
appearance was actually extended in PFOA treated groups.  While it is not certain what drove 
this decrease in tumorigenicity, the fact that there was a dramatically smaller population of 
target cells for DMBA-induced mutagenesis – as suggested by extensive histological 
observation – is a likely contributor. This reduction in tumorigenesis, however, should not 
suggest that PFOA does not have deleterious effects in the mammary gland, or that PFOA 
exercises any protective effect in the tissue.  In the face of such potential misunderstanding of 
these data, further testing will be necessary, to determine the underlying reason for this 
decreased tumor formation. 
Our final goal of this research was to determine whether peroxisome proliferator-
activated receptor alpha (PPAR!) agonism – the mode of action proposed for PFOA-induced 
hepatotoxicity – was responsible for the alterations in the mammary gland that we observed 
over the course of these studies (Chapter 5).  To do this we examined mammary gland 
morphology in control and PFOA-treated PPAR!-knock-out (KO) and wild-type (WT) mice, 
at time points previously assessed in the outbred CD-1 mouse strain used in our prior studies.  
In the treated dam mammary gland at weaning, comparing KO and WT strains, it was 
evident that PFOA-induced changes were PPAR!-mediated, given their absence in KO 
mammary gland whole mounts compared to WT glands.  In the resulting offspring at 
weaning, however, both KO and WT mammary glands exhibited a PFOA response similar to 
the ductal stunting observed in developmentally PFOA-exposed CD-1 offspring in the three 
prior studies.  This suggests that PFOA-induced changes in the mammary gland at the level 
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of dam lactational differentiation are PPAR!-mediated, but that some component involved in 
early development of the mammary gland parenchyma, is mediated by an alternative 
pathway.  Gene expression analysis in developing and lactating mammary tissue from 
PFOA-treated CD-1 mice revealed only that explicit agonism of PPAR! was not acting 
locally in the mammary gland at the time points addressed -- mid-lactation, at PND 10, and 
weaning, at PND 22 -- and thus, while PPAR! seems to mediate at least dam mammary 
gland effects, it must be doing so either at an earlier time point than we have assessed, or else 
upstream of the mammary gland in the lactogenic pathway. 
These studies have been part of a larger effort to understand exactly what the toxic 
profile for PFOA consists of, and whether it poses a true hazard to human health.  Some of 
the stated research needs following the Science Advisory Board report on the PFOA draft 
risk assessment were to study the effects of developmental PFOA exposure using appropriate 
animal models, to identify sensitive tissues to the effect of PFOA and to understand the 
timing or exposure parameters necessary for the effects. This research has been in direct 
response to those needs and has provided data for each of those requests. Furthermore, the 
data that we have provided is unique in that some of the most important results – including 
impaired lactational differentiation and neonatal mammary epithelial arborization – have 
been repeated in multiple studies, at more than one dose, and have been consistent across 
studies. Unlike the hepatic effects, extensively cataloged in association with animal model 
exposure, these mammary gland effects are a relatively new observation, and one that is not 
strictly mediated by PPAR!.  Given these facts, observation of mammary-specific effects in 
PPAR! null mice are some of the first reported data concerning potentially novel modes of 
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action for PFOA, which may elicit new thoughts in the regulatory action arena due to the 
potential to impact human populations in ways other than PPAR signaling. 
The findings uncovered in the course of my research would not likely have 
spontaneously come to the fore, in part due to the small contingency of the scientific 
community that studies environmental insults and mammary gland biology in terms of hazard 
characterization, rather than at the specific level of breast cancer or agricultural milk 
production.  Because our lab studies the mammary gland as a potentially sensitive tissue 
endpoint, with respect to toxicant exposure during gestation, we were eager to determine the 
role that altered dam lactation might play in PFOA induced developmental toxicity in 
neonates.  After our first paper was published, concluding that gestational PFOA exposure 
altered both dam and offspring mammary gland development and differentiation, other labs 
began studies to expand on our initial findings.  Now, work has been conducted to address 
mammary gland effects of peripubertal exposure to PFOA with respect to differential 
response across multiple inbred mouse strains [3], as well as the influence that early life 
PFOA exposure may have on pubertal timing, body mass index, and breast development 
timing in girls (work taking place in the NIEHS Breast Cancer and the Environment 
Research Centers – University of Cincinnati, Ohio). 
A final important conclusion from this work is the reporting of invaluable serum 
PFOA concentrations that allowed us, and risk managers, to begin to understand the true 
timing and body burdens of exposure associated with developmental exposures. We now 
have a better understanding of how quickly and at what serum concentration we could 
anticipate hindered lactational differentiation. We have the data in hand to model lactational 
transfer to the pup, as this type of PFOA transmission unmistakably impacts the mammary 
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gland development of the resulting offspring in our studies. We have shown also, that the 
mammary developmental effects persist beyond the time at which serum PFOA is elevated 
above background levels.  These data will allow comparison to the contaminated 
communities in the US and Germany, leaving fewer assumptions and less uncertainty in 
health risk assessment for these populations.      
Undoubtedly, PFOA is a high-profile compound, given its ubiquity in biota, from 
polar bears to humans, and its far-flung distribution in the environment.  As such, every 
individual or group that knows of its ubiquitous contamination wants to know whether it is 
safe for them to have had, or continue having, an exposure which they formerly did not know 
existed.  Answers to these questions will be slow to evolve, but our studies demonstrate both 
the potential for PFOA to impair development in a PPAR!-independent manner, and the 
potential for chronic, human-relevant exposures to PFOA to affect mammals.   
Because there is currently a “voluntary phase-out” of PFOA in the US [4], the EPA 
may not perform a formal IRIS assessment or develop formal regulation on this compound.  
However, the large volume of data supporting the relatively low dose and persistent health 
effects in mice following developmental exposure to this compound keep risk assessors 
interested in this compound and those that are coming onto the market to replace it. 
Understanding the modes of action for the effects of PFOA in the mammary gland and other 
affected organs will allow improved hazard identification and characterization of these new 
replacement compounds as they enter the marketplace and may result in altered testing 
requirements in the future.  
Recently, the State Assembly and Senate of California, a state known for its early and 
often efforts to regulate identified toxicants not yet federally regulated, passed Senate Bill 
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1313 (SB 1313; passed August 30, 2008).  Should the Governor of California sign this bill 
into law, it would take effect on January 1st, 2010, and would “prohibit the manufacture, 
sale, or distribution of any food contact substance, as defined, that contains perfluorinated 
compounds, as defined, in any concentration exceeding 10 parts per billion.”  This type of 
strong environmental leadership, supported by such on-going research as that presented here, 
will help assure the timely phase-out of this compound, which has the potential to 
permanently affect the mammary gland of both the nursing dam and her offspring, and has 
as-yet unknown effects in the human mammary gland.   
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